{"PMC7443178": [["IntroductionIn the last few decades, many new tertiary education facilities have been established all over the world, especially in highly-populated, fast-developing countries like China (Altbach & Knight 2007; Mok & Xu 2008; Rhoads & Hu 2012; Feng 2013; Xie et al. 2014; Marginson 2016; Kim et al. 2018; Guim\u00f3n & Narula 2020).", [["Altbach & Knight 2007; Mok & Xu 2008; Rhoads & Hu 2012; Feng 2013; Xie et al. 2014; Marginson 2016; Kim et al. 2018", "SPECIES", 188, 303], ["new", "OBSERVATION_MODIFIER", 42, 45]]], ["Many factors \u2013 including the government\u2019s commitment to develop science & technology and accelerate economic development \u2013 have contributed to the rapid expansion of universities in China (Bie & Yi 2014; Marginson 2018).", [["rapid", "OBSERVATION_MODIFIER", 147, 152], ["expansion", "OBSERVATION_MODIFIER", 153, 162]]], ["However, the social impacts created by this process have largely been ignored (Chen et al. 2019).IntroductionAn increase in the number or size of tertiary education facilities, along with the corresponding regional multipliers, would normally result in local people experiencing a more crowded community, a change in their local environment, and other social impacts (Vanclay 2002; IFC 2009; Smyth & Vanclay 2017; Chen et al. 2019).", [["people", "ORGANISM", 259, 265], ["people", "SPECIES", 259, 265], ["increase", "OBSERVATION_MODIFIER", 112, 120], ["size", "OBSERVATION_MODIFIER", 138, 142], ["change", "OBSERVATION_MODIFIER", 307, 313], ["local environment", "OBSERVATION", 323, 340]]], ["Where a new institution needs land, local people will likely experience physical displacement, especially if expropriation (the acquisition of land by the state) is applied (Vanclay 2017a; Chen et al. 2020).", [["people", "ORGANISM", 42, 48], ["people", "SPECIES", 42, 48], ["physical displacement", "PROBLEM", 72, 93]]], ["In cases of an upgrade of a tertiary institution, there may not need to be physical displacement of people (because the campus was already in existence), however, the existing employees of the former institution may lose their jobs, especially if they do not meet the skill requirements of the upgraded university.", [["people", "ORGANISM", 100, 106], ["people", "SPECIES", 100, 106]]], ["In other words, they experience economic displacement.IntroductionEconomic displacement occurs when people\u2019s livelihoods (i.e. their means of making a living) are negatively affected by a planned intervention or project (Vanclay 2017a).", [["people", "ORGANISM", 100, 106], ["people", "SPECIES", 100, 106], ["economic displacement", "PROBLEM", 32, 53], ["IntroductionEconomic displacement", "PROBLEM", 54, 87], ["a planned intervention", "TREATMENT", 186, 208], ["displacement", "OBSERVATION_MODIFIER", 75, 87]]], ["Economic displacement is an inevitable part of the upgrading of institutions, and therefore more consideration needs to be given to reducing the negative social impacts of this displacement.", [["Economic displacement", "PROBLEM", 0, 21], ["this displacement", "PROBLEM", 172, 189], ["displacement", "OBSERVATION", 9, 21]]], ["Compared to the attention given to the impacts created by large-scale physical displacement and resettlement, economic displacement generally receives much less attention (Vanclay 2017a).", [["large-scale physical displacement", "PROBLEM", 58, 91], ["economic displacement", "PROBLEM", 110, 131], ["large", "OBSERVATION_MODIFIER", 58, 63], ["displacement", "OBSERVATION_MODIFIER", 79, 91], ["displacement", "OBSERVATION_MODIFIER", 119, 131]]], ["In some situations, governments and corporations offer new jobs or financial compensation to affected persons, often without thinking about the impacts this compensation will have on the lives of the affected people.", [["persons", "ORGANISM", 102, 109], ["people", "ORGANISM", 209, 215], ["persons", "SPECIES", 102, 109], ["people", "SPECIES", 209, 215]]], ["In addition to the lack of attention given to persons living nearby (new) universities, the impacts on the former employees of institutions being upgraded have also received little attention.", [["persons", "ORGANISM", 46, 53], ["persons", "SPECIES", 46, 53]]], ["Although it was being developed as a branch campus of the Netherlands-based University of Groningen, from a local Yantai perspective, the planned institution was just an upgrade, changing a current local level university into an international university, albeit with an intended increase in the number of students.", [["branch", "OBSERVATION_MODIFIER", 37, 43], ["increase", "OBSERVATION_MODIFIER", 279, 287]]], ["Even though the University of Groningen opted out of the arrangement in 2018 after three years of development, the case is still valid to consider because many impacts were created during that time, and the project is (or, given the longer-term implications of COVID-19, was) likely to be taken over by another international university.", [["COVID", "TEST", 261, 266]]], ["In this paper, we assess the economic displacement that has been and will be created by this planned upgrade, and we consider the social impacts of this displacement on existing employees, most of whom would be retrenched.", [["the economic displacement", "PROBLEM", 25, 50]]], ["In general terms, we seek to raise awareness of the social responsibility obligations of higher education institutions, something we feel is much ignored.Economic displacement and its social impactsProject-induced displacement creates many social and environmental impacts.", [["Economic displacement", "PROBLEM", 154, 175], ["induced displacement", "PROBLEM", 206, 226], ["displacement", "OBSERVATION_MODIFIER", 163, 175], ["displacement", "OBSERVATION_MODIFIER", 214, 226], ["many", "OBSERVATION_MODIFIER", 235, 239], ["social", "OBSERVATION_MODIFIER", 240, 246]]], ["Projects also create impacts irrespective of whether or not people are displaced (Vanclay 2002, 2017a; Cernea 2003).", [["people", "ORGANISM", 60, 66], ["people", "SPECIES", 60, 66], ["impacts", "OBSERVATION_MODIFIER", 21, 28]]], ["Due to their varying characteristics, people are affected by projects and displacement in different ways (Cernea 1997; Oliver-Smith 2010; Vanclay 2012).", [["people", "ORGANISM", 38, 44], ["people", "SPECIES", 38, 44], ["varying", "OBSERVATION_MODIFIER", 13, 20], ["displacement", "OBSERVATION_MODIFIER", 74, 86]]], ["Some people benefit, while others suffer various social impacts, impoverishment risks, and changes to their lives and livelihoods that frequently are not compensated, and generally cannot be compensated for by money (Cernea 2003; Vanclay 2017a).Economic displacement and its social impactsSocial impacts are everything that affect people and communities.", [["people", "ORGANISM", 5, 11], ["people", "ORGANISM", 331, 337], ["people", "SPECIES", 5, 11], ["people", "SPECIES", 331, 337], ["Economic displacement", "PROBLEM", 245, 266], ["displacement", "OBSERVATION_MODIFIER", 254, 266]]], ["They can be physical in that they are felt by the body, or cognitive in that they can be perceived (Vanclay 2002).", [["body", "ANATOMY", 50, 54], ["body", "ORGANISM_SUBDIVISION", 50, 54]]], ["Amongst the many impacts created are uncertainty, anxiety and stress (McDonald-Wilmsen & Webber 2010; Vanclay 2012).", [["anxiety", "DISEASE", 50, 57], ["anxiety", "PROBLEM", 50, 57], ["many", "OBSERVATION_MODIFIER", 12, 16], ["impacts", "OBSERVATION", 17, 24]]], ["Anxieties are real social impacts, even though they may be based on perceptions.", [["Anxieties", "DISEASE", 0, 9], ["Anxieties", "PROBLEM", 0, 9]]], ["Anxiety can arise from rumours, regardless of whether or not these rumours have any foundation.", [["Anxiety", "DISEASE", 0, 7], ["Anxiety", "PROBLEM", 0, 7]]], ["Fear and anxiety can be severe social impacts whether or not the project actually eventuates (Vanclay 2012; Vanclay et al. 2015).", [["Fear", "DISEASE", 0, 4], ["anxiety", "DISEASE", 9, 16], ["Fear", "PROBLEM", 0, 4], ["anxiety", "PROBLEM", 9, 16]]], ["Therefore, a postponed or cancelled project still creates social impacts, because rumours and expectations abound (Chen et al. 2019).Economic displacement and its social impactsThe extent and kinds of social impacts created depend on many factors, including the quality of the engagement between project and community, the characteristics and impact history of the local community, as well as the effectiveness of any mitigation activities implemented (Franks & Vanclay 2013; Vanclay et al. 2015; Hanna et al. 2016; Esteves et al. 2012, 2017; van der Ploeg & Vanclay 2018).", [["Economic displacement", "PROBLEM", 133, 154], ["displacement", "OBSERVATION_MODIFIER", 142, 154], ["extent", "OBSERVATION_MODIFIER", 181, 187], ["kinds", "OBSERVATION_MODIFIER", 192, 197], ["social impacts", "OBSERVATION", 201, 215]]], ["People displaced by projects (whether physically or economically) experience multidimensional stress, i.e. stress in physiological, psychological and sociocultural terms, and stress in every aspect of life (Scudder & Colson 1982; Vanclay 2017a).", [["People", "ORGANISM", 0, 6], ["People", "SPECIES", 0, 6], ["multidimensional stress", "PROBLEM", 77, 100]]], ["An inverse relationship exists between the extent of participation of affected people in the project and the level of stress they suffer (Wilmsen & Webber 2015).University social responsibility and international standardsAll organisations (including universities) are expected to observe human rights (United Nations 2011) and various other international standards, and they should contribute to shared value (Vanclay & Hanna 2019).", [["people", "ORGANISM", 79, 85], ["human", "ORGANISM", 288, 293], ["people", "SPECIES", 79, 85], ["human", "SPECIES", 288, 293], ["human", "SPECIES", 288, 293], ["extent", "OBSERVATION_MODIFIER", 43, 49]]], ["In short, key aspects of international standards are that: projects should not create harm; people should not be made worse off; where physical or economic displacement occurs, affected people must be properly compensated; people must be adequately informed about the planned developments and have the ability to put their point of view across; and appropriate and effective grievance redress mechanisms must be implemented (Vanclay & Hanna 2019).University social responsibility and international standardsA significant consideration is that all organisations (private and public, thus including universities) are generally expected to consider human rights and other ESG issues throughout their whole supply chain.", [["people", "ORGANISM", 92, 98], ["people", "ORGANISM", 186, 192], ["people", "ORGANISM", 223, 229], ["human", "ORGANISM", 646, 651], ["people", "SPECIES", 92, 98], ["people", "SPECIES", 186, 192], ["people", "SPECIES", 223, 229], ["human", "SPECIES", 646, 651], ["human", "SPECIES", 646, 651], ["economic displacement", "PROBLEM", 147, 168], ["human rights", "TREATMENT", 646, 658], ["other ESG issues", "PROBLEM", 663, 679], ["significant", "OBSERVATION_MODIFIER", 509, 520]]], ["Principle 13 of the United Nations Guiding Principles on Business and Human Rights states that business enterprises and other organisations must \u201cseek to prevent or mitigate adverse human rights impacts that are directly linked to their operations, products or services by their business relationships, even if they have not contributed to those impacts\u201d (United Nations 2011 p.14).", [["Human", "ORGANISM", 70, 75], ["human", "ORGANISM", 182, 187], ["Human", "SPECIES", 70, 75], ["human", "SPECIES", 182, 187], ["human", "SPECIES", 182, 187]]], ["Organisations are expected to apply leverage to their business partners, including States, to ensure that there are no human rights harms anywhere in their supply chain.", [["human", "ORGANISM", 119, 124], ["human", "SPECIES", 119, 124], ["human", "SPECIES", 119, 124]]], ["All organisations are expected to have responsible sourcing policies and procedures in place (Vanclay & Hanna 2019).University social responsibility and international standardsCSR is usually considered to be the voluntary commitments (i.e. above minimum legal requirements) that are made by a business or other organisation to manage social and environmental issues and to improve the quality of life of host communities and employees (Dahlsrud 2008).", [["procedures", "TREATMENT", 73, 83]]], ["In developing countries, especially now after the introduction of modern slavery legislation in some countries, concern has primarily focussed on labour standards and workplace human rights issues (Gold et al. 2015; Jamali & Karam 2016; Nguyen et al. 2018), without considering the full range of issues (van der Ploeg & Vanclay, 2017; 2018).", [["human", "ORGANISM", 177, 182], ["human", "SPECIES", 177, 182], ["human", "SPECIES", 177, 182], ["modern slavery legislation", "TREATMENT", 66, 92]]], ["By analysing a case of a transnational university in China, even if it was only an institutional upgrading, we reveal how little consideration was given to issues such as economic displacement.MethodsUsing a case study approach, we studied the development of the University of Groningen Yantai campus from prior to its inception to after its cancellation in 2018.", [["economic displacement", "PROBLEM", 171, 192], ["economic displacement", "OBSERVATION", 171, 192]]], ["UGY was to be located in the City of Yantai, a coastal city of 7 million people in the Shandong Province of China.", [["UGY", "CHEMICAL", 0, 3], ["people", "ORGANISM", 73, 79], ["people", "SPECIES", 73, 79]]], ["A multi-methods approach to collecting data was used involving document analysis, a review of media reports, key informant interviews, and field observation.", [["A multi-methods approach", "TREATMENT", 0, 24], ["collecting data", "TEST", 28, 43], ["field observation", "TEST", 139, 156]]], ["We reviewed all relevant internal documents that we were able to access from the various institutional partners \u2013 University of Groningen (UG), China Agricultural University (CAU), China Agricultural University Yantai (CAUY), Yantai Agricultural Secondary School (YASS), and the Yantai City Council (YCC) \u2013 including documents provided to us by our research contacts.MethodsIn total, 101 people were interviewed.", [["people", "ORGANISM", 388, 394], ["people", "SPECIES", 388, 394]]], ["He was born and raised in Qingdao, near Yantai, and thus he understands the local dialect.", [["He", "ORGANISM", 0, 2]]], ["Where possible and/or appropriate, data were triangulated and/or cross-checked.The evolution of the Yantai campusThere have been two upgrades at the Yantai site, the first (circa 2002) was from the Yantai Agricultural Secondary School (YASS) to the China Agricultural University Yantai (CAUY); and the second (circa 2015) was to have been from CAUY to UGY.", [["two", "OBSERVATION_MODIFIER", 129, 132], ["upgrades", "OBSERVATION", 133, 141]]], ["An important difference between the two upgrades was that in the first, YASS employees retained their jobs at CAUY (although technically they remained employed by YASS), but in the second upgrade to UGY, most employees would have been made redundant (retrenched), thus the creation of the UGY campus would have caused economic displacement.", [["economic displacement", "PROBLEM", 318, 339], ["important", "OBSERVATION_MODIFIER", 3, 12], ["difference", "OBSERVATION_MODIFIER", 13, 23], ["economic displacement", "OBSERVATION", 318, 339]]], ["The upgrade to UGY would also have caused many other social impacts.", [["UGY", "CHEMICAL", 15, 18], ["social impacts", "OBSERVATION", 53, 67]]], ["Furthermore, the failure to proceed with the UGYplans also caused many social impacts (Chen et al. 2019).The evolution of the Yantai campusThe long history of the development of the Yantai campus was partly responsible for many of the social impacts that had already been created and that would be created into the future.", [["UGYplans", "DISEASE", 45, 53], ["the failure", "PROBLEM", 13, 24], ["failure", "OBSERVATION", 17, 24]]], ["To further assist the CAUY project, YCC, which was responsible for YASS, required YASS to relinquish its land holding, and YASS employees were required to work simultaneously for CAUY and YASS.The evolution of the Yantai campusA change in the CAU Board around 2007 led to the CAUY plan being postponed indefinitely.", [["YASS", "TREATMENT", 82, 86], ["the Yantai campusA change", "PROBLEM", 210, 235], ["the CAUY plan", "TREATMENT", 272, 285], ["Yantai campusA", "OBSERVATION", 214, 228]]], ["CAU together with YCC were thus left with an underutilised established campus in Yantai.", [["YCC", "CANCER", 18, 21], ["left", "ANATOMY_MODIFIER", 32, 36]]], ["After considering various options, and given the favourable national situation, from 2010 on, CAU and YCC searched for a foreign university to take over the campus.", [["a foreign university", "TREATMENT", 119, 139]]], ["When UG cancelled its UGY plans (Jan 2018), there was only very limited distribution of this information in Yantai, and even two years later many local people were not aware that UGY had been cancelled.", [["UGY", "CHEMICAL", 179, 182], ["people", "ORGANISM", 152, 158], ["people", "SPECIES", 152, 158]]], ["Some employees of CAUY and YCC became confused by the varying and sometimes contradictory information, and when we checked with our sources in early 2020, they indicated that many people in Yantai were still uncertain about the situation.The evolution of the Yantai campusIn 2018, around 300 people worked at CAUY, including about 100 so-called academic staff and 200 administrative staff.", [["people", "ORGANISM", 180, 186], ["people", "SPECIES", 180, 186], ["people", "SPECIES", 292, 298], ["confused", "PROBLEM", 38, 46]]], ["These students expected high-quality education from highly qualified academic staff.", [["high", "OBSERVATION_MODIFIER", 24, 28]]], ["Therefore, CAUY recruited some new academic staff with higher degrees from more reputable institutions.", [["higher degrees", "OBSERVATION_MODIFIER", 55, 69]]], ["This affected their wellbeing (especially their personal sense of security of employment), and led to them being reluctant to speak up within their own organisation about the developments.The evolution of the Yantai campusThe main source of revenue for CAUY was student tuition fees.", [["main", "OBSERVATION_MODIFIER", 226, 230]]], ["With the restriction on recruiting students, for several years CAUY became trapped in a financial crisis, as it had massive capital costs it had to pay off relating to a campus constructed for a much larger number of students.", [["a financial crisis", "PROBLEM", 86, 104], ["massive capital costs", "PROBLEM", 116, 137]]], ["The low student-to-staff ratio, together with repayments and maintenance on the buildings, was a huge burden for CAUY.", [["repayments", "TREATMENT", 46, 56]]], ["We were told that CAUY was defaulting on its repayments, and that employees (CAUY and YASS) had not received their full salary entitlements.The evolution of the Yantai campusThere were many unused buildings.", [["many", "OBSERVATION_MODIFIER", 185, 189], ["unused buildings", "OBSERVATION", 190, 206]]], ["Worse still, from a local employee perspective, was that the rental income was not used to pay the YASS bonuses or the salary of CAUY employees, rather the money was used to repay debts.The evolution of the Yantai campusUGY was going to hire academic employees based on stringent quality requirements, including English language skills.", [["the Yantai campusUGY", "PROBLEM", 203, 223]]], ["Although UGY might give priority to existing employees, the CAUY and YASS employees had no confidence they would get jobs, since most of them could not speak English (and in fact some could not even speak Mandarin!), and did not have a PhD or appropriate academic achievement (publications, teaching experience in English etc).", [["UGY", "CHEMICAL", 9, 12]]], ["In order to meet the UGY expectations, current employees needed additional training and would need to work harder, even though their salary would not be significantly higher than their current salary.The evolution of the Yantai campusDue to uncertainty about the future and arrears in the payment of wages, about 20 of the 100 CAUY employees resigned between 2009 and 2018.", [["additional training", "TREATMENT", 64, 83], ["the Yantai campusDue", "PROBLEM", 217, 237]]], ["Other employees, however, had only limited employment options.The evolution of the Yantai campusSince the establishment of UGY would influence the leisurely lifestyle of existing employees, most had negative views about UGY, and privately wanted the proposal to fail.", [["UGY", "CHEMICAL", 123, 126], ["UGY", "CANCER", 123, 126], ["the Yantai campusSince", "TREATMENT", 79, 101]]], ["In 2017, CAUY used the UGY plan as an opportunity to be registered as a legal entity, which meant that employees from CAUY finally had an official institution, although their informal contracts were not revised.Reduction in employment benefits ::: Economic displacement and its social impactsMost former YASS and CAUY employees do not meet the credentials, experience, or English language requirements of UGY2 and therefore will be made redundant.", [["UGY2", "GENE_OR_GENE_PRODUCT", 405, 409], ["UGY2", "PROTEIN", 405, 409], ["Economic displacement", "PROBLEM", 248, 269], ["displacement", "OBSERVATION_MODIFIER", 257, 269]]], ["Even those who meet the minimum requirements will likely be uncompetitive in the international recruitment process UGY2 will implement.", [["UGY2", "SIMPLE_CHEMICAL", 115, 119], ["uncompetitive", "PROBLEM", 60, 73]]], ["As discussed above, former YASS employees will continue to work for YCC, while the CAUY employees will be retrenched.", [["YCC", "DISEASE", 68, 71]]], ["Likely, only a few people will continue to work for UGY2.", [["UGY2", "CHEMICAL", 52, 56], ["people", "ORGANISM", 19, 25], ["UGY2", "GENE_OR_GENE_PRODUCT", 52, 56], ["UGY2", "PROTEIN", 52, 56], ["people", "SPECIES", 19, 25]]], ["The retrenched people will receive some severance pay, but, at least until they find alternative jobs, they will be worse off.", [["people", "ORGANISM", 15, 21], ["people", "SPECIES", 15, 21]]], ["The former YASS employees will retain their jobs, but they will lose their bonus, and will have other changes in their employment conditions.Reduction in employment benefits ::: Economic displacement and its social impactsSalary is not the only point of consideration for employees working at the Yantai campus.", [["Economic displacement", "PROBLEM", 178, 199], ["displacement", "OBSERVATION_MODIFIER", 187, 199]]], ["They will also experience a reduction in non-salary benefits.", [["a reduction in non-salary benefits", "TREATMENT", 26, 60]]], ["For those who will stay on, performance expectations will likely increase, and the nature of their duties will change.Reduction in employment benefits ::: Economic displacement and its social impactsMany academic employees traded on the reputation of CAU by claiming that they were \u201cacademics from CAU, the best agricultural university in China\u201d, even though they actually belonged to another institution with a lower academic ranking (CAUY).", [["Economic displacement", "PROBLEM", 155, 176], ["displacement", "OBSERVATION_MODIFIER", 164, 176]]], ["Although such subterfuge might not work in Beijing (where the other official campuses of CAU were located) or in other big cities with high-level universities, it has worked well in Yantai and many people gained benefit this way.", [["people", "ORGANISM", 198, 204], ["people", "SPECIES", 198, 204]]], ["These spurious benefits will be lost with UGY2.Reduction in employment benefits ::: Economic displacement and its social impactsSome employees who had already reached retirement age could not retire because of the uncertain legal status of CAUY.", [["UGY2", "CHEMICAL", 42, 46], ["UGY2", "CHEMICAL", 42, 46], ["UGY2", "GENE_OR_GENE_PRODUCT", 42, 46], ["UGY2", "PROTEIN", 42, 46], ["Economic displacement", "PROBLEM", 84, 105], ["displacement", "OBSERVATION_MODIFIER", 93, 105]]], ["They would get much less (about 60%) from CAUY than they would have received from a government body like YCC.", [["body", "ANATOMY", 95, 99], ["body", "ORGANISM_SUBDIVISION", 95, 99], ["YCC", "CANCER", 105, 108]]], ["In 2019, there were still some employees of post-retirement age who insisted on working, hoping that YCC would include them in the government system enabling them to get a better retirement package.Decline in social status ::: Economic displacement and its social impactsWorking in a higher education institution is generally considered respectable in China, especially if it is a university with a good reputation, like the China Agricultural University.", [["Economic displacement", "PROBLEM", 227, 248], ["displacement", "OBSERVATION_MODIFIER", 236, 248]]], ["In many people\u2019s opinions, as one employee said, \u201cworking in such a high-level university was much better than working for a company\u201d.", [["people", "ORGANISM", 8, 14], ["people", "SPECIES", 8, 14]]], ["However, most employees will be forced to leave the institution and will experience a decline in their social status.", [["a decline", "PROBLEM", 84, 93]]], ["Many employees, especially those in top positions who have become used to being important, will lose their jobs and/or will become subordinate to new managers in UGY2 or in other organisations, and will suffer from reduced social standing.Decline in social status ::: Economic displacement and its social impactsAnother issue is that, in CAUY, the ratio of manager to staff was high.", [["Economic displacement", "PROBLEM", 268, 289], ["displacement", "OBSERVATION_MODIFIER", 277, 289]]], ["Because of the low number of students, each academic department and service division had a Head, but only a few staff.", [["Head", "ANATOMY", 91, 95]]], ["It is likely that many of them will not find equivalent management positions in other institutions.", [["is likely", "UNCERTAINTY", 3, 12]]], ["It might be hard for them to adjust to this change in their function.Impacts on health and wellbeing ::: Economic displacement and its social impactsBecause of the small number of students and a degree of over-staffing, employees at Yantai campus had been used to a leisurely style of working.", [["Economic displacement", "PROBLEM", 105, 126], ["displacement", "OBSERVATION_MODIFIER", 114, 126], ["small", "OBSERVATION_MODIFIER", 164, 169], ["number", "OBSERVATION_MODIFIER", 170, 176]]], ["With the establishment of UGY2, employees will work either in UGY2 or in a company, and they will have to give more attention and energy to their new job than they did in the past.", [["UGY2", "CHEMICAL", 62, 66], ["UGY2", "GENE_OR_GENE_PRODUCT", 26, 30]]], ["This increased work burden and associated stress will have negative impacts on their health.Impacts on health and wellbeing ::: Economic displacement and its social impactsSome younger academics from CAUY tried to improve their skills and/or get a PhD so that they might be more competitive in applying for new jobs.", [["This increased work burden", "PROBLEM", 0, 26], ["Economic displacement", "PROBLEM", 128, 149], ["displacement", "OBSERVATION_MODIFIER", 137, 149]]], ["Because of the uncertainty, and the fact that employees would be competing with each other for future jobs, they were not sure about who they could trust, which impacted on their social relationships.Impacts on health and wellbeing ::: Economic displacement and its social impactsMany employees were in their 40s or 50s, and had enjoyed being the affluent middle class of Yantai for many years.", [["Economic displacement", "PROBLEM", 236, 257], ["displacement", "OBSERVATION_MODIFIER", 245, 257]]], ["The establishment of UGY2 will make them unemployed and force them to become job seekers.", [["UGY2", "GENE_OR_GENE_PRODUCT", 21, 25], ["UGY2", "PROTEIN", 21, 25]]], ["For people who previously had management positions, the feeling of a loss of power will be considerable.", [["people", "ORGANISM", 4, 10], ["people", "SPECIES", 4, 10], ["management positions", "TREATMENT", 30, 50], ["a loss of power", "PROBLEM", 67, 82]]], ["All this stress will influence their mental health and general wellbeing.Conflicts within the family ::: Economic displacement and its social impactsWorking at CAUY had various advantages, such as being able to leave work early to pick up children from school, a chance to have contact with famous academics, being familiar with the Chinese educational system and knowing how to work the system for the advantage of one\u2019s own children.", [["children", "ORGANISM", 239, 247], ["children", "ORGANISM", 426, 434], ["children", "SPECIES", 239, 247], ["children", "SPECIES", 426, 434], ["Economic displacement", "PROBLEM", 105, 126], ["displacement", "OBSERVATION_MODIFIER", 114, 126]]], ["Depression from stress and lost social status will also lead to a decline in social relationships within the family.Social responsibility considerationsThe plans for a campus at Yantai have caused and will continue to cause economic displacement, and many various social impacts on existing employees and the wider community.", [["Depression", "DISEASE", 0, 10], ["Depression", "PROBLEM", 0, 10], ["stress", "PROBLEM", 16, 22], ["economic displacement", "PROBLEM", 224, 245]]], ["Many of these impacts also affected how people make their living.", [["people", "ORGANISM", 40, 46], ["people", "SPECIES", 40, 46]]], ["Since many employees were middle-aged, the economic displacement will seriously influence their life.", [["the economic displacement", "PROBLEM", 39, 64]]], ["Although physical displacement of some local people happened with the creation of the high-tech zone before the appointment of staff to CAUY (Chen et al. 2019), existing employees have experienced several rounds of potential economic displacement.", [["people", "ORGANISM", 45, 51], ["people", "SPECIES", 45, 51], ["potential economic displacement", "PROBLEM", 215, 246], ["displacement", "OBSERVATION_MODIFIER", 18, 30], ["some", "OBSERVATION_MODIFIER", 34, 38], ["local", "OBSERVATION_MODIFIER", 39, 44], ["economic displacement", "OBSERVATION", 225, 246]]], ["They have had to withstand much stress, and if they could not adequately cope, they became depressed and alienated.", [["depressed", "DISEASE", 91, 100], ["depressed", "PROBLEM", 91, 100]]], ["Clearly, there are human rights, CSR and ESG issues that the various institutions should have considered more seriously.Social responsibility considerationsAlthough most employees claimed to be supportive of the UGY project in public, many expressed adverse views in private.", [["human", "ORGANISM", 19, 24], ["human", "SPECIES", 19, 24], ["human", "SPECIES", 19, 24]]], ["Perhaps they expected other parties (e.g. YCC) to address the issues, but even then they would be negligent in failing to ensure that there were no ESG issues throughout the supply chain.", [["ESG issues", "PROBLEM", 148, 158]]], ["A supply chain analysis of any organisation must include, not only consideration of who was displaced by land acquisition, but also of those who were economically displaced by the project (Vanclay 2017a, 2017b; Vanclay & Hanna 2019).", [["A supply chain analysis", "TEST", 0, 23], ["chain", "OBSERVATION_MODIFIER", 9, 14]]], ["The grand plan for the Yantai site only considered the local community, but not the interests of the employees in the pre-existing institutions.", [["the Yantai site", "PROBLEM", 19, 34]]], ["Although UGY2 might still be achieved, the lack of consideration of economic displacement and its social consequences has and will create many social impacts.Social responsibility considerationsOne specific element of the failure of the various institutions was that no grievance redress mechanism was implemented.", [["UGY2", "CHEMICAL", 9, 13], ["UGY2", "GENE_OR_GENE_PRODUCT", 9, 13], ["UGY2", "PROTEIN", 9, 13], ["UGY2", "TEST", 9, 13], ["economic displacement", "PROBLEM", 68, 89], ["failure", "OBSERVATION", 222, 229]]], ["Principle 29 of the United Nations Guiding Principles on Business and Human Rights (United Nations 2011, p.31) indicates that organisations \u201cshould establish or participate in effective operational-level grievance mechanisms for individuals and communities who may be adversely impacted\u201d.", [["Human", "ORGANISM", 70, 75], ["Human", "SPECIES", 70, 75]]], ["The lack of adequate compensation for losses was also an issue that would make this situation at odds with international standards.ConclusionThe upgrading of higher education institutions is likely to create economic displacement and/or cause other social impacts on existing employees, potentially including a reduction in their income, a decline in their social status, impacts on their health and wellbeing, family conflict, and other impacts.", [["economic displacement", "PROBLEM", 208, 229], ["adequate compensation", "OBSERVATION", 12, 33]]], ["In the case of the University of Groningen Yantai campus, the existing employees had little opportunity to express their views, and they struggled to cope with economic displacement and its social impacts.", [["economic displacement", "PROBLEM", 160, 181]]], ["There was no grievance redress mechanism in place.", [["no", "UNCERTAINTY", 10, 12]]], ["Development projects and institutional upgrading processes happen everywhere in the world.", [["institutional upgrading processes", "TREATMENT", 25, 58]]], ["The potential for economic displacement, with impacts on people\u2019s livelihoods and income-generating activities, exists in most projects.", [["people", "ORGANISM", 57, 63], ["people", "SPECIES", 57, 63], ["economic displacement", "PROBLEM", 18, 39], ["potential for", "UNCERTAINTY", 4, 17], ["economic displacement", "OBSERVATION", 18, 39]]], ["If managed properly, it is possible to reduce the negative social impacts created by economic displacement, and to increase the benefits from projects.", [["economic displacement", "PROBLEM", 85, 106]]], ["If not managed properly, local people will suffer from various social impacts, and organisations will be at risk of being in breach of human rights, international standards, ESG obligations and CSR expectations.", [["people", "ORGANISM", 31, 37], ["human", "ORGANISM", 135, 140], ["people", "SPECIES", 31, 37], ["human", "SPECIES", 135, 140], ["human", "SPECIES", 135, 140]]], ["Therefore, project developers need to fully consider the impacts on employees in order to meet international standards and fulfil expectations about their duty to perform CSR and observe ESG.ConclusionA project can interfere with people\u2019s normal life and create social impacts even when it is cancelled or postponed.", [["people", "ORGANISM", 230, 236], ["people", "SPECIES", 230, 236]]], ["People make plans based on the information they believe to be true, including on the basis of rumours.", [["People", "ORGANISM", 0, 6], ["People", "SPECIES", 0, 6]]], ["Organisations are responsible for ensuring that employees are clearly and timely informed of plans, and of any changes to plans.ConclusionCompared to physical displacement, economic displacement has received much less attention and is under-considered in project development generally.", [["physical displacement", "PROBLEM", 150, 171], ["economic displacement", "PROBLEM", 173, 194], ["displacement", "OBSERVATION_MODIFIER", 159, 171], ["economic", "OBSERVATION_MODIFIER", 173, 181], ["displacement", "OBSERVATION_MODIFIER", 182, 194]]], ["Nevertheless, economic displacement has major impacts on people.", [["people", "ORGANISM", 57, 63], ["people", "SPECIES", 57, 63], ["economic displacement", "PROBLEM", 14, 35], ["displacement", "OBSERVATION_MODIFIER", 23, 35], ["major", "OBSERVATION_MODIFIER", 40, 45], ["impacts", "OBSERVATION_MODIFIER", 46, 53]]], ["Economic displacement creates social impacts not only on local residents, but also on existing employees.", [["Economic displacement", "PROBLEM", 0, 21], ["displacement", "OBSERVATION_MODIFIER", 9, 21]]], ["Regardless of any compensation that might be provided, their livelihood and lifestyle will be severely affected by an upgrading process.", [["any compensation", "PROBLEM", 14, 30]]], ["It is important that the field of higher education management expand its awareness of social issues, and consider how new universities and the upgrading of institutions potentially bring harm, even though they may also create benefits for local communities.", [["higher education management", "TREATMENT", 34, 61]]]], "PMC7294072": [["As a consequence, there is a risk that attention is diverted from other important issues, some having implications for the UK's ability to mount an effective response to the pandemic.", [["UK", "GENE_OR_GENE_PRODUCT", 123, 125], ["the pandemic", "PROBLEM", 170, 182]]], ["The worst outcomes for health have been avoided so far, by the entry into force of the Withdrawal Agreement on 1 February 2020, a formal international treaty that establishes a transition period during which the UK is no longer an EU Member State but both parties agree to apply most EU law and policy as if it were.", [["no longer", "UNCERTAINTY", 218, 227]]], ["Despite the disruption caused by the spread of the virus and increasing voices calling for an extension to the transition period, the UK government has rejected asking for one and, as things currently stand, the UK's relationship with the EU will be on a \u2018No Deal\u2019 basis if an agreement is not in place by 31 December 2020.IntroductionWhile the EU\u2212UK agreement(s) will primarily concern trade, with health a peripheral matter at best, trade agreements have important consequences for health (Gleeson and Labonte, 2019), and, as our previous analyses showed (Fahy et al., 2017, 2019) although all forms of Brexit are bad for health, some forms are worse than others.IntroductionThis analysis considers the formal negotiating positions of the EU and the UK.", [["UK", "GENE_OR_GENE_PRODUCT", 752, 754], ["the disruption", "PROBLEM", 8, 22], ["the virus", "PROBLEM", 47, 56], ["increasing voices", "PROBLEM", 61, 78], ["This analysis", "TEST", 677, 690], ["disruption", "OBSERVATION", 12, 22]]], ["The EU is negotiating with the UK under its general \u2018external relations\u2019 powers, using a procedure which gives power both to the European Parliament and to domestic parliaments in the 27 Member States.", [["a procedure", "TREATMENT", 87, 98]]], ["The UK's position is that it is seeking a \u2018comprehensive free trade agreement\u2019 with the EU, along with a number of other supplementary agreements, some of which would be relevant for health in the UK.IntroductionThe formal negotiations began in the first week of March 2020, but were temporarily halted in mid-March, when both chief negotiators, Michel Barnier and David Frost, tested positive for COVID-19.", [["UK", "GENE_OR_GENE_PRODUCT", 197, 199], ["COVID", "TEST", 398, 403]]], ["This leaves a short window of opportunity during which the implications for health of any agreement should be understood by health policy stakeholders, and appropriate engagement with government (and the EU) should take place.MethodAs in our 2017 and 2019 papers, our method uses the WHO's health system building blocks to assess the likely effects on each aspect of the NHS in the UK.", [["UK", "GENE_OR_GENE_PRODUCT", 382, 384]]], ["This is necessary because of the way that implications of Brexit for health have unfolded.", [["unfolded", "OBSERVATION", 81, 89]]], ["Where the draft legal texts illuminate the negotiating positions, we have included those in our analysis.MethodWe first examine and classify the compatibility of the negotiating positions: compatible, so agreement likely (green); basic aims compatible but differences mean agreement uncertain (yellow); no agreement likely because of fundamental incompatibility of aims (red) (Table 1, column 5).", [["our analysis", "TEST", 92, 104], ["fundamental incompatibility of aims", "PROBLEM", 334, 369]]], ["We categorise these effects as unchanged (grey); positive (green); moderate negative (pink); major negative (red).", [["unchanged", "OBSERVATION_MODIFIER", 31, 40], ["moderate", "OBSERVATION_MODIFIER", 67, 75], ["negative", "OBSERVATION", 76, 84]]], ["To reach this conclusion, we are also comparing with our previous analysis of the Political Declaration (Fahy et al., 2019), also categorised as unchanged (grey); positive (green); moderate negative (pink); major negative (red) (Table 1, column 2), as against the comparative baseline of the UK remaining in the EU.", [["unchanged", "OBSERVATION_MODIFIER", 145, 154], ["moderate", "OBSERVATION_MODIFIER", 181, 189], ["negative", "OBSERVATION", 190, 198]]]], "PMC7097103": [["Phosphatidylserine acquisition by virionsDuring apoptosis, the asymmetrical distribution of phospholipids in the plasma membrane is disrupted, which results in the externalization of phosphatidylserine to the outer leaflet5.", [["plasma membrane", "ANATOMY", 113, 128], ["outer leaflet5", "ANATOMY", 209, 223], ["Phosphatidylserine", "CHEMICAL", 0, 18], ["phosphatidylserine", "CHEMICAL", 183, 201], ["Phosphatidylserine", "CHEMICAL", 0, 18], ["phosphatidylserine", "CHEMICAL", 183, 201], ["Phosphatidylserine", "SIMPLE_CHEMICAL", 0, 18], ["phospholipids", "SIMPLE_CHEMICAL", 92, 105], ["plasma membrane", "CELLULAR_COMPONENT", 113, 128], ["phosphatidylserine", "AMINO_ACID", 183, 201], ["outer leaflet5", "CELLULAR_COMPONENT", 209, 223], ["Phosphatidylserine acquisition", "TREATMENT", 0, 30], ["phospholipids in the plasma membrane", "TEST", 92, 128], ["asymmetrical", "OBSERVATION_MODIFIER", 63, 75], ["distribution", "OBSERVATION_MODIFIER", 76, 88], ["plasma membrane", "ANATOMY", 113, 128], ["externalization", "OBSERVATION_MODIFIER", 164, 179], ["outer", "ANATOMY_MODIFIER", 209, 214], ["leaflet5", "ANATOMY_MODIFIER", 215, 223]]], ["As phosphatidylserine exposure is essential for apoptotic clearance4, the acquisition of this membrane phospholipid during viral assembly is critical for viral apoptotic mimicry.", [["membrane", "ANATOMY", 94, 102], ["phosphatidylserine", "CHEMICAL", 3, 21], ["phosphatidylserine", "CHEMICAL", 3, 21], ["phosphatidylserine", "AMINO_ACID", 3, 21], ["membrane phospholipid", "CELLULAR_COMPONENT", 94, 115], ["apoptotic clearance4", "TREATMENT", 48, 68], ["this membrane phospholipid", "TREATMENT", 89, 115], ["viral apoptotic mimicry", "PROBLEM", 154, 177], ["viral apoptotic mimicry", "OBSERVATION", 154, 177]]], ["The mechanisms by which viruses acquire phosphatidylserine are poorly understood, but possible strategies include hijacking phosphatidylserine-rich cellular membranes by budding from intracellular organelles or the plasma membrane23 (Fig. 1).", [["cellular membranes", "ANATOMY", 148, 166], ["intracellular organelles", "ANATOMY", 183, 207], ["plasma", "ANATOMY", 215, 221], ["phosphatidylserine", "CHEMICAL", 40, 58], ["phosphatidylserine", "CHEMICAL", 124, 142], ["phosphatidylserine", "CHEMICAL", 40, 58], ["phosphatidylserine", "CHEMICAL", 124, 142], ["phosphatidylserine", "SIMPLE_CHEMICAL", 40, 58], ["phosphatidylserine", "SIMPLE_CHEMICAL", 124, 142], ["cellular membranes", "CELLULAR_COMPONENT", 148, 166], ["budding", "CELLULAR_COMPONENT", 170, 177], ["intracellular organelles", "CELLULAR_COMPONENT", 183, 207], ["plasma membrane23", "CELLULAR_COMPONENT", 215, 232], ["hijacking phosphatidylserine", "PROBLEM", 114, 142], ["cellular membranes", "OBSERVATION", 148, 166]]], ["DENV and other flaviviruses derive their membrane from the endoplasmic reticulum (ER) via budding24.", [["membrane", "ANATOMY", 41, 49], ["endoplasmic reticulum", "ANATOMY", 59, 80], ["ER", "ANATOMY", 82, 84], ["DENV", "ORGANISM", 0, 4], ["membrane", "CELLULAR_COMPONENT", 41, 49], ["endoplasmic reticulum", "CELLULAR_COMPONENT", 59, 80], ["ER", "GENE_OR_GENE_PRODUCT", 82, 84], ["ER", "PROTEIN", 82, 84], ["budding24", "PROTEIN", 90, 99], ["DENV", "SPECIES", 0, 4], ["DENV", "PROBLEM", 0, 4], ["other flaviviruses", "PROBLEM", 9, 27], ["flaviviruses", "OBSERVATION", 15, 27], ["endoplasmic reticulum", "OBSERVATION", 59, 80]]], ["The luminal leaflet of the ER membrane is enriched for phosphatidylserine25,26, which suggests a potential mechanism by which flaviviruses acquire this phospholipid.", [["luminal leaflet", "ANATOMY", 4, 19], ["ER membrane", "ANATOMY", 27, 38], ["luminal", "CHEMICAL", 4, 11], ["phosphatidylserine25,26", "CHEMICAL", 55, 78], ["phosphatidylserine", "CHEMICAL", 55, 73], ["luminal leaflet", "MULTI-TISSUE_STRUCTURE", 4, 19], ["ER membrane", "CELLULAR_COMPONENT", 27, 38], ["phosphatidylserine25,26", "GENE_OR_GENE_PRODUCT", 55, 78], ["phospholipid", "SIMPLE_CHEMICAL", 152, 164], ["ER", "PROTEIN", 27, 29], ["phosphatidylserine", "TEST", 55, 73], ["luminal", "ANATOMY_MODIFIER", 4, 11], ["leaflet", "ANATOMY_MODIFIER", 12, 19], ["ER membrane", "ANATOMY", 27, 38]]], ["It has been reported that the membrane of VACV is derived from membrane sheets that are generated by the rupture of ER cisternae27.", [["membrane", "ANATOMY", 30, 38], ["membrane sheets", "ANATOMY", 63, 78], ["ER cisternae27", "ANATOMY", 116, 130], ["membrane", "CELLULAR_COMPONENT", 30, 38], ["VACV", "ORGANISM", 42, 46], ["membrane sheets", "CELLULAR_COMPONENT", 63, 78], ["ER", "GENE_OR_GENE_PRODUCT", 116, 118], ["ER cisternae27", "PROTEIN", 116, 130], ["VACV", "SPECIES", 42, 46], ["the membrane of VACV", "PROBLEM", 26, 46], ["membrane sheets", "TREATMENT", 63, 78], ["VACV", "OBSERVATION", 42, 46], ["rupture", "OBSERVATION", 105, 112]]], ["A recent study of a VACV mutant arrested during membrane formation shows that viral membranes were contiguous with the ER and oriented such that the external leaflet of the viral membrane faced the ER lumen28.", [["membrane", "ANATOMY", 48, 56], ["membranes", "ANATOMY", 84, 93], ["ER", "ANATOMY", 119, 121], ["external leaflet", "ANATOMY", 149, 165], ["membrane", "ANATOMY", 179, 187], ["ER lumen28", "ANATOMY", 198, 208], ["VACV mutant", "ORGANISM", 20, 31], ["membrane", "CELLULAR_COMPONENT", 48, 56], ["membranes", "CELLULAR_COMPONENT", 84, 93], ["ER", "GENE_OR_GENE_PRODUCT", 119, 121], ["membrane", "CELLULAR_COMPONENT", 179, 187], ["ER", "GENE_OR_GENE_PRODUCT", 198, 200], ["VACV mutant", "PROTEIN", 20, 31], ["ER", "PROTEIN", 119, 121], ["ER lumen28", "PROTEIN", 198, 208], ["VACV", "SPECIES", 20, 24], ["A recent study", "TEST", 0, 14], ["a VACV mutant arrested", "PROBLEM", 18, 40], ["viral membranes", "PROBLEM", 78, 93], ["viral membranes", "OBSERVATION", 78, 93], ["external leaflet", "ANATOMY", 149, 165], ["viral membrane", "OBSERVATION", 173, 187]]], ["These findings further indicate that the phosphatidylserine-rich luminal leaflet of the ER becomes the external leaflet of the viral membrane.", [["luminal leaflet", "ANATOMY", 65, 80], ["ER", "ANATOMY", 88, 90], ["external leaflet", "ANATOMY", 103, 119], ["membrane", "ANATOMY", 133, 141], ["phosphatidylserine", "CHEMICAL", 41, 59], ["luminal", "CHEMICAL", 65, 72], ["phosphatidylserine", "CHEMICAL", 41, 59], ["phosphatidylserine", "SIMPLE_CHEMICAL", 41, 59], ["luminal leaflet", "CELLULAR_COMPONENT", 65, 80], ["ER", "GENE_OR_GENE_PRODUCT", 88, 90], ["external leaflet", "CELLULAR_COMPONENT", 103, 119], ["viral membrane", "CELLULAR_COMPONENT", 127, 141], ["ER", "PROTEIN", 88, 90], ["the phosphatidylserine", "TEST", 37, 59], ["rich", "ANATOMY_MODIFIER", 60, 64], ["luminal", "ANATOMY_MODIFIER", 65, 72], ["leaflet", "ANATOMY_MODIFIER", 73, 80], ["external leaflet", "OBSERVATION", 103, 119], ["viral membrane", "OBSERVATION", 127, 141]]], ["Such a mechanism would explain how VACV and other poxviruses obtain a phosphatidylserine-rich membrane.", [["membrane", "ANATOMY", 94, 102], ["phosphatidylserine", "CHEMICAL", 70, 88], ["phosphatidylserine", "CHEMICAL", 70, 88], ["VACV", "ORGANISM", 35, 39], ["phosphatidylserine", "SIMPLE_CHEMICAL", 70, 88], ["rich membrane", "CELLULAR_COMPONENT", 89, 102], ["VACV", "SPECIES", 35, 39], ["VACV", "PROBLEM", 35, 39], ["a phosphatidylserine-rich membrane", "TREATMENT", 68, 102]]], ["Several enveloped viruses that use apoptotic mimicry, such as EBOV and Marburg virus (MARV), have been suggested to bud from plasma membrane microdomains called lipid rafts, which are highly enriched for phosphatidylserine in the external leaflet29,30.", [["bud", "ANATOMY", 116, 119], ["plasma membrane microdomains", "ANATOMY", 125, 153], ["lipid rafts", "ANATOMY", 161, 172], ["phosphatidylserine", "CHEMICAL", 204, 222], ["phosphatidylserine", "CHEMICAL", 204, 222], ["EBOV", "ORGANISM", 62, 66], ["Marburg virus", "ORGANISM", 71, 84], ["MARV", "ORGANISM", 86, 90], ["plasma", "ORGANISM_SUBSTANCE", 125, 131], ["membrane microdomains", "CELLULAR_COMPONENT", 132, 153], ["lipid rafts", "CELLULAR_COMPONENT", 161, 172], ["phosphatidylserine", "SIMPLE_CHEMICAL", 204, 222], ["Marburg virus", "SPECIES", 71, 84], ["EBOV", "SPECIES", 62, 66], ["Marburg virus", "SPECIES", 71, 84], ["MARV", "SPECIES", 86, 90], ["Several enveloped viruses", "PROBLEM", 0, 25], ["apoptotic mimicry", "PROBLEM", 35, 52], ["EBOV", "PROBLEM", 62, 66], ["Marburg virus", "PROBLEM", 71, 84], ["lipid rafts", "TREATMENT", 161, 172], ["phosphatidylserine", "TREATMENT", 204, 222], ["enveloped", "OBSERVATION_MODIFIER", 8, 17], ["viruses", "OBSERVATION", 18, 25], ["lipid rafts", "OBSERVATION", 161, 172]]], ["Infection by many viruses triggers apoptosis of the target cell; thus, it is likely that these viruses acquire phosphatidylserine by budding from the surface of apoptotic cells, as has been suggested for the arenavirus Pichinde virus (PICV)31.", [["cell", "ANATOMY", 59, 63], ["surface", "ANATOMY", 150, 157], ["cells", "ANATOMY", 171, 176], ["phosphatidylserine", "CHEMICAL", 111, 129], ["phosphatidylserine", "CHEMICAL", 111, 129], ["cell", "CELL", 59, 63], ["phosphatidylserine", "SIMPLE_CHEMICAL", 111, 129], ["surface", "CELLULAR_COMPONENT", 150, 157], ["cells", "CELL", 171, 176], ["arenavirus Pichinde virus", "ORGANISM", 208, 233], ["target cell", "CELL_TYPE", 52, 63], ["apoptotic cells", "CELL_TYPE", 161, 176], ["arenavirus Pichinde virus", "SPECIES", 208, 233], ["arenavirus Pichinde virus", "SPECIES", 208, 233], ["PICV", "SPECIES", 235, 239], ["Infection", "PROBLEM", 0, 9], ["many viruses", "PROBLEM", 13, 25], ["the target cell", "PROBLEM", 48, 63], ["these viruses acquire phosphatidylserine", "PROBLEM", 89, 129], ["apoptotic cells", "PROBLEM", 161, 176], ["the arenavirus Pichinde virus (PICV)", "TREATMENT", 204, 240], ["many", "OBSERVATION_MODIFIER", 13, 17], ["viruses", "OBSERVATION", 18, 25], ["target cell", "OBSERVATION", 52, 63], ["is likely", "UNCERTAINTY", 74, 83], ["viruses", "OBSERVATION", 95, 102], ["apoptotic cells", "OBSERVATION", 161, 176]]], ["In lieu of inducing apoptosis, cell surface phosphatidylserine exposure may be the consequence of a virus-induced increase in intracellular calcium concentrations32.", [["cell surface", "ANATOMY", 31, 43], ["intracellular", "ANATOMY", 126, 139], ["phosphatidylserine", "CHEMICAL", 44, 62], ["calcium", "CHEMICAL", 140, 147], ["phosphatidylserine", "CHEMICAL", 44, 62], ["calcium", "CHEMICAL", 140, 147], ["cell", "CELL", 31, 35], ["phosphatidylserine", "AMINO_ACID", 44, 62], ["intracellular", "IMMATERIAL_ANATOMICAL_ENTITY", 126, 139], ["calcium", "SIMPLE_CHEMICAL", 140, 147], ["inducing apoptosis", "PROBLEM", 11, 29], ["cell surface phosphatidylserine exposure", "TREATMENT", 31, 71], ["a virus", "PROBLEM", 98, 105], ["intracellular calcium concentrations", "TEST", 126, 162], ["apoptosis", "OBSERVATION", 20, 29], ["cell", "OBSERVATION", 31, 35], ["surface phosphatidylserine exposure", "OBSERVATION", 36, 71]]], ["This rise in calcium levels can inactivate lipid flippases \u2014 proteins that translocate phospholipids between membrane leaflets and thus maintain phosphatidylserine asymmetry \u2014 and result in phosphatidylserine externalization33.", [["membrane leaflets", "ANATOMY", 109, 126], ["calcium", "CHEMICAL", 13, 20], ["phosphatidylserine", "CHEMICAL", 145, 163], ["phosphatidylserine", "CHEMICAL", 190, 208], ["calcium", "CHEMICAL", 13, 20], ["phosphatidylserine", "CHEMICAL", 145, 163], ["phosphatidylserine", "CHEMICAL", 190, 208], ["calcium", "SIMPLE_CHEMICAL", 13, 20], ["phospholipids", "SIMPLE_CHEMICAL", 87, 100], ["membrane leaflets", "CELLULAR_COMPONENT", 109, 126], ["phosphatidylserine", "AMINO_ACID", 145, 163], ["phosphatidylserine externalization33", "SIMPLE_CHEMICAL", 190, 226], ["calcium levels", "TEST", 13, 27], ["lipid flippases", "PROBLEM", 43, 58], ["phospholipids between membrane leaflets", "TREATMENT", 87, 126], ["phosphatidylserine asymmetry", "PROBLEM", 145, 173], ["phosphatidylserine externalization33", "TREATMENT", 190, 226], ["phosphatidylserine asymmetry", "OBSERVATION", 145, 173]]], ["It is likely that enveloped and non-enveloped viruses alike would be able to exploit such a mechanism; however, as there is no literature to support this theory, it remains to be determined whether viruses use this strategy to acquire phosphatidylserine.Host cell entry via apoptotic mimicryMany of the viruses that have been reported to use apoptotic mimicry do so to facilitate host cell entry (Table 1).", [["cell", "ANATOMY", 259, 263], ["cell", "ANATOMY", 385, 389], ["phosphatidylserine", "CHEMICAL", 235, 253], ["phosphatidylserine", "CHEMICAL", 235, 253], ["phosphatidylserine", "SIMPLE_CHEMICAL", 235, 253], ["Host cell", "CELL", 254, 263], ["host cell", "CELL", 380, 389], ["non-enveloped viruses", "PROBLEM", 32, 53], ["this strategy", "TREATMENT", 210, 223], ["phosphatidylserine", "TREATMENT", 235, 253], ["the viruses", "PROBLEM", 299, 310], ["likely that", "UNCERTAINTY", 6, 17], ["non-enveloped", "OBSERVATION_MODIFIER", 32, 45], ["viruses", "OBSERVATION", 46, 53], ["cell entry", "OBSERVATION", 259, 269], ["apoptotic mimicry", "OBSERVATION", 274, 291], ["viruses", "OBSERVATION", 303, 310]]], ["As mentioned above, divergent mechanisms of apoptotic mimicry have been described, so we introduce the terms classic and non-classic apoptotic mimicry.", [["apoptotic mimicry", "PROBLEM", 44, 61], ["apoptotic mimicry", "OBSERVATION", 44, 61], ["non-classic apoptotic mimicry", "OBSERVATION", 121, 150]]], ["Classic apoptotic mimicry refers to an enveloped virus that exposes phosphatidylserine on the external leaflet of its membrane to engage phosphatidylserine receptors for uptake and/or immunomodulatory purposes.", [["external leaflet", "ANATOMY", 94, 110], ["membrane", "ANATOMY", 118, 126], ["phosphatidylserine", "CHEMICAL", 68, 86], ["phosphatidylserine", "CHEMICAL", 137, 155], ["phosphatidylserine", "CHEMICAL", 68, 86], ["phosphatidylserine", "CHEMICAL", 137, 155], ["phosphatidylserine", "AMINO_ACID", 68, 86], ["external leaflet", "CELLULAR_COMPONENT", 94, 110], ["membrane", "CELLULAR_COMPONENT", 118, 126], ["phosphatidylserine receptors", "GENE_OR_GENE_PRODUCT", 137, 165], ["phosphatidylserine receptors", "PROTEIN", 137, 165], ["Classic apoptotic mimicry", "PROBLEM", 0, 25], ["an enveloped virus", "PROBLEM", 36, 54], ["phosphatidylserine receptors", "TREATMENT", 137, 165], ["uptake", "PROBLEM", 170, 176], ["immunomodulatory purposes", "TEST", 184, 209], ["apoptotic mimicry", "OBSERVATION", 8, 25], ["virus", "OBSERVATION", 49, 54], ["external leaflet", "ANATOMY", 94, 110]]], ["Conversely, non-classic apoptotic mimicry refers to a non-enveloped virus that, through the use of mimicry or host membrane hijacking, engages apoptotic clearance receptors to infect cells.Host cell entry via apoptotic mimicryClassic apoptotic mimicry.", [["membrane", "ANATOMY", 115, 123], ["cells", "ANATOMY", 183, 188], ["cell", "ANATOMY", 194, 198], ["membrane", "CELLULAR_COMPONENT", 115, 123], ["cells", "CELL", 183, 188], ["Host cell", "CELL", 189, 198], ["apoptotic clearance receptors", "PROTEIN", 143, 172], ["a non-enveloped virus", "PROBLEM", 52, 73], ["host membrane hijacking", "TREATMENT", 110, 133], ["apoptotic mimicry", "OBSERVATION", 24, 41], ["host membrane", "OBSERVATION", 110, 123], ["infect cells", "OBSERVATION", 176, 188], ["cell entry", "OBSERVATION", 194, 204], ["apoptotic mimicry", "OBSERVATION", 209, 226], ["apoptotic mimicry", "OBSERVATION", 234, 251]]], ["Viruses hijack various endocytic mechanisms of a host cell for internalization (reviewed in Ref.", [["cell", "ANATOMY", 54, 58], ["host cell", "CELL", 49, 58], ["endocytic mechanisms", "OBSERVATION", 23, 43], ["host cell", "OBSERVATION", 49, 58]]], ["Clathrin-mediated endocytosis (CME) and macropinocytosis (reviewed in Ref.", [["Clathrin", "GENE_OR_GENE_PRODUCT", 0, 8], ["Clathrin", "PROTEIN", 0, 8], ["Clathrin-mediated endocytosis", "PROBLEM", 0, 29], ["macropinocytosis", "PROBLEM", 40, 56], ["endocytosis", "OBSERVATION_MODIFIER", 18, 29]]], ["35) are the two most common host mechanisms that are subverted for virus entry.", [["virus entry", "PROBLEM", 67, 78]]], ["CME is a constitutive process driven by the formation of clathrin-coated vesicles with a diameter of 100 nm.", [["vesicles", "ANATOMY", 73, 81], ["clathrin", "GENE_OR_GENE_PRODUCT", 57, 65], ["vesicles", "CELLULAR_COMPONENT", 73, 81], ["clathrin", "PROTEIN", 57, 65], ["a constitutive process", "PROBLEM", 7, 29], ["constitutive process", "OBSERVATION", 9, 29], ["diameter", "OBSERVATION_MODIFIER", 89, 97], ["100 nm", "OBSERVATION_MODIFIER", 101, 107]]], ["During macropinocytosis, which is not constitutive and requires induction, a large volume of extracellular material is endocytosed in macropinosomes, which are vesicles with a diameter of up to 10 \u03bcm that form without a coat35,36.", [["extracellular material", "ANATOMY", 93, 115], ["macropinosomes", "ANATOMY", 134, 148], ["vesicles", "ANATOMY", 160, 168], ["extracellular material", "CELLULAR_COMPONENT", 93, 115], ["macropinosomes", "GENE_OR_GENE_PRODUCT", 134, 148], ["vesicles", "CELLULAR_COMPONENT", 160, 168], ["coat35,36", "PROTEIN", 220, 229], ["macropinocytosis", "PROBLEM", 7, 23], ["induction", "TREATMENT", 64, 73], ["a large volume of extracellular material", "PROBLEM", 75, 115], ["a coat", "TEST", 218, 224], ["macropinocytosis", "OBSERVATION", 7, 23], ["not", "UNCERTAINTY", 34, 37], ["constitutive", "OBSERVATION_MODIFIER", 38, 50], ["large", "OBSERVATION_MODIFIER", 77, 82], ["volume", "OBSERVATION_MODIFIER", 83, 89], ["extracellular material", "OBSERVATION", 93, 115], ["endocytosed", "OBSERVATION_MODIFIER", 119, 130], ["vesicles", "OBSERVATION_MODIFIER", 160, 168], ["diameter", "OBSERVATION_MODIFIER", 176, 184], ["up to 10 \u03bcm", "OBSERVATION_MODIFIER", 188, 199]]], ["After endocytosis, clathrin-coated vesicles feed into the classic endosome trafficking pathway, whereas macropinosomes traffic and mature in parallel.", [["vesicles", "ANATOMY", 35, 43], ["endosome", "ANATOMY", 66, 74], ["macropinosomes", "ANATOMY", 104, 118], ["clathrin", "GENE_OR_GENE_PRODUCT", 19, 27], ["endosome", "CELLULAR_COMPONENT", 66, 74], ["clathrin", "PROTEIN", 19, 27], ["macropinosomes", "PROTEIN", 104, 118], ["clathrin-coated vesicles feed", "TREATMENT", 19, 48], ["mature", "OBSERVATION_MODIFIER", 131, 137]]], ["In both cases, maturation of the vesicular compartments provide the virus with a plethora of cues that facilitate infection, including decreasing pH and the presence of proteases and inorganic ions.", [["vesicular compartments", "ANATOMY", 33, 55], ["infection", "DISEASE", 114, 123], ["vesicular compartments", "MULTI-TISSUE_STRUCTURE", 33, 55], ["inorganic ions", "SIMPLE_CHEMICAL", 183, 197], ["proteases", "PROTEIN", 169, 178], ["the virus", "PROBLEM", 64, 73], ["infection", "PROBLEM", 114, 123], ["decreasing pH", "PROBLEM", 135, 148], ["proteases", "PROBLEM", 169, 178], ["inorganic ions", "TREATMENT", 183, 197], ["vesicular", "ANATOMY", 33, 42], ["infection", "OBSERVATION", 114, 123], ["inorganic ions", "OBSERVATION", 183, 197]]], ["However, there are differences between classic endosomes and macropinosomes, including intraluminal vesicle formation, and the presence of RAB effectors, major histocompatibility complex (MHC) class II molecules and Toll-like receptors (TLRs)37.", [["endosomes", "ANATOMY", 47, 56], ["macropinosomes", "ANATOMY", 61, 75], ["intraluminal vesicle", "ANATOMY", 87, 107], ["endosomes", "CELLULAR_COMPONENT", 47, 56], ["macropinosomes", "GENE_OR_GENE_PRODUCT", 61, 75], ["intraluminal vesicle", "CELLULAR_COMPONENT", 87, 107], ["RAB", "GENE_OR_GENE_PRODUCT", 139, 142], ["Toll-like receptors", "GENE_OR_GENE_PRODUCT", 216, 235], ["macropinosomes", "PROTEIN", 61, 75], ["RAB effectors", "PROTEIN", 139, 152], ["major histocompatibility complex (MHC) class II molecules", "PROTEIN", 154, 211], ["Toll-like receptors (TLRs)37", "PROTEIN", 216, 244], ["classic endosomes and macropinosomes", "PROBLEM", 39, 75], ["intraluminal vesicle formation", "PROBLEM", 87, 117], ["RAB effectors", "PROBLEM", 139, 152], ["Toll-like receptors (TLRs)", "TREATMENT", 216, 242], ["endosomes", "OBSERVATION", 47, 56], ["intraluminal", "ANATOMY_MODIFIER", 87, 99], ["vesicle formation", "OBSERVATION", 100, 117], ["RAB effectors", "OBSERVATION", 139, 152]]], ["Together, these two pathways facilitate the internalization of most viruses, regardless of their varying size and intracellular trafficking requirements.Host cell entry via apoptotic mimicryApoptotic cells are phagocytosed by a mechanism that closely resembles macropinocytosis.", [["intracellular", "ANATOMY", 114, 127], ["cell", "ANATOMY", 158, 162], ["cells", "ANATOMY", 200, 205], ["intracellular", "IMMATERIAL_ANATOMICAL_ENTITY", 114, 127], ["Host cell", "CELL", 153, 162], ["Apoptotic cells", "CELL", 190, 205], ["Apoptotic cells", "CELL_TYPE", 190, 205], ["most viruses", "PROBLEM", 63, 75], ["Apoptotic cells", "PROBLEM", 190, 205], ["phagocytosed", "PROBLEM", 210, 222], ["macropinocytosis", "PROBLEM", 261, 277], ["most viruses", "OBSERVATION", 63, 75], ["varying", "OBSERVATION_MODIFIER", 97, 104], ["size", "OBSERVATION_MODIFIER", 105, 109], ["intracellular trafficking requirements", "OBSERVATION", 114, 152], ["cell entry", "OBSERVATION", 158, 168], ["apoptotic mimicry", "OBSERVATION", 173, 190], ["macropinocytosis", "OBSERVATION", 261, 277]]], ["Some viruses that use classic apoptotic mimicry, such as poxviruses and filoviruses, have been shown to enter cells by inducing this endocytic pathway.", [["cells", "ANATOMY", 110, 115], ["filoviruses", "GENE_OR_GENE_PRODUCT", 72, 83], ["cells", "CELL", 110, 115], ["Some viruses", "PROBLEM", 0, 12], ["classic apoptotic mimicry", "PROBLEM", 22, 47], ["poxviruses", "PROBLEM", 57, 67], ["filoviruses", "PROBLEM", 72, 83], ["viruses", "OBSERVATION", 5, 12], ["apoptotic mimicry", "OBSERVATION", 30, 47]]], ["However, as we describe below, other viruses, including flaviviruses and alphaviruses, enter host cells using CME (Fig. 1).", [["cells", "ANATOMY", 98, 103], ["host cells", "CELL", 93, 103], ["host cells", "CELL_TYPE", 93, 103], ["other viruses", "PROBLEM", 31, 44], ["flaviviruses", "PROBLEM", 56, 68], ["alphaviruses", "PROBLEM", 73, 85], ["viruses", "OBSERVATION", 37, 44]]], ["In either case, phosphatidylserine exposed on the virion membrane initiates viral uptake by binding to direct phosphatidylserine receptors, such as T cell immunoglobulin and mucin receptor 1 (TIM1; also known as HAVCR1) and other members of the TIM family, or, via bridging molecules, to indirect phosphatidylserine receptors, such as the receptor tyrosine kinase AXL (also known as UFO) and other members of the TYRO3\u2013AXL\u2013MER (TAM) family (Box 1).Host cell entry via apoptotic mimicryThe first experimental evidence of a virus using apoptotic mimicry for entry was provided in 2008 for VACV mature virions18.", [["virion membrane", "ANATOMY", 50, 65], ["cell", "ANATOMY", 453, 457], ["phosphatidylserine", "CHEMICAL", 16, 34], ["phosphatidylserine", "CHEMICAL", 110, 128], ["phosphatidylserine", "CHEMICAL", 297, 315], ["tyrosine", "CHEMICAL", 348, 356], ["TAM", "CHEMICAL", 428, 431], ["phosphatidylserine", "CHEMICAL", 16, 34], ["phosphatidylserine", "CHEMICAL", 110, 128], ["phosphatidylserine", "CHEMICAL", 297, 315], ["tyrosine", "CHEMICAL", 348, 356], ["phosphatidylserine", "AMINO_ACID", 16, 34], ["virion membrane", "CELLULAR_COMPONENT", 50, 65], ["phosphatidylserine receptors", "GENE_OR_GENE_PRODUCT", 110, 138], ["T cell immunoglobulin", "GENE_OR_GENE_PRODUCT", 148, 169], ["mucin receptor 1", "GENE_OR_GENE_PRODUCT", 174, 190], ["TIM1", "GENE_OR_GENE_PRODUCT", 192, 196], ["HAVCR1", "GENE_OR_GENE_PRODUCT", 212, 218], ["TIM", "GENE_OR_GENE_PRODUCT", 245, 248], ["phosphatidylserine receptors", "GENE_OR_GENE_PRODUCT", 297, 325], ["receptor tyrosine kinase AXL", "GENE_OR_GENE_PRODUCT", 339, 367], ["UFO", "GENE_OR_GENE_PRODUCT", 383, 386], ["TYRO3", "GENE_OR_GENE_PRODUCT", 413, 418], ["AXL\u2013MER (TAM)", "GENE_OR_GENE_PRODUCT", 419, 432], ["Box 1", "GENE_OR_GENE_PRODUCT", 441, 446], ["Host cell", "CELL", 448, 457], ["VACV", "ORGANISM", 587, 591], ["phosphatidylserine receptors", "PROTEIN", 110, 138], ["T cell immunoglobulin", "PROTEIN", 148, 169], ["mucin receptor 1", "PROTEIN", 174, 190], ["TIM1", "PROTEIN", 192, 196], ["HAVCR1", "PROTEIN", 212, 218], ["TIM family", "PROTEIN", 245, 255], ["phosphatidylserine receptors", "PROTEIN", 297, 325], ["receptor tyrosine kinase", "PROTEIN", 339, 363], ["AXL", "PROTEIN", 364, 367], ["UFO", "PROTEIN", 383, 386], ["TYRO3", "PROTEIN", 413, 418], ["AXL", "PROTEIN", 419, 422], ["MER (TAM) family", "PROTEIN", 423, 439], ["Box 1", "PROTEIN", 441, 446], ["VACV", "SPECIES", 587, 591], ["phosphatidylserine", "TREATMENT", 16, 34], ["the virion membrane", "TREATMENT", 46, 65], ["viral uptake", "PROBLEM", 76, 88], ["direct phosphatidylserine receptors", "TREATMENT", 103, 138], ["T cell immunoglobulin", "TREATMENT", 148, 169], ["mucin receptor", "TREATMENT", 174, 188], ["indirect phosphatidylserine receptors", "TREATMENT", 288, 325], ["the receptor tyrosine kinase AXL", "TREATMENT", 335, 367], ["a virus", "PROBLEM", 520, 527], ["VACV mature virions", "TREATMENT", 587, 606], ["virion membrane", "OBSERVATION", 50, 65], ["viral uptake", "OBSERVATION", 76, 88], ["cell entry", "OBSERVATION", 453, 463], ["apoptotic mimicry", "OBSERVATION", 468, 485]]], ["Previous studies had indicated that the VACV membrane is phosphatidylserine rich and that phosphatidylserine can reactivate VACV virions that have been delipidated38.", [["membrane", "ANATOMY", 45, 53], ["phosphatidylserine", "CHEMICAL", 57, 75], ["phosphatidylserine", "CHEMICAL", 90, 108], ["phosphatidylserine", "CHEMICAL", 57, 75], ["phosphatidylserine", "CHEMICAL", 90, 108], ["VACV", "ORGANISM", 40, 44], ["membrane", "CELLULAR_COMPONENT", 45, 53], ["phosphatidylserine", "AMINO_ACID", 57, 75], ["phosphatidylserine", "AMINO_ACID", 90, 108], ["VACV", "ORGANISM", 124, 128], ["VACV", "SPECIES", 40, 44], ["VACV", "SPECIES", 124, 128], ["Previous studies", "TEST", 0, 16], ["the VACV membrane", "TREATMENT", 36, 53], ["phosphatidylserine", "TREATMENT", 90, 108], ["VACV virions", "TREATMENT", 124, 136], ["VACV membrane", "OBSERVATION", 40, 53]]], ["More recently, detailed analysis of the entry mechanism of VACV mature virions showed that the virus enters host cells by macropinocytosis.", [["cells", "ANATOMY", 113, 118], ["VACV", "ORGANISM", 59, 63], ["host cells", "CELL", 108, 118], ["host cells", "CELL_TYPE", 108, 118], ["VACV", "SPECIES", 59, 63], ["VACV mature virions", "PROBLEM", 59, 78], ["the virus", "PROBLEM", 91, 100], ["macropinocytosis", "PROBLEM", 122, 138], ["host cells", "OBSERVATION", 108, 118], ["macropinocytosis", "OBSERVATION_MODIFIER", 122, 138]]], ["Masking phosphatidylserine using annexin V (also known as annexin A5; a protein that binds to phosphatidylserine with very high affinity) indicated that phosphatidylserine on the viral surface is required for the induction of macropinocytosis and, thus, for productive infection18,36.", [["surface", "ANATOMY", 185, 192], ["phosphatidylserine", "CHEMICAL", 8, 26], ["annexin V", "CHEMICAL", 33, 42], ["phosphatidylserine", "CHEMICAL", 94, 112], ["phosphatidylserine", "CHEMICAL", 153, 171], ["infection", "DISEASE", 269, 278], ["phosphatidylserine", "CHEMICAL", 8, 26], ["phosphatidylserine", "CHEMICAL", 94, 112], ["phosphatidylserine", "CHEMICAL", 153, 171], ["phosphatidylserine", "AMINO_ACID", 8, 26], ["annexin V", "GENE_OR_GENE_PRODUCT", 33, 42], ["annexin A5", "GENE_OR_GENE_PRODUCT", 58, 68], ["phosphatidylserine", "SIMPLE_CHEMICAL", 94, 112], ["phosphatidylserine", "SIMPLE_CHEMICAL", 153, 171], ["annexin V", "PROTEIN", 33, 42], ["annexin A5", "PROTEIN", 58, 68], ["Masking phosphatidylserine", "TREATMENT", 0, 26], ["annexin V", "TREATMENT", 33, 42], ["annexin A5", "TREATMENT", 58, 68], ["phosphatidylserine", "TEST", 94, 112], ["very high affinity", "PROBLEM", 118, 136], ["phosphatidylserine on the viral surface", "PROBLEM", 153, 192], ["macropinocytosis", "PROBLEM", 226, 242], ["productive infection", "PROBLEM", 258, 278], ["macropinocytosis", "OBSERVATION", 226, 242], ["productive", "OBSERVATION_MODIFIER", 258, 268], ["infection", "OBSERVATION", 269, 278]]], ["A subsequent study confirmed that phosphatidylserine is the only biologically relevant, naturally occurring lipid constituent of VACV mature virions that can rescue infection39, and further work implicated AXL as the phosphatidylserine receptor for these viruses40 (Fig. 1).", [["virions", "ANATOMY", 141, 148], ["phosphatidylserine", "CHEMICAL", 34, 52], ["phosphatidylserine", "CHEMICAL", 34, 52], ["phosphatidylserine", "CHEMICAL", 217, 235], ["phosphatidylserine", "SIMPLE_CHEMICAL", 34, 52], ["VACV", "ORGANISM", 129, 133], ["AXL", "GENE_OR_GENE_PRODUCT", 206, 209], ["phosphatidylserine receptor", "GENE_OR_GENE_PRODUCT", 217, 244], ["AXL", "PROTEIN", 206, 209], ["phosphatidylserine receptor", "PROTEIN", 217, 244], ["VACV", "SPECIES", 129, 133], ["A subsequent study", "TEST", 0, 18], ["phosphatidylserine", "TREATMENT", 34, 52], ["VACV mature virions", "TREATMENT", 129, 148], ["the phosphatidylserine receptor", "TREATMENT", 213, 244], ["these viruses40 (Fig", "TREATMENT", 249, 269], ["VACV mature virions", "OBSERVATION", 129, 148]]], ["Overexpression of the TAM ligand GAS6, which acts as a bridging molecule between phosphatidylserine and AXL (Box 1), was also reported to enhance infection of VACV extracellular virions20, a second form of infectious VACV that is produced when mature virions acquire additional membranes from host cell organelles.", [["extracellular virions", "ANATOMY", 164, 185], ["virions", "ANATOMY", 251, 258], ["membranes", "ANATOMY", 278, 287], ["cell organelles", "ANATOMY", 298, 313], ["TAM", "CHEMICAL", 22, 25], ["phosphatidylserine", "CHEMICAL", 81, 99], ["infection", "DISEASE", 146, 155], ["TAM", "CHEMICAL", 22, 25], ["phosphatidylserine", "CHEMICAL", 81, 99], ["TAM ligand", "GENE_OR_GENE_PRODUCT", 22, 32], ["GAS6", "GENE_OR_GENE_PRODUCT", 33, 37], ["phosphatidylserine", "SIMPLE_CHEMICAL", 81, 99], ["AXL (Box 1", "GENE_OR_GENE_PRODUCT", 104, 114], ["VACV", "ORGANISM", 159, 163], ["extracellular", "IMMATERIAL_ANATOMICAL_ENTITY", 164, 177], ["virions", "ORGANISM", 178, 185], ["VACV", "ORGANISM", 217, 221], ["membranes", "CELLULAR_COMPONENT", 278, 287], ["cell organelles", "CELLULAR_COMPONENT", 298, 313], ["TAM ligand", "PROTEIN", 22, 32], ["GAS6", "PROTEIN", 33, 37], ["AXL", "PROTEIN", 104, 107], ["Box 1", "PROTEIN", 109, 114], ["VACV", "SPECIES", 159, 163], ["VACV", "SPECIES", 217, 221], ["the TAM ligand GAS6", "TEST", 18, 37], ["phosphatidylserine and AXL (Box", "TREATMENT", 81, 112], ["VACV extracellular virions", "TREATMENT", 159, 185], ["infectious VACV", "TREATMENT", 206, 221], ["AXL", "ANATOMY", 104, 107], ["infection", "OBSERVATION", 146, 155], ["VACV extracellular virions", "OBSERVATION", 159, 185], ["infectious", "OBSERVATION_MODIFIER", 206, 216], ["VACV", "OBSERVATION", 217, 221], ["host cell organelles", "OBSERVATION", 293, 313]]], ["Although it has not been demonstrated that the membranes of extracellular virions contain exposed phosphatidylserine (as the mature-virion membrane does), these virions do enter host cells using macropinocytosis41, suggesting that they too rely on apoptotic mimicry for infection.Host cell entry via apoptotic mimicrySimilarly to VACV and apoptotic cells, EBOV uses macropinocytosis for host cell entry42,43.", [["membranes", "ANATOMY", 47, 56], ["extracellular virions", "ANATOMY", 60, 81], ["membrane", "ANATOMY", 139, 147], ["virions", "ANATOMY", 161, 168], ["cells", "ANATOMY", 183, 188], ["cell", "ANATOMY", 285, 289], ["cells", "ANATOMY", 349, 354], ["cell", "ANATOMY", 392, 396], ["phosphatidylserine", "CHEMICAL", 98, 116], ["infection", "DISEASE", 270, 279], ["phosphatidylserine", "CHEMICAL", 98, 116], ["membranes", "CELLULAR_COMPONENT", 47, 56], ["extracellular virions", "CELLULAR_COMPONENT", 60, 81], ["phosphatidylserine", "AMINO_ACID", 98, 116], ["membrane", "CELLULAR_COMPONENT", 139, 147], ["host cells", "CELL", 178, 188], ["macropinocytosis41", "GENE_OR_GENE_PRODUCT", 195, 213], ["cell", "CELL", 285, 289], ["VACV", "ORGANISM", 330, 334], ["cells", "CELL", 349, 354], ["EBOV", "ORGANISM", 356, 360], ["host cell", "CELL", 387, 396], ["host cells", "CELL_TYPE", 178, 188], ["macropinocytosis41", "PROTEIN", 195, 213], ["apoptotic cells", "CELL_TYPE", 339, 354], ["VACV", "SPECIES", 330, 334], ["EBOV", "SPECIES", 356, 360], ["extracellular virions", "PROBLEM", 60, 81], ["exposed phosphatidylserine", "PROBLEM", 90, 116], ["these virions", "PROBLEM", 155, 168], ["macropinocytosis41", "TREATMENT", 195, 213], ["infection", "PROBLEM", 270, 279], ["apoptotic mimicrySimilarly", "TREATMENT", 300, 326], ["VACV", "PROBLEM", 330, 334], ["apoptotic cells", "PROBLEM", 339, 354], ["macropinocytosis", "PROBLEM", 366, 382], ["host cell entry", "TEST", 387, 402], ["extracellular virions", "OBSERVATION", 60, 81], ["exposed phosphatidylserine", "OBSERVATION", 90, 116], ["infection", "OBSERVATION", 270, 279], ["apoptotic cells", "OBSERVATION", 339, 354]]], ["The finding that ectopic expression of the phosphatidylserine receptors tyrosine protein kinase receptor 3 (TYRO3), AXL or TIM1 enhanced macropinocytic virus entry provided the first link between apoptotic mimicry and EBOV16,44,45.", [["phosphatidylserine", "CHEMICAL", 43, 61], ["tyrosine", "CHEMICAL", 72, 80], ["phosphatidylserine", "CHEMICAL", 43, 61], ["tyrosine", "CHEMICAL", 72, 80], ["phosphatidylserine receptors tyrosine protein kinase receptor 3", "GENE_OR_GENE_PRODUCT", 43, 106], ["TYRO3", "GENE_OR_GENE_PRODUCT", 108, 113], ["AXL", "GENE_OR_GENE_PRODUCT", 116, 119], ["TIM1", "GENE_OR_GENE_PRODUCT", 123, 127], ["macropinocytic virus", "ORGANISM", 137, 157], ["EBOV16", "GENE_OR_GENE_PRODUCT", 218, 224], ["phosphatidylserine receptors tyrosine protein kinase receptor 3", "PROTEIN", 43, 106], ["TYRO3", "PROTEIN", 108, 113], ["AXL", "PROTEIN", 116, 119], ["TIM1", "PROTEIN", 123, 127], ["ectopic expression", "PROBLEM", 17, 35], ["the phosphatidylserine receptors tyrosine protein kinase receptor", "TEST", 39, 104], ["AXL", "TEST", 116, 119], ["TIM1 enhanced macropinocytic virus entry", "PROBLEM", 123, 163], ["ectopic", "OBSERVATION", 17, 24]]], ["It was originally proposed that EBOV glycoproteins mediate the association with TIM1 (Ref.", [["EBOV", "ORGANISM", 32, 36], ["TIM1", "GENE_OR_GENE_PRODUCT", 80, 84], ["EBOV glycoproteins", "PROTEIN", 32, 50], ["TIM1", "PROTEIN", 80, 84], ["EBOV", "SPECIES", 32, 36], ["EBOV glycoproteins", "TREATMENT", 32, 50]]], ["However, recent studies showed that exposure of phosphatidylserine on viral particles is essential for EBOV binding to TIM1 and subsequent virus entry15,19 (Fig. 1), demonstrating that phosphatidylserine within the EBOV membrane was responsible for the phosphatidylserine receptor-mediated enhancement of infection.", [["membrane", "ANATOMY", 220, 228], ["phosphatidylserine", "CHEMICAL", 48, 66], ["phosphatidylserine", "CHEMICAL", 185, 203], ["phosphatidylserine", "CHEMICAL", 253, 271], ["infection", "DISEASE", 305, 314], ["phosphatidylserine", "CHEMICAL", 48, 66], ["phosphatidylserine", "CHEMICAL", 185, 203], ["phosphatidylserine", "CHEMICAL", 253, 271], ["phosphatidylserine", "SIMPLE_CHEMICAL", 48, 66], ["EBOV", "ORGANISM", 103, 107], ["TIM1", "GENE_OR_GENE_PRODUCT", 119, 123], ["Fig. 1", "GENE_OR_GENE_PRODUCT", 157, 163], ["phosphatidylserine", "SIMPLE_CHEMICAL", 185, 203], ["EBOV", "ORGANISM", 215, 219], ["membrane", "CELLULAR_COMPONENT", 220, 228], ["phosphatidylserine receptor", "GENE_OR_GENE_PRODUCT", 253, 280], ["TIM1", "PROTEIN", 119, 123], ["phosphatidylserine receptor", "PROTEIN", 253, 280], ["EBOV", "SPECIES", 103, 107], ["recent studies", "TEST", 9, 23], ["phosphatidylserine on viral particles", "PROBLEM", 48, 85], ["EBOV binding", "PROBLEM", 103, 115], ["TIM1", "TEST", 119, 123], ["subsequent virus entry", "TEST", 128, 150], ["phosphatidylserine within the EBOV membrane", "PROBLEM", 185, 228], ["the phosphatidylserine receptor", "TREATMENT", 249, 280], ["infection", "PROBLEM", 305, 314], ["viral particles", "OBSERVATION", 70, 85], ["EBOV membrane", "OBSERVATION", 215, 228], ["infection", "OBSERVATION", 305, 314]]], ["Consistent with this, phosphatidylserine-containing liposomes and annexin V can both inhibit TIM1-mediated enhancement of EBOV infection, as they compete for phosphatidylserine receptors and mask phosphatidylserine, respectively15,19.Host cell entry via apoptotic mimicryMembers of the Flavivirus genus, such as DENV, West Nile virus (WNV) and yellow fever virus (YFV), are mosquito-borne enveloped RNA viruses that cause various medically relevant human diseases, including haemorrhagic fever and encephalitis46.", [["cell", "ANATOMY", 239, 243], ["phosphatidylserine", "CHEMICAL", 22, 40], ["annexin V", "CHEMICAL", 66, 75], ["EBOV infection", "DISEASE", 122, 136], ["phosphatidylserine", "CHEMICAL", 158, 176], ["phosphatidylserine", "CHEMICAL", 196, 214], ["yellow fever", "DISEASE", 344, 356], ["human diseases", "DISEASE", 449, 463], ["haemorrhagic fever", "DISEASE", 475, 493], ["encephalitis", "DISEASE", 498, 510], ["phosphatidylserine", "CHEMICAL", 22, 40], ["phosphatidylserine", "CHEMICAL", 158, 176], ["phosphatidylserine", "CHEMICAL", 196, 214], ["phosphatidylserine", "SIMPLE_CHEMICAL", 22, 40], ["liposomes", "SIMPLE_CHEMICAL", 52, 61], ["annexin V", "GENE_OR_GENE_PRODUCT", 66, 75], ["TIM1", "GENE_OR_GENE_PRODUCT", 93, 97], ["EBOV", "ORGANISM", 122, 126], ["phosphatidylserine receptors", "GENE_OR_GENE_PRODUCT", 158, 186], ["phosphatidylserine", "AMINO_ACID", 196, 214], ["Host cell", "CELL", 234, 243], ["Flavivirus genus", "ORGANISM", 286, 302], ["DENV", "ORGANISM", 312, 316], ["West Nile virus", "ORGANISM", 318, 333], ["WNV", "ORGANISM", 335, 338], ["yellow fever virus", "ORGANISM", 344, 362], ["YFV", "ORGANISM", 364, 367], ["human", "ORGANISM", 449, 454], ["annexin V", "PROTEIN", 66, 75], ["TIM1", "PROTEIN", 93, 97], ["phosphatidylserine receptors", "PROTEIN", 158, 186], ["West Nile virus", "SPECIES", 318, 333], ["yellow fever virus", "SPECIES", 344, 362], ["human", "SPECIES", 449, 454], ["EBOV", "SPECIES", 122, 126], ["DENV", "SPECIES", 312, 316], ["West Nile virus", "SPECIES", 318, 333], ["WNV", "SPECIES", 335, 338], ["yellow fever virus", "SPECIES", 344, 362], ["YFV", "SPECIES", 364, 367], ["human", "SPECIES", 449, 454], ["phosphatidylserine-containing liposomes", "TREATMENT", 22, 61], ["annexin V", "TREATMENT", 66, 75], ["EBOV infection", "PROBLEM", 122, 136], ["phosphatidylserine receptors", "TREATMENT", 158, 186], ["mask phosphatidylserine", "TREATMENT", 191, 214], ["the Flavivirus genus", "PROBLEM", 282, 302], ["DENV", "PROBLEM", 312, 316], ["West Nile virus (WNV", "PROBLEM", 318, 338], ["yellow fever virus (YFV", "PROBLEM", 344, 367], ["mosquito-borne enveloped RNA viruses", "PROBLEM", 374, 410], ["various medically relevant human diseases", "PROBLEM", 422, 463], ["haemorrhagic fever", "PROBLEM", 475, 493], ["encephalitis", "PROBLEM", 498, 510], ["EBOV infection", "OBSERVATION", 122, 136], ["cell entry", "OBSERVATION", 239, 249], ["apoptotic mimicry", "OBSERVATION", 254, 271], ["human diseases", "OBSERVATION", 449, 463], ["haemorrhagic", "OBSERVATION_MODIFIER", 475, 487], ["encephalitis", "OBSERVATION", 498, 510]]], ["It was recently shown that ectopic expression of either TIM receptors (TIM1, TIM3 (also known as HAVR2) and TIM4 (also known as TIMD4)) or TAM receptors (AXL and TYRO3) enhanced flavivirus endocytosis through CME (A.A., unpublished observations) (Fig. 1) and that subsequent infection by all DENV serotypes, WNV and YFV was also enhanced14,15,17.", [["TAM", "CHEMICAL", 139, 142], ["infection", "DISEASE", 275, 284], ["TAM", "CHEMICAL", 139, 142], ["TIM receptors", "GENE_OR_GENE_PRODUCT", 56, 69], ["TIM1", "GENE_OR_GENE_PRODUCT", 71, 75], ["TIM3", "GENE_OR_GENE_PRODUCT", 77, 81], ["HAVR2", "GENE_OR_GENE_PRODUCT", 97, 102], ["TIM4", "GENE_OR_GENE_PRODUCT", 108, 112], ["TIMD4", "GENE_OR_GENE_PRODUCT", 128, 133], ["TAM receptors", "GENE_OR_GENE_PRODUCT", 139, 152], ["AXL", "GENE_OR_GENE_PRODUCT", 154, 157], ["TYRO3", "GENE_OR_GENE_PRODUCT", 162, 167], ["DENV", "ORGANISM", 292, 296], ["WNV", "ORGANISM", 308, 311], ["YFV", "ORGANISM", 316, 319], ["TIM receptors", "PROTEIN", 56, 69], ["TIM1", "PROTEIN", 71, 75], ["TIM3", "PROTEIN", 77, 81], ["HAVR2", "PROTEIN", 97, 102], ["TIM4", "PROTEIN", 108, 112], ["TIMD4", "PROTEIN", 128, 133], ["TAM receptors", "PROTEIN", 139, 152], ["AXL", "PROTEIN", 154, 157], ["TYRO3", "PROTEIN", 162, 167], ["DENV", "SPECIES", 292, 296], ["WNV", "SPECIES", 308, 311], ["YFV", "SPECIES", 316, 319], ["ectopic expression", "PROBLEM", 27, 45], ["TIM receptors", "TEST", 56, 69], ["TIM1", "TEST", 71, 75], ["TIM3", "TEST", 77, 81], ["TIM4", "TEST", 108, 112], ["TAM receptors (AXL and TYRO3) enhanced flavivirus endocytosis", "PROBLEM", 139, 200], ["subsequent infection", "PROBLEM", 264, 284], ["all DENV serotypes", "PROBLEM", 288, 306], ["WNV", "PROBLEM", 308, 311], ["YFV", "PROBLEM", 316, 319], ["ectopic", "OBSERVATION", 27, 34], ["flavivirus endocytosis", "OBSERVATION", 178, 200], ["infection", "OBSERVATION", 275, 284]]], ["Moreover, it was shown that phosphatidylserine is incorporated into the membrane of flavivirus particles and is essential for infection of TIM- or TAM-expressing cells, suggesting that flaviviruses use apoptotic mimicry to invade host cells.", [["membrane", "ANATOMY", 72, 80], ["cells", "ANATOMY", 162, 167], ["cells", "ANATOMY", 235, 240], ["phosphatidylserine", "CHEMICAL", 28, 46], ["infection", "DISEASE", 126, 135], ["TAM", "CHEMICAL", 147, 150], ["phosphatidylserine", "CHEMICAL", 28, 46], ["phosphatidylserine", "SIMPLE_CHEMICAL", 28, 46], ["membrane", "CELLULAR_COMPONENT", 72, 80], ["TIM", "GENE_OR_GENE_PRODUCT", 139, 142], ["TAM", "CELL", 147, 150], ["cells", "CELL", 162, 167], ["host cells", "CELL", 230, 240], ["TIM- or TAM-expressing cells", "CELL_LINE", 139, 167], ["host cells", "CELL_TYPE", 230, 240], ["phosphatidylserine", "TREATMENT", 28, 46], ["flavivirus particles", "PROBLEM", 84, 104], ["infection of TIM", "PROBLEM", 126, 142], ["expressing cells", "PROBLEM", 151, 167], ["flaviviruses", "PROBLEM", 185, 197], ["apoptotic mimicry", "TREATMENT", 202, 219], ["phosphatidylserine", "OBSERVATION", 28, 46], ["flavivirus", "OBSERVATION", 84, 94], ["essential for", "UNCERTAINTY", 112, 125], ["infection", "OBSERVATION", 126, 135], ["flaviviruses", "OBSERVATION", 185, 197], ["host cells", "OBSERVATION", 230, 240]]], ["Characterization of the interactions revealed that virions bind directly to the TIM receptors TIM1 and TIM4 and require the metal ion-dependent ligand-binding site in these receptors.", [["virions", "ANATOMY", 51, 58], ["TIM1", "GENE_OR_GENE_PRODUCT", 94, 98], ["TIM4", "GENE_OR_GENE_PRODUCT", 103, 107], ["TIM receptors", "PROTEIN", 80, 93], ["TIM1", "PROTEIN", 94, 98], ["TIM4", "PROTEIN", 103, 107], ["metal ion-dependent ligand-binding site", "PROTEIN", 124, 163], ["virions bind", "PROBLEM", 51, 63], ["TIM4", "TREATMENT", 103, 107], ["the metal ion-dependent ligand", "TREATMENT", 120, 150]]], ["By contrast, binding of TAM receptors occurred indirectly via the bridging molecules GAS6 or protein S (PROS).", [["TAM", "CHEMICAL", 24, 27], ["TAM", "CHEMICAL", 24, 27], ["TAM receptors", "GENE_OR_GENE_PRODUCT", 24, 37], ["GAS6", "GENE_OR_GENE_PRODUCT", 85, 89], ["protein S", "GENE_OR_GENE_PRODUCT", 93, 102], ["PROS", "GENE_OR_GENE_PRODUCT", 104, 108], ["TAM receptors", "PROTEIN", 24, 37], ["bridging molecules", "PROTEIN", 66, 84], ["GAS6", "PROTEIN", 85, 89], ["protein S", "PROTEIN", 93, 102], ["PROS", "PROTEIN", 104, 108], ["TAM receptors", "PROBLEM", 24, 37]]], ["These data strongly argue for a tripartite model, whereby TAM ligands bind to phosphatidylserine exposed on DENV particles and bridge virions to TAM receptors.Host cell entry via apoptotic mimicryCollectively, these studies suggest that viruses which use classic apoptotic mimicry to enter cells undergo macropinocytosis or CME.", [["virions", "ANATOMY", 134, 141], ["cell", "ANATOMY", 164, 168], ["cells", "ANATOMY", 290, 295], ["TAM", "CHEMICAL", 58, 61], ["phosphatidylserine", "CHEMICAL", 78, 96], ["TAM", "CHEMICAL", 145, 148], ["TAM", "CHEMICAL", 58, 61], ["phosphatidylserine", "CHEMICAL", 78, 96], ["TAM", "CHEMICAL", 145, 148], ["TAM", "SIMPLE_CHEMICAL", 58, 61], ["phosphatidylserine", "SIMPLE_CHEMICAL", 78, 96], ["TAM receptors", "GENE_OR_GENE_PRODUCT", 145, 158], ["Host cell", "CELL", 159, 168], ["cells", "CELL", 290, 295], ["TAM receptors", "PROTEIN", 145, 158], ["a tripartite model", "TREATMENT", 30, 48], ["phosphatidylserine", "TREATMENT", 78, 96], ["DENV particles", "TREATMENT", 108, 122], ["bridge virions to TAM receptors", "TREATMENT", 127, 158], ["these studies", "TEST", 210, 223], ["viruses", "PROBLEM", 237, 244], ["classic apoptotic mimicry", "TREATMENT", 255, 280], ["macropinocytosis", "PROBLEM", 304, 320], ["CME", "PROBLEM", 324, 327], ["cell entry", "OBSERVATION", 164, 174], ["apoptotic mimicry", "OBSERVATION", 179, 196], ["viruses", "OBSERVATION", 237, 244]]], ["Currently, no clear pattern linking the choice of endocytic mechanism to receptor preference can be delineated, nor can alternative endocytic mechanisms be ruled out.", [["no", "UNCERTAINTY", 11, 13], ["clear", "OBSERVATION", 14, 19]]], ["For viruses using CME, many of the studies are gain-of-function assays performed in non-permissive cell lines; therefore, additional experimental evidence is needed to determine whether phosphatidylserine receptor engagement by enveloped viruses is required for CME.", [["cell lines", "ANATOMY", 99, 109], ["phosphatidylserine", "CHEMICAL", 186, 204], ["phosphatidylserine", "CHEMICAL", 186, 204], ["cell lines", "CELL", 99, 109], ["phosphatidylserine receptor", "GENE_OR_GENE_PRODUCT", 186, 213], ["non-permissive cell lines", "CELL_LINE", 84, 109], ["phosphatidylserine receptor", "PROTEIN", 186, 213], ["viruses", "PROBLEM", 4, 11], ["the studies", "TEST", 31, 42], ["function assays", "TEST", 55, 70], ["non-permissive cell lines", "TREATMENT", 84, 109], ["phosphatidylserine receptor engagement", "TREATMENT", 186, 224], ["CME", "PROBLEM", 262, 265], ["non-permissive cell lines", "OBSERVATION", 84, 109]]], ["Thus, it may be important to reinvestigate the endocytic mechanism of virus internalization in the context of apoptotic mimicry.Host cell entry via apoptotic mimicryThe molecular mechanisms by which phosphatidylserine receptors mediate virus entry are poorly understood.", [["cell", "ANATOMY", 133, 137], ["phosphatidylserine", "CHEMICAL", 199, 217], ["phosphatidylserine", "CHEMICAL", 199, 217], ["Host cell", "CELL", 128, 137], ["phosphatidylserine receptors", "GENE_OR_GENE_PRODUCT", 199, 227], ["phosphatidylserine receptors", "PROTEIN", 199, 227], ["virus internalization", "PROBLEM", 70, 91], ["The molecular mechanisms", "PROBLEM", 165, 189], ["phosphatidylserine receptors", "TREATMENT", 199, 227], ["virus", "OBSERVATION", 70, 75], ["apoptotic mimicry", "OBSERVATION", 110, 127], ["cell entry", "OBSERVATION", 133, 143], ["apoptotic mimicry", "OBSERVATION", 148, 165]]], ["It remains to be clarified whether phosphatidylserine receptors mediate virus internalization directly or act in concert with unknown molecules to coordinate viral endocytosis.", [["phosphatidylserine", "CHEMICAL", 35, 53], ["phosphatidylserine", "CHEMICAL", 35, 53], ["phosphatidylserine receptors", "GENE_OR_GENE_PRODUCT", 35, 63], ["phosphatidylserine receptors", "PROTEIN", 35, 63], ["phosphatidylserine receptors", "TREATMENT", 35, 63], ["virus internalization", "PROBLEM", 72, 93], ["viral endocytosis", "PROBLEM", 158, 175], ["viral endocytosis", "OBSERVATION", 158, 175]]], ["In addition, as these receptors are used by various viruses with different entry mechanisms, it is plausible that the receptors are exploited for different purposes, depending on the virus.", [["various viruses", "PROBLEM", 44, 59], ["the virus", "PROBLEM", 179, 188]]], ["For instance, several enveloped viruses enter host cells by receptor-mediated endocytosis and deliver their genome into the host cytosol through low-pH-triggered fusion of the viral and endosomal membranes47.", [["cells", "ANATOMY", 51, 56], ["cytosol", "ANATOMY", 129, 136], ["endosomal membranes", "ANATOMY", 186, 205], ["host cells", "CELL", 46, 56], ["cytosol", "CELLULAR_COMPONENT", 129, 136], ["endosomal membranes", "CELLULAR_COMPONENT", 186, 205], ["host cells", "CELL_TYPE", 46, 56], ["several enveloped viruses", "PROBLEM", 14, 39], ["receptor-mediated endocytosis", "TREATMENT", 60, 89], ["the viral and endosomal membranes", "PROBLEM", 172, 205], ["enveloped", "OBSERVATION_MODIFIER", 22, 31], ["viruses", "OBSERVATION", 32, 39], ["viral", "OBSERVATION", 176, 181], ["endosomal membranes", "OBSERVATION", 186, 205]]], ["For flaviviruses and alphaviruses, this membrane fusion reaction is exclusively dependent on endosome acidification.", [["membrane", "ANATOMY", 40, 48], ["endosome", "ANATOMY", 93, 101], ["membrane", "CELLULAR_COMPONENT", 40, 48], ["endosome", "CELLULAR_COMPONENT", 93, 101], ["flaviviruses", "PROBLEM", 4, 16], ["alphaviruses", "PROBLEM", 21, 33], ["this membrane fusion reaction", "PROBLEM", 35, 64], ["endosome acidification", "PROBLEM", 93, 115], ["flaviviruses", "OBSERVATION", 4, 16], ["alphaviruses", "OBSERVATION", 21, 33], ["fusion", "OBSERVATION", 49, 55], ["endosome acidification", "OBSERVATION", 93, 115]]], ["The fact that phosphatidylserine receptors are not required for this step suggests that they act as bona fide entry receptors that are necessary and sufficient to promote infection.", [["phosphatidylserine", "CHEMICAL", 14, 32], ["infection", "DISEASE", 171, 180], ["phosphatidylserine", "CHEMICAL", 14, 32], ["phosphatidylserine receptors", "GENE_OR_GENE_PRODUCT", 14, 42], ["phosphatidylserine receptors", "PROTEIN", 14, 42], ["bona fide entry receptors", "PROTEIN", 100, 125], ["phosphatidylserine receptors", "TREATMENT", 14, 42], ["infection", "PROBLEM", 171, 180], ["infection", "OBSERVATION", 171, 180]]], ["Conversely, for the filoviruses MARV and EBOV, TIM1 overexpression does not enhance virus entry in cells lacking the cognate entry receptor for these viruses, NPC1 (Ref.", [["cells", "ANATOMY", 99, 104], ["filoviruses MARV", "ORGANISM", 20, 36], ["EBOV", "ORGANISM", 41, 45], ["TIM1", "GENE_OR_GENE_PRODUCT", 47, 51], ["cells", "CELL", 99, 104], ["NPC1", "GENE_OR_GENE_PRODUCT", 159, 163], ["TIM1", "PROTEIN", 47, 51], ["cognate entry receptor", "PROTEIN", 117, 139], ["NPC1", "PROTEIN", 159, 163], ["MARV", "SPECIES", 32, 36], ["EBOV", "SPECIES", 41, 45], ["the filoviruses MARV", "PROBLEM", 16, 36]]], ["15), suggesting that these viruses use an entry mechanism that requires interactions with both phosphatidylserine receptors and virus-specific entry receptors.", [["phosphatidylserine", "CHEMICAL", 95, 113], ["phosphatidylserine", "CHEMICAL", 95, 113], ["phosphatidylserine receptors", "GENE_OR_GENE_PRODUCT", 95, 123], ["phosphatidylserine receptors", "PROTEIN", 95, 123], ["virus-specific entry receptors", "PROTEIN", 128, 158], ["these viruses", "PROBLEM", 21, 34], ["both phosphatidylserine receptors", "TREATMENT", 90, 123], ["virus", "TREATMENT", 128, 133], ["viruses", "OBSERVATION", 27, 34]]], ["Infectivity of the arenavirus Lassa virus (LASV) is also enhanced by phosphatidylserine48.", [["phosphatidylserine48", "CHEMICAL", 69, 89], ["phosphatidylserine48", "CHEMICAL", 69, 89], ["arenavirus Lassa virus", "ORGANISM", 19, 41], ["LASV", "ORGANISM", 43, 47], ["phosphatidylserine48", "SIMPLE_CHEMICAL", 69, 89], ["phosphatidylserine48", "PROTEIN", 69, 89], ["arenavirus Lassa virus", "SPECIES", 19, 41], ["Lassa virus", "SPECIES", 30, 41], ["LASV", "SPECIES", 43, 47], ["the arenavirus Lassa virus", "PROBLEM", 15, 41], ["arenavirus", "OBSERVATION_MODIFIER", 19, 29], ["Lassa virus", "OBSERVATION", 30, 41]]], ["LASV binds to well-described extracellular (\u03b1-dystroglycan) and intracellular (lysosomal-associated membrane protein 1 (LAMP1)) receptors on host cells to facilitate entry49,50,51, but it is not known whether these receptors are required for phosphatidylserine-mediated enhancement of LASV infection or whether phosphatidylserine receptors are sufficient for infection in the absence of these virus-specific receptors.", [["extracellular", "ANATOMY", 29, 42], ["intracellular", "ANATOMY", 64, 77], ["cells", "ANATOMY", 146, 151], ["phosphatidylserine", "CHEMICAL", 242, 260], ["LASV infection", "DISEASE", 285, 299], ["phosphatidylserine", "CHEMICAL", 311, 329], ["infection", "DISEASE", 359, 368], ["phosphatidylserine", "CHEMICAL", 242, 260], ["phosphatidylserine", "CHEMICAL", 311, 329], ["LASV", "ORGANISM", 0, 4], ["extracellular", "IMMATERIAL_ANATOMICAL_ENTITY", 29, 42], ["\u03b1-dystroglycan", "GENE_OR_GENE_PRODUCT", 44, 58], ["intracellular", "IMMATERIAL_ANATOMICAL_ENTITY", 64, 77], ["lysosomal-associated membrane protein 1", "GENE_OR_GENE_PRODUCT", 79, 118], ["LAMP1", "GENE_OR_GENE_PRODUCT", 120, 125], ["host cells", "CELL", 141, 151], ["phosphatidylserine", "SIMPLE_CHEMICAL", 242, 260], ["LASV", "ORGANISM", 285, 289], ["phosphatidylserine receptors", "GENE_OR_GENE_PRODUCT", 311, 339], ["LASV", "PROTEIN", 0, 4], ["extracellular (\u03b1-dystroglycan", "PROTEIN", 29, 58], ["intracellular (lysosomal-associated membrane protein 1 (LAMP1)) receptors", "PROTEIN", 64, 137], ["host cells", "CELL_TYPE", 141, 151], ["phosphatidylserine receptors", "PROTEIN", 311, 339], ["virus-specific receptors", "PROTEIN", 393, 417], ["LASV", "SPECIES", 0, 4], ["LASV", "SPECIES", 285, 289], ["LASV binds", "PROBLEM", 0, 10], ["extracellular (\u03b1-dystroglycan)", "TEST", 29, 59], ["intracellular (lysosomal-associated membrane protein", "PROBLEM", 64, 116], ["receptors on host cells", "PROBLEM", 128, 151], ["phosphatidylserine", "PROBLEM", 242, 260], ["LASV infection", "PROBLEM", 285, 299], ["phosphatidylserine receptors", "PROBLEM", 311, 339], ["infection", "PROBLEM", 359, 368], ["these virus", "PROBLEM", 387, 398], ["LASV", "OBSERVATION_MODIFIER", 285, 289], ["infection", "OBSERVATION", 290, 299]]], ["It is possible that, in some cases, phosphatidylserine receptors act as a scaffold, recruiting additional virus-specific receptors or cell factors that are required to assemble an entry complex for viral endocytosis.", [["cell", "ANATOMY", 134, 138], ["phosphatidylserine", "CHEMICAL", 36, 54], ["phosphatidylserine", "CHEMICAL", 36, 54], ["phosphatidylserine receptors", "GENE_OR_GENE_PRODUCT", 36, 64], ["cell", "CELL", 134, 138], ["phosphatidylserine receptors", "PROTEIN", 36, 64], ["virus-specific receptors", "PROTEIN", 106, 130], ["cell factors", "PROTEIN", 134, 146], ["entry complex", "PROTEIN", 180, 193], ["phosphatidylserine receptors", "TREATMENT", 36, 64], ["a scaffold", "TREATMENT", 72, 82], ["additional virus", "PROBLEM", 95, 111], ["cell factors", "PROBLEM", 134, 146], ["viral endocytosis", "PROBLEM", 198, 215], ["possible", "UNCERTAINTY", 6, 14], ["viral endocytosis", "OBSERVATION", 198, 215]]], ["However, these proposed mechanisms of apoptotic mimicry have yet to be experimentally tested.Host cell entry via apoptotic mimicryClassic apoptotic mimicry may also enhance virus binding to host cells.", [["cell", "ANATOMY", 98, 102], ["cells", "ANATOMY", 195, 200], ["Host cell", "CELL", 93, 102], ["host cells", "CELL", 190, 200], ["host cells", "CELL_TYPE", 190, 200], ["apoptotic mimicry", "PROBLEM", 38, 55], ["Classic apoptotic mimicry", "PROBLEM", 130, 155], ["apoptotic mimicry", "OBSERVATION", 38, 55], ["cell entry", "OBSERVATION", 98, 108], ["apoptotic mimicry", "OBSERVATION", 113, 130], ["apoptotic mimicry", "OBSERVATION", 138, 155], ["host cells", "OBSERVATION", 190, 200]]], ["The first link between cellular phosphatidylserine receptors and enhanced virus binding was provided by a study investigating the mechanism of residual transduction of pseudotyped lentiviruses in which the natural envelope proteins had been substituted to ablate receptor-binding activity20.", [["cellular", "ANATOMY", 23, 31], ["phosphatidylserine", "CHEMICAL", 32, 50], ["phosphatidylserine", "CHEMICAL", 32, 50], ["cellular", "CELL", 23, 31], ["phosphatidylserine receptors", "GENE_OR_GENE_PRODUCT", 32, 60], ["pseudotyped", "ORGANISM", 168, 179], ["lentiviruses", "ORGANISM", 180, 192], ["cellular phosphatidylserine receptors", "PROTEIN", 23, 60], ["natural envelope proteins", "PROTEIN", 206, 231], ["cellular phosphatidylserine receptors", "TREATMENT", 23, 60], ["enhanced virus binding", "PROBLEM", 65, 87], ["a study", "TEST", 104, 111], ["residual transduction of pseudotyped lentiviruses", "PROBLEM", 143, 192], ["the natural envelope proteins", "TREATMENT", 202, 231], ["cellular phosphatidylserine receptors", "OBSERVATION", 23, 60], ["virus binding", "OBSERVATION", 74, 87], ["residual transduction of", "OBSERVATION", 143, 167], ["pseudotyped lentiviruses", "OBSERVATION", 168, 192]]], ["Although the endocytic pathway used by these pseudotyped lentiviruses when engaging phosphatidylserine receptors was not determined, the authors showed that the TAM ligands GAS6 and PROS enhanced lentiviral binding to target cells expressing AXL and TYRO3, thus leading to increased transduction.", [["cells", "ANATOMY", 225, 230], ["phosphatidylserine", "CHEMICAL", 84, 102], ["TAM", "CHEMICAL", 161, 164], ["phosphatidylserine", "CHEMICAL", 84, 102], ["TAM", "CHEMICAL", 161, 164], ["pseudotyped lentiviruses", "ORGANISM", 45, 69], ["phosphatidylserine receptors", "GENE_OR_GENE_PRODUCT", 84, 112], ["TAM", "SIMPLE_CHEMICAL", 161, 164], ["GAS6", "GENE_OR_GENE_PRODUCT", 173, 177], ["PROS", "GENE_OR_GENE_PRODUCT", 182, 186], ["lentiviral", "ORGANISM", 196, 206], ["cells", "CELL", 225, 230], ["AXL", "GENE_OR_GENE_PRODUCT", 242, 245], ["TYRO3", "GENE_OR_GENE_PRODUCT", 250, 255], ["phosphatidylserine receptors", "PROTEIN", 84, 112], ["GAS6", "PROTEIN", 173, 177], ["PROS", "PROTEIN", 182, 186], ["target cells", "CELL_TYPE", 218, 230], ["AXL", "PROTEIN", 242, 245], ["TYRO3", "PROTEIN", 250, 255], ["these pseudotyped lentiviruses", "PROBLEM", 39, 69], ["engaging phosphatidylserine receptors", "TEST", 75, 112], ["the TAM ligands GAS6", "TEST", 157, 177], ["PROS enhanced lentiviral binding", "PROBLEM", 182, 214], ["increased transduction", "PROBLEM", 273, 295]]], ["Staining of pseudovirus particles with the phosphatidylserine-binding protein annexin V showed that the lentiviral vectors contained phosphatidylserine regardless of the viral envelope protein used for pseudotyping.", [["phosphatidylserine", "CHEMICAL", 43, 61], ["phosphatidylserine", "CHEMICAL", 133, 151], ["phosphatidylserine", "CHEMICAL", 43, 61], ["phosphatidylserine", "CHEMICAL", 133, 151], ["pseudovirus", "ORGANISM", 12, 23], ["phosphatidylserine-binding protein annexin V", "GENE_OR_GENE_PRODUCT", 43, 87], ["lentiviral", "ORGANISM", 104, 114], ["phosphatidylserine", "AMINO_ACID", 133, 151], ["phosphatidylserine-binding protein annexin V", "PROTEIN", 43, 87], ["viral envelope protein", "PROTEIN", 170, 192], ["pseudovirus particles", "PROBLEM", 12, 33], ["the phosphatidylserine-binding protein annexin V", "TEST", 39, 87], ["the lentiviral vectors", "TREATMENT", 100, 122], ["phosphatidylserine", "TREATMENT", 133, 151], ["the viral envelope protein", "PROBLEM", 166, 192], ["pseudotyping", "PROBLEM", 202, 214], ["pseudovirus particles", "OBSERVATION", 12, 33], ["lentiviral vectors", "OBSERVATION", 104, 122], ["viral envelope protein", "OBSERVATION", 170, 192]]], ["This suggests that phosphatidylserine acquisition, and thus apoptotic mimicry, is an intrinsic feature of lentiviruses.", [["phosphatidylserine", "CHEMICAL", 19, 37], ["phosphatidylserine", "CHEMICAL", 19, 37], ["phosphatidylserine", "SIMPLE_CHEMICAL", 19, 37], ["lentiviruses", "ORGANISM", 106, 118], ["phosphatidylserine acquisition", "TEST", 19, 49], ["lentiviruses", "PROBLEM", 106, 118], ["phosphatidylserine acquisition", "OBSERVATION", 19, 49], ["apoptotic mimicry", "OBSERVATION", 60, 77], ["lentiviruses", "OBSERVATION", 106, 118]]], ["Overexpression of the TAM receptors TYRO3 and AXL in a non-permissive cell line enhanced GAS6-mediated transduction20.", [["cell line", "ANATOMY", 70, 79], ["TAM", "CHEMICAL", 22, 25], ["TAM", "CHEMICAL", 22, 25], ["TAM", "GENE_OR_GENE_PRODUCT", 22, 25], ["TYRO3", "GENE_OR_GENE_PRODUCT", 36, 41], ["AXL", "GENE_OR_GENE_PRODUCT", 46, 49], ["cell line", "CELL", 70, 79], ["GAS6", "GENE_OR_GENE_PRODUCT", 89, 93], ["TAM receptors", "PROTEIN", 22, 35], ["TYRO3", "PROTEIN", 36, 41], ["AXL", "PROTEIN", 46, 49], ["non-permissive cell line", "CELL_LINE", 55, 79], ["GAS6", "PROTEIN", 89, 93], ["a non-permissive cell line enhanced GAS6-mediated transduction20", "TREATMENT", 53, 117], ["AXL", "ANATOMY", 46, 49], ["non-permissive cell line", "OBSERVATION", 55, 79]]], ["The link between lentiviral phosphatidylserine, GAS6 and AXL was confirmed by showing that either mutation of the phosphatidylserine-binding domain of GAS6 or incubation with AXL-specific antibodies could abrogate viral transduction20.", [["phosphatidylserine", "CHEMICAL", 28, 46], ["phosphatidylserine", "CHEMICAL", 114, 132], ["phosphatidylserine", "CHEMICAL", 28, 46], ["phosphatidylserine", "CHEMICAL", 114, 132], ["lentiviral", "ORGANISM", 17, 27], ["phosphatidylserine", "AMINO_ACID", 28, 46], ["GAS6", "GENE_OR_GENE_PRODUCT", 48, 52], ["AXL", "GENE_OR_GENE_PRODUCT", 57, 60], ["phosphatidylserine", "AMINO_ACID", 114, 132], ["GAS6", "GENE_OR_GENE_PRODUCT", 151, 155], ["AXL", "GENE_OR_GENE_PRODUCT", 175, 178], ["GAS6", "PROTEIN", 48, 52], ["AXL", "PROTEIN", 57, 60], ["phosphatidylserine-binding domain", "PROTEIN", 114, 147], ["GAS6", "PROTEIN", 151, 155], ["AXL", "PROTEIN", 175, 178], ["specific antibodies", "PROTEIN", 179, 198], ["lentiviral phosphatidylserine", "TEST", 17, 46], ["AXL", "TEST", 175, 178], ["viral transduction20", "TREATMENT", 214, 234], ["lentiviral phosphatidylserine", "OBSERVATION", 17, 46]]], ["Apoptotic mimicry by lentiviruses does not seem to be limited to the use of TAM receptors, as bridging of viral phosphatidylserine to integrin by the phosphatidylserine receptor MFGE8 (also known as lactadherin) has also been observed52.", [["TAM", "CHEMICAL", 76, 79], ["phosphatidylserine", "CHEMICAL", 112, 130], ["phosphatidylserine", "CHEMICAL", 150, 168], ["TAM", "CHEMICAL", 76, 79], ["phosphatidylserine", "CHEMICAL", 112, 130], ["phosphatidylserine", "CHEMICAL", 150, 168], ["lentiviruses", "ORGANISM", 21, 33], ["TAM receptors", "GENE_OR_GENE_PRODUCT", 76, 89], ["phosphatidylserine", "AMINO_ACID", 112, 130], ["integrin", "GENE_OR_GENE_PRODUCT", 134, 142], ["phosphatidylserine receptor", "GENE_OR_GENE_PRODUCT", 150, 177], ["MFGE8", "GENE_OR_GENE_PRODUCT", 178, 183], ["lactadherin", "GENE_OR_GENE_PRODUCT", 199, 210], ["TAM receptors", "PROTEIN", 76, 89], ["integrin", "PROTEIN", 134, 142], ["phosphatidylserine receptor", "PROTEIN", 150, 177], ["MFGE8", "PROTEIN", 178, 183], ["lactadherin", "PROTEIN", 199, 210], ["TAM receptors", "TREATMENT", 76, 89], ["viral phosphatidylserine", "TREATMENT", 106, 130], ["integrin", "TREATMENT", 134, 142], ["the phosphatidylserine receptor MFGE8", "TREATMENT", 146, 183], ["lentiviruses", "OBSERVATION", 21, 33], ["viral phosphatidylserine", "OBSERVATION", 106, 130]]], ["In addition, transduction of a baculovirus was enhanced by the expression of TIM1 in non-permissive cell lines, and this enhancement was shown to occur in a phosphatidylserine-dependent manner19.", [["cell lines", "ANATOMY", 100, 110], ["phosphatidylserine", "CHEMICAL", 157, 175], ["phosphatidylserine", "CHEMICAL", 157, 175], ["baculovirus", "ORGANISM", 31, 42], ["TIM1", "GENE_OR_GENE_PRODUCT", 77, 81], ["cell lines", "CELL", 100, 110], ["phosphatidylserine", "SIMPLE_CHEMICAL", 157, 175], ["TIM1", "PROTEIN", 77, 81], ["non-permissive cell lines", "CELL_LINE", 85, 110], ["phosphatidylserine-dependent manner19", "PROTEIN", 157, 194], ["baculovirus", "SPECIES", 31, 42], ["a baculovirus", "TREATMENT", 29, 42], ["non-permissive cell lines", "TREATMENT", 85, 110], ["non-permissive cell lines", "OBSERVATION", 85, 110]]], ["Both baculoviruses and lentiviruses are used as viral vectors for gene delivery.", [["lentiviruses", "ORGANISM", 23, 35], ["Both baculoviruses", "TREATMENT", 0, 18], ["lentiviruses", "TREATMENT", 23, 35], ["viral vectors", "TREATMENT", 48, 61], ["gene delivery", "TREATMENT", 66, 79], ["lentiviruses", "OBSERVATION", 23, 35]]], ["The fact that these unrelated viral vectors were found to use apoptotic mimicry for enhanced transduction suggests that it is important to consider the consequences of phosphatidylserine-mediated residual transduction before the use of these vectors for gene delivery.Host cell entry via apoptotic mimicryNon-classic apoptotic mimicry.", [["cell", "ANATOMY", 273, 277], ["phosphatidylserine", "CHEMICAL", 168, 186], ["phosphatidylserine", "CHEMICAL", 168, 186], ["phosphatidylserine", "SIMPLE_CHEMICAL", 168, 186], ["Host cell", "CELL", 268, 277], ["these unrelated viral vectors", "PROBLEM", 14, 43], ["enhanced transduction", "TREATMENT", 84, 105], ["phosphatidylserine-mediated residual transduction", "TREATMENT", 168, 217], ["these vectors", "TREATMENT", 236, 249], ["gene delivery", "TREATMENT", 254, 267], ["Non-classic apoptotic mimicry", "PROBLEM", 305, 334], ["cell entry", "OBSERVATION", 273, 283], ["apoptotic mimicry", "OBSERVATION", 288, 305], ["apoptotic mimicry", "OBSERVATION", 317, 334]]], ["Recent findings indicate that even non-enveloped viruses have evolved strategies to engage apoptotic clearance receptors for internalization (Fig. 2), underscoring the adaptive advantage offered by apoptotic mimicry to a wide range of viruses.", [["apoptotic clearance receptors", "PROTEIN", 91, 120], ["non-enveloped viruses", "PROBLEM", 35, 56], ["apoptotic clearance receptors", "TREATMENT", 91, 120], ["the adaptive advantage", "TREATMENT", 164, 186], ["non-enveloped", "OBSERVATION_MODIFIER", 35, 48], ["viruses", "OBSERVATION", 49, 56], ["viruses", "OBSERVATION", 235, 242]]], ["Non-enveloped viruses do not have a membrane in which to incorporate phosphatidylserine and so are not able to engage in classic apoptotic mimicry.", [["membrane", "ANATOMY", 36, 44], ["phosphatidylserine", "CHEMICAL", 69, 87], ["phosphatidylserine", "CHEMICAL", 69, 87], ["membrane", "CELLULAR_COMPONENT", 36, 44], ["phosphatidylserine", "SIMPLE_CHEMICAL", 69, 87], ["Non-enveloped viruses", "PROBLEM", 0, 21], ["phosphatidylserine", "TREATMENT", 69, 87], ["viruses", "OBSERVATION", 14, 21], ["apoptotic mimicry", "OBSERVATION", 129, 146]]], ["In the most divergent viral apoptotic mimicry mechanism, SV40, a non-enveloped polyomavirus, displays its own ligand for AXL in lieu of a bridging molecule, thereby circumventing the requirement for phosphatidylserine53.", [["phosphatidylserine53", "CHEMICAL", 199, 219], ["phosphatidylserine53", "CHEMICAL", 199, 219], ["SV40", "ORGANISM", 57, 61], ["AXL", "GENE_OR_GENE_PRODUCT", 121, 124], ["phosphatidylserine53", "SIMPLE_CHEMICAL", 199, 219], ["AXL", "PROTEIN", 121, 124], ["phosphatidylserine53", "PROTEIN", 199, 219], ["a non-enveloped polyomavirus", "PROBLEM", 63, 91], ["a bridging molecule", "PROBLEM", 136, 155], ["phosphatidylserine53", "TREATMENT", 199, 219], ["most divergent", "OBSERVATION_MODIFIER", 7, 21], ["viral apoptotic mimicry", "OBSERVATION", 22, 45], ["non-enveloped", "OBSERVATION_MODIFIER", 65, 78], ["polyomavirus", "OBSERVATION", 79, 91], ["bridging molecule", "OBSERVATION", 138, 155]]], ["An elegant predictive approach was taken to identify this SV40 receptor, based on the principle that pathogens have evolved to exploit the cellular machinery of target cells and on the resultant hypothesis that proteins from pathogens mimic the structure of host proteins which are recognized by cellular receptors.", [["cellular", "ANATOMY", 139, 147], ["cells", "ANATOMY", 168, 173], ["cellular", "ANATOMY", 296, 304], ["SV40", "ORGANISM", 58, 62], ["cellular", "CELL", 139, 147], ["cells", "CELL", 168, 173], ["cellular", "CELL", 296, 304], ["SV40 receptor", "PROTEIN", 58, 71], ["target cells", "CELL_TYPE", 161, 173], ["host proteins", "PROTEIN", 258, 271], ["cellular receptors", "PROTEIN", 296, 314], ["this SV40 receptor", "TREATMENT", 53, 71], ["pathogens", "PROBLEM", 101, 110], ["host proteins", "PROBLEM", 258, 271], ["target cells", "OBSERVATION", 161, 173], ["host proteins", "OBSERVATION", 258, 271], ["cellular receptors", "OBSERVATION", 296, 314]]], ["In silico ligand\u2013receptor modelling of the SV40 major capsid protein VP1 against a library of known receptor structures suggested that VP1 structurally mimics the bridging molecule GAS6 to bind TAM receptors.", [["TAM", "CHEMICAL", 194, 197], ["TAM", "CHEMICAL", 194, 197], ["SV40", "ORGANISM", 43, 47], ["VP1", "GENE_OR_GENE_PRODUCT", 69, 72], ["VP1", "GENE_OR_GENE_PRODUCT", 135, 138], ["GAS6", "GENE_OR_GENE_PRODUCT", 181, 185], ["TAM receptors", "GENE_OR_GENE_PRODUCT", 194, 207], ["SV40 major capsid protein VP1", "PROTEIN", 43, 72], ["VP1", "PROTEIN", 135, 138], ["bridging molecule", "PROTEIN", 163, 180], ["GAS6", "PROTEIN", 181, 185], ["TAM receptors", "PROTEIN", 194, 207], ["the SV40 major capsid protein VP1", "TREATMENT", 39, 72], ["a library of known receptor structures", "PROBLEM", 81, 119], ["VP1", "PROBLEM", 135, 138]]], ["This prediction was experimentally confirmed53 by binding studies between SV40 and both TYRO3\u2013Fc and AXL\u2013Fc soluble recombinant proteins, and also by infection experiments in which SV40 colocalized with AXL-expressing cells immediately after viral adsorption.", [["cells", "ANATOMY", 218, 223], ["infection", "DISEASE", 150, 159], ["SV40", "ORGANISM", 74, 78], ["TYRO3\u2013Fc", "GENE_OR_GENE_PRODUCT", 88, 96], ["AXL\u2013Fc", "GENE_OR_GENE_PRODUCT", 101, 107], ["SV40", "ORGANISM", 181, 185], ["AXL", "GENE_OR_GENE_PRODUCT", 203, 206], ["cells", "CELL", 218, 223], ["TYRO3\u2013Fc", "PROTEIN", 88, 96], ["AXL\u2013Fc soluble recombinant proteins", "PROTEIN", 101, 136], ["AXL", "PROTEIN", 203, 206], ["expressing cells", "CELL_TYPE", 207, 223], ["binding studies", "TEST", 50, 65], ["SV40", "TEST", 74, 78], ["AXL\u2013Fc soluble recombinant proteins", "TREATMENT", 101, 136], ["infection experiments", "PROBLEM", 150, 171], ["AXL-expressing cells", "TREATMENT", 203, 223], ["viral adsorption", "TREATMENT", 242, 258], ["infection", "OBSERVATION", 150, 159]]], ["Apoptotic mimicry seems to be required for SV40 infectivity, as AXL knockdown in SV40-permissive cells inhibits infection53.", [["cells", "ANATOMY", 97, 102], ["SV40", "ORGANISM", 43, 47], ["AXL", "GENE_OR_GENE_PRODUCT", 64, 67], ["SV40", "ORGANISM", 81, 85], ["cells", "CELL", 97, 102], ["infection53", "CELL", 112, 123], ["AXL", "PROTEIN", 64, 67], ["SV40-permissive cells", "CELL_LINE", 81, 102], ["Apoptotic mimicry", "PROBLEM", 0, 17], ["SV40 infectivity", "PROBLEM", 43, 59], ["AXL knockdown", "TEST", 64, 77], ["infection53", "PROBLEM", 112, 123], ["permissive cells", "OBSERVATION", 86, 102]]], ["The fact that SV40 usurps the apoptotic clearance pathway by mimicking the phosphatidylserine-bridging molecule GAS6 suggests that the use of phosphatidylserine receptors and the concept of viral apoptotic mimicry is not restricted to enveloped viruses harbouring exposed phosphatidylserine on their membranes.Host cell entry via apoptotic mimicryHepatitis A virus (HAV), which is a member of the Picornaviridae family, uses TIM1 as an entry receptor54, suggesting that this virus uses apoptotic mimicry for infection (Fig. 2).", [["membranes", "ANATOMY", 300, 309], ["cell", "ANATOMY", 315, 319], ["phosphatidylserine", "CHEMICAL", 75, 93], ["phosphatidylserine", "CHEMICAL", 142, 160], ["phosphatidylserine", "CHEMICAL", 272, 290], ["Hepatitis A", "DISEASE", 347, 358], ["infection", "DISEASE", 508, 517], ["phosphatidylserine", "CHEMICAL", 75, 93], ["phosphatidylserine", "CHEMICAL", 142, 160], ["phosphatidylserine", "CHEMICAL", 272, 290], ["SV40", "ORGANISM", 14, 18], ["phosphatidylserine", "SIMPLE_CHEMICAL", 75, 93], ["GAS6", "GENE_OR_GENE_PRODUCT", 112, 116], ["phosphatidylserine receptors", "GENE_OR_GENE_PRODUCT", 142, 170], ["phosphatidylserine", "SIMPLE_CHEMICAL", 272, 290], ["membranes", "CELLULAR_COMPONENT", 300, 309], ["Host cell", "CELL", 310, 319], ["Hepatitis A virus", "ORGANISM", 347, 364], ["HAV", "ORGANISM", 366, 369], ["TIM1", "GENE_OR_GENE_PRODUCT", 425, 429], ["receptor54", "GENE_OR_GENE_PRODUCT", 442, 452], ["phosphatidylserine-bridging molecule", "PROTEIN", 75, 111], ["GAS6", "PROTEIN", 112, 116], ["phosphatidylserine receptors", "PROTEIN", 142, 170], ["TIM1", "PROTEIN", 425, 429], ["entry receptor54", "PROTEIN", 436, 452], ["Hepatitis A virus", "SPECIES", 347, 364], ["Hepatitis A virus", "SPECIES", 347, 364], ["HAV", "SPECIES", 366, 369], ["SV40", "TREATMENT", 14, 18], ["the phosphatidylserine-bridging molecule GAS6", "TREATMENT", 71, 116], ["phosphatidylserine receptors", "TREATMENT", 142, 170], ["viral apoptotic mimicry", "PROBLEM", 190, 213], ["Hepatitis A virus", "PROBLEM", 347, 364], ["TIM1", "TREATMENT", 425, 429], ["this virus", "PROBLEM", 470, 480], ["infection", "PROBLEM", 508, 517], ["viral apoptotic mimicry", "OBSERVATION", 190, 213], ["cell entry", "OBSERVATION", 315, 325], ["apoptotic mimicry", "OBSERVATION", 330, 347]]], ["As HAV is a non-enveloped virus and thus has no membrane, it is possible that it exploits TIM1 by mechanisms other than phosphatidylserine binding.", [["membrane", "ANATOMY", 48, 56], ["phosphatidylserine", "CHEMICAL", 120, 138], ["phosphatidylserine", "CHEMICAL", 120, 138], ["HAV", "ORGANISM", 3, 6], ["membrane", "CELLULAR_COMPONENT", 48, 56], ["TIM1", "GENE_OR_GENE_PRODUCT", 90, 94], ["phosphatidylserine", "SIMPLE_CHEMICAL", 120, 138], ["TIM1", "PROTEIN", 90, 94], ["HAV", "SPECIES", 3, 6], ["a non-enveloped virus", "PROBLEM", 10, 31], ["phosphatidylserine binding", "PROBLEM", 120, 146], ["non-enveloped", "OBSERVATION_MODIFIER", 12, 25], ["virus", "OBSERVATION", 26, 31], ["no", "UNCERTAINTY", 45, 47]]], ["However, it has been proposed that HAV particles become enveloped in host cell membrane when they bud into host cell organelles known as multivesicular bodies (MVBs)55.", [["cell membrane", "ANATOMY", 74, 87], ["bud", "ANATOMY", 98, 101], ["cell organelles", "ANATOMY", 112, 127], ["multivesicular bodies", "ANATOMY", 137, 158], ["MVBs", "ANATOMY", 160, 164], ["HAV particles", "ORGANISM", 35, 48], ["cell membrane", "CELLULAR_COMPONENT", 74, 87], ["cell organelles", "CELLULAR_COMPONENT", 112, 127], ["multivesicular bodies", "CELLULAR_COMPONENT", 137, 158], ["MVBs", "CELLULAR_COMPONENT", 160, 164], ["HAV", "SPECIES", 35, 38], ["HAV particles", "PROBLEM", 35, 48], ["particles", "OBSERVATION_MODIFIER", 39, 48], ["enveloped", "OBSERVATION_MODIFIER", 56, 65], ["host cell membrane", "OBSERVATION", 69, 87], ["host cell organelles", "OBSERVATION", 107, 127], ["multivesicular bodies", "OBSERVATION", 137, 158]]], ["These organelles are thought to release vesicles known as exosomes into the extracellular space on fusion with the plasma membrane.", [["organelles", "ANATOMY", 6, 16], ["vesicles", "ANATOMY", 40, 48], ["exosomes", "ANATOMY", 58, 66], ["extracellular space", "ANATOMY", 76, 95], ["plasma membrane", "ANATOMY", 115, 130], ["organelles", "CELLULAR_COMPONENT", 6, 16], ["vesicles", "CELLULAR_COMPONENT", 40, 48], ["exosomes", "CELL", 58, 66], ["extracellular space", "CELLULAR_COMPONENT", 76, 95], ["plasma membrane", "CELLULAR_COMPONENT", 115, 130], ["exosomes", "CELL_TYPE", 58, 66], ["the plasma membrane", "TREATMENT", 111, 130], ["extracellular", "ANATOMY_MODIFIER", 76, 89], ["fusion", "OBSERVATION", 99, 105], ["plasma membrane", "OBSERVATION", 115, 130]]], ["HAV particles that bud into MVBs may exit cells as exosome-like membrane vesicles55.", [["MVBs", "ANATOMY", 28, 32], ["cells", "ANATOMY", 42, 47], ["exosome-like membrane vesicles", "ANATOMY", 51, 81], ["HAV", "ORGANISM", 0, 3], ["MVBs", "CELLULAR_COMPONENT", 28, 32], ["cells", "CELL", 42, 47], ["exosome", "CELLULAR_COMPONENT", 51, 58], ["membrane vesicles", "CELLULAR_COMPONENT", 64, 81], ["MVBs", "CELL_TYPE", 28, 32], ["exosome", "PROTEIN", 51, 58], ["HAV", "SPECIES", 0, 3], ["HAV particles", "PROBLEM", 0, 13], ["exosome", "TEST", 51, 58], ["particles", "OBSERVATION", 4, 13], ["exit cells", "OBSERVATION", 37, 47]]], ["It is therefore plausible that phosphatidylserine within this acquired membrane engages TIM1 directly, thereby facilitating an apoptotic mimicry mechanism.Host cell entry via apoptotic mimicryAnother recent example of non-classic apoptotic mimicry posits that the spread of enteroviruses, including poliovirus (PV), is facilitated by bulk transfer of virions within phosphatidylserine vesicles56.", [["membrane", "ANATOMY", 71, 79], ["cell", "ANATOMY", 160, 164], ["virions", "ANATOMY", 351, 358], ["phosphatidylserine vesicles", "ANATOMY", 366, 393], ["phosphatidylserine", "CHEMICAL", 31, 49], ["enteroviruses", "DISEASE", 274, 287], ["phosphatidylserine", "CHEMICAL", 366, 384], ["phosphatidylserine", "CHEMICAL", 31, 49], ["phosphatidylserine", "CHEMICAL", 366, 384], ["phosphatidylserine", "SIMPLE_CHEMICAL", 31, 49], ["membrane", "CELLULAR_COMPONENT", 71, 79], ["TIM1", "GENE_OR_GENE_PRODUCT", 88, 92], ["Host cell", "CELL", 155, 164], ["enteroviruses", "ORGANISM", 274, 287], ["poliovirus", "ORGANISM", 299, 309], ["phosphatidylserine vesicles", "CELLULAR_COMPONENT", 366, 393], ["TIM1", "PROTEIN", 88, 92], ["PV", "SPECIES", 311, 313], ["non-classic apoptotic mimicry posits", "PROBLEM", 218, 254], ["enteroviruses", "PROBLEM", 274, 287], ["poliovirus", "PROBLEM", 299, 309], ["apoptotic mimicry", "OBSERVATION", 127, 144], ["cell entry", "OBSERVATION", 160, 170], ["apoptotic mimicry", "OBSERVATION", 175, 192], ["non-classic apoptotic mimicry", "OBSERVATION", 218, 247], ["spread", "OBSERVATION_MODIFIER", 264, 270], ["enteroviruses", "OBSERVATION", 274, 287]]], ["After assembly, non-enveloped cytoplasmic PV virions are captured by large double-membrane autophagosome-like vesicles.", [["cytoplasmic", "ANATOMY", 30, 41], ["membrane", "ANATOMY", 82, 90], ["vesicles", "ANATOMY", 110, 118], ["cytoplasmic", "ORGANISM_SUBSTANCE", 30, 41], ["membrane autophagosome", "CELLULAR_COMPONENT", 82, 104], ["vesicles", "CELLULAR_COMPONENT", 110, 118], ["PV", "SPECIES", 42, 44], ["non-enveloped cytoplasmic PV virions", "PROBLEM", 16, 52], ["non-enveloped", "OBSERVATION_MODIFIER", 16, 29], ["cytoplasmic PV virions", "OBSERVATION", 30, 52], ["large", "OBSERVATION_MODIFIER", 69, 74], ["double", "OBSERVATION_MODIFIER", 75, 81], ["membrane autophagosome", "OBSERVATION", 82, 104], ["vesicles", "ANATOMY", 110, 118]]], ["These vesicles then bud from the cell, leaving behind the outermost membrane, resulting in extracellular PV-containing vesicles with phosphatidylserine exposed on their outer leaflet.", [["vesicles", "ANATOMY", 6, 14], ["bud", "ANATOMY", 20, 23], ["cell", "ANATOMY", 33, 37], ["outermost membrane", "ANATOMY", 58, 76], ["extracellular", "ANATOMY", 91, 104], ["vesicles", "ANATOMY", 119, 127], ["outer leaflet", "ANATOMY", 169, 182], ["phosphatidylserine", "CHEMICAL", 133, 151], ["phosphatidylserine", "CHEMICAL", 133, 151], ["vesicles", "CELLULAR_COMPONENT", 6, 14], ["cell", "CELL", 33, 37], ["outermost membrane", "CELLULAR_COMPONENT", 58, 76], ["extracellular PV", "CELLULAR_COMPONENT", 91, 107], ["vesicles", "CELLULAR_COMPONENT", 119, 127], ["phosphatidylserine", "SIMPLE_CHEMICAL", 133, 151], ["outer leaflet", "CELLULAR_COMPONENT", 169, 182], ["phosphatidylserine", "TREATMENT", 133, 151], ["vesicles", "OBSERVATION", 6, 14], ["bud", "OBSERVATION_MODIFIER", 20, 23], ["cell", "OBSERVATION_MODIFIER", 33, 37], ["outermost", "ANATOMY_MODIFIER", 58, 67], ["membrane", "ANATOMY_MODIFIER", 68, 76], ["extracellular", "ANATOMY_MODIFIER", 91, 104], ["PV", "ANATOMY", 105, 107], ["vesicles", "ANATOMY_MODIFIER", 119, 127], ["phosphatidylserine exposed", "OBSERVATION", 133, 159], ["outer leaflet", "ANATOMY_MODIFIER", 169, 182]]], ["Blocking experiments using annexin V indicated that, in addition to the PV receptors, phosphatidylserine on these vesicles was required for infection56.", [["vesicles", "ANATOMY", 114, 122], ["phosphatidylserine", "CHEMICAL", 86, 104], ["phosphatidylserine", "CHEMICAL", 86, 104], ["annexin V", "GENE_OR_GENE_PRODUCT", 27, 36], ["PV receptors", "GENE_OR_GENE_PRODUCT", 72, 84], ["phosphatidylserine", "SIMPLE_CHEMICAL", 86, 104], ["vesicles", "CELLULAR_COMPONENT", 114, 122], ["annexin V", "PROTEIN", 27, 36], ["PV receptors", "PROTEIN", 72, 84], ["infection56", "PROTEIN", 140, 151], ["annexin V", "TREATMENT", 27, 36], ["the PV receptors", "TREATMENT", 68, 84], ["phosphatidylserine", "TREATMENT", 86, 104], ["these vesicles", "TREATMENT", 108, 122], ["infection56", "PROBLEM", 140, 151]]], ["Although the phosphatidylserine receptors and endocytic mechanism exploited for entry remain to be determined, infection by PV within phosphatidylserine vesicles was more efficient than infection by free PV, emphasizing the advantage of this non-classic apoptotic mimicry strategy.Host cell entry via apoptotic mimicryTo date, viruses from at least nine different families have been shown to use an apoptotic mimicry strategy to engage host cell phosphatidylserine receptors (Table 1).", [["phosphatidylserine vesicles", "ANATOMY", 134, 161], ["cell", "ANATOMY", 286, 290], ["cell", "ANATOMY", 441, 445], ["phosphatidylserine", "CHEMICAL", 13, 31], ["infection", "DISEASE", 111, 120], ["phosphatidylserine", "CHEMICAL", 134, 152], ["infection", "DISEASE", 186, 195], ["phosphatidylserine", "CHEMICAL", 13, 31], ["phosphatidylserine", "CHEMICAL", 134, 152], ["phosphatidylserine", "CHEMICAL", 446, 464], ["phosphatidylserine receptors", "GENE_OR_GENE_PRODUCT", 13, 41], ["phosphatidylserine vesicles", "CELLULAR_COMPONENT", 134, 161], ["Host cell", "CELL", 281, 290], ["host cell phosphatidylserine receptors", "GENE_OR_GENE_PRODUCT", 436, 474], ["Table 1", "GENE_OR_GENE_PRODUCT", 476, 483], ["phosphatidylserine receptors", "PROTEIN", 13, 41], ["host cell phosphatidylserine receptors", "PROTEIN", 436, 474], ["Table 1", "PROTEIN", 476, 483], ["PV", "SPECIES", 124, 126], ["PV", "SPECIES", 204, 206], ["the phosphatidylserine receptors", "TREATMENT", 9, 41], ["infection", "PROBLEM", 111, 120], ["PV within phosphatidylserine vesicles", "PROBLEM", 124, 161], ["infection", "PROBLEM", 186, 195], ["this non-classic apoptotic mimicry strategy", "TREATMENT", 237, 280], ["viruses", "PROBLEM", 327, 334], ["an apoptotic mimicry strategy", "TREATMENT", 396, 425], ["host cell phosphatidylserine receptors", "TREATMENT", 436, 474], ["infection", "OBSERVATION", 111, 120], ["cell entry", "OBSERVATION", 286, 296], ["apoptotic mimicry", "OBSERVATION", 301, 318]]], ["However, it should be noted that conflicting results have been observed in the case of the Old World arenaviruses LASV and lymphocytic choriomeningitis virus (LCMV).", [["arenaviruses LASV", "DISEASE", 101, 118], ["lymphocytic choriomeningitis virus", "DISEASE", 123, 157], ["Old World arenaviruses LASV", "ORGANISM", 91, 118], ["lymphocytic choriomeningitis virus", "ORGANISM", 123, 157], ["LCMV", "ORGANISM", 159, 163], ["lymphocytic choriomeningitis virus", "SPECIES", 123, 157], ["Old World arenaviruses LASV", "SPECIES", 91, 118], ["lymphocytic choriomeningitis virus", "SPECIES", 123, 157], ["LCMV", "SPECIES", 159, 163], ["lymphocytic choriomeningitis virus", "PROBLEM", 123, 157], ["lymphocytic choriomeningitis", "OBSERVATION", 123, 151]]], ["Whether these discrepancies are due to experimental approaches (differences in infection readouts, cell types and virus production protocols) remains to be clarified15,19,21,48.", [["cell", "ANATOMY", 99, 103], ["infection", "DISEASE", 79, 88], ["cell", "CELL", 99, 103], ["these discrepancies", "PROBLEM", 8, 27], ["experimental approaches", "PROBLEM", 39, 62], ["infection readouts", "PROBLEM", 79, 97], ["cell types", "TREATMENT", 99, 109], ["virus production protocols", "TREATMENT", 114, 140]]], ["The most striking similarity between all these viruses is their broad in vitro and in vivo cell type specificity.", [["cell", "ANATOMY", 91, 95], ["cell type", "CELL", 91, 100], ["viruses", "OBSERVATION", 47, 54], ["broad", "OBSERVATION_MODIFIER", 64, 69]]], ["This broad tropism is possibly facilitated by the expression of phosphatidylserine receptors on various different host cell types.Viral immune evasionExperimental evidence suggests that in addition to subverting host cell apoptotic clearance machinery for the promotion of virus binding and uptake, viruses subvert this machinery for other purposes.", [["cell", "ANATOMY", 119, 123], ["cell", "ANATOMY", 217, 221], ["phosphatidylserine", "CHEMICAL", 64, 82], ["phosphatidylserine", "CHEMICAL", 64, 82], ["phosphatidylserine receptors", "GENE_OR_GENE_PRODUCT", 64, 92], ["cell", "CELL", 119, 123], ["host cell", "CELL", 212, 221], ["phosphatidylserine receptors", "PROTEIN", 64, 92], ["host cell types", "CELL_TYPE", 114, 129], ["This broad tropism", "PROBLEM", 0, 18], ["phosphatidylserine receptors", "PROBLEM", 64, 92], ["subverting host cell apoptotic clearance machinery", "TREATMENT", 201, 251], ["virus binding", "PROBLEM", 273, 286], ["broad", "OBSERVATION_MODIFIER", 5, 10], ["tropism", "OBSERVATION", 11, 18], ["possibly", "UNCERTAINTY", 22, 30], ["phosphatidylserine receptors", "OBSERVATION", 64, 92], ["various different", "OBSERVATION_MODIFIER", 96, 113], ["host cell types", "OBSERVATION", 114, 129], ["host cell apoptotic", "OBSERVATION", 212, 231]]], ["For filoviruses as well as some arenaviruses and some flaviviruses, TAM receptor kinase activity has been implicated in the enhancement of infection14,17,21,57.", [["arenaviruses", "DISEASE", 32, 44], ["TAM", "CHEMICAL", 68, 71], ["infection", "DISEASE", 139, 148], ["TAM", "CHEMICAL", 68, 71], ["TAM receptor", "GENE_OR_GENE_PRODUCT", 68, 80], ["TAM receptor kinase", "PROTEIN", 68, 87], ["filoviruses", "PROBLEM", 4, 15], ["some arenaviruses", "PROBLEM", 27, 44], ["some flaviviruses", "PROBLEM", 49, 66], ["TAM receptor kinase activity", "TREATMENT", 68, 96], ["infection", "PROBLEM", 139, 148], ["flaviviruses", "OBSERVATION", 54, 66], ["enhancement", "OBSERVATION_MODIFIER", 124, 135], ["infection", "OBSERVATION", 139, 148]]], ["Deletion of the cytoplasmic tail of AXL or mutation of its ATP-binding site \u2014 a site that is essential for AXL kinase activity \u2014 inhibits DENV and WNV infection without having an effect on endocytosis14,17.", [["cytoplasmic", "ANATOMY", 16, 27], ["ATP", "CHEMICAL", 59, 62], ["WNV infection", "DISEASE", 147, 160], ["ATP", "CHEMICAL", 59, 62], ["cytoplasmic", "ORGANISM_SUBSTANCE", 16, 27], ["AXL", "GENE_OR_GENE_PRODUCT", 36, 39], ["ATP", "SIMPLE_CHEMICAL", 59, 62], ["AXL kinase", "GENE_OR_GENE_PRODUCT", 107, 117], ["DENV", "ORGANISM", 138, 142], ["WNV", "ORGANISM", 147, 150], ["cytoplasmic tail", "PROTEIN", 16, 32], ["AXL", "PROTEIN", 36, 39], ["ATP-binding site", "DNA", 59, 75], ["AXL kinase", "PROTEIN", 107, 117], ["DENV", "SPECIES", 138, 142], ["WNV", "SPECIES", 147, 150], ["Deletion of the cytoplasmic tail of AXL", "PROBLEM", 0, 39], ["mutation of its ATP", "PROBLEM", 43, 62], ["binding site", "PROBLEM", 63, 75], ["AXL kinase activity", "TEST", 107, 126], ["DENV", "PROBLEM", 138, 142], ["WNV infection", "PROBLEM", 147, 160], ["endocytosis", "TEST", 189, 200], ["cytoplasmic", "OBSERVATION_MODIFIER", 16, 27], ["tail", "OBSERVATION_MODIFIER", 28, 32], ["AXL", "ANATOMY", 36, 39], ["DENV", "OBSERVATION", 138, 142], ["WNV", "OBSERVATION_MODIFIER", 147, 150], ["infection", "OBSERVATION", 151, 160]]], ["Although the underlying mechanism remains unknown, these results suggest that activation of AXL facilitates a post-entry step of flavivirus infection.", [["flavivirus infection", "DISEASE", 129, 149], ["AXL", "GENE_OR_GENE_PRODUCT", 92, 95], ["flavivirus", "ORGANISM", 129, 139], ["AXL", "PROTEIN", 92, 95], ["flavivirus infection", "PROBLEM", 129, 149], ["flavivirus", "OBSERVATION_MODIFIER", 129, 139], ["infection", "OBSERVATION", 140, 149]]], ["Interestingly, apoptotic clearance is intimately linked with a dampening of inflammatory responses (Box 1; Fig. 3).", [["a dampening of inflammatory responses", "PROBLEM", 61, 98], ["apoptotic clearance", "OBSERVATION", 15, 34], ["dampening", "OBSERVATION_MODIFIER", 63, 72], ["inflammatory", "OBSERVATION_MODIFIER", 76, 88]]], ["On formation of a tripartite complex with phosphatidylserine and GAS6, TAM receptors have been shown to heterodimerize with type I interferon receptor (IFNAR).", [["phosphatidylserine", "CHEMICAL", 42, 60], ["TAM", "CHEMICAL", 71, 74], ["phosphatidylserine", "CHEMICAL", 42, 60], ["TAM", "CHEMICAL", 71, 74], ["phosphatidylserine", "SIMPLE_CHEMICAL", 42, 60], ["GAS6", "GENE_OR_GENE_PRODUCT", 65, 69], ["TAM receptors", "GENE_OR_GENE_PRODUCT", 71, 84], ["type I interferon receptor", "GENE_OR_GENE_PRODUCT", 124, 150], ["IFNAR", "GENE_OR_GENE_PRODUCT", 152, 157], ["tripartite complex", "PROTEIN", 18, 36], ["GAS6", "PROTEIN", 65, 69], ["TAM receptors", "PROTEIN", 71, 84], ["type I interferon receptor", "PROTEIN", 124, 150], ["IFNAR", "PROTEIN", 152, 157], ["phosphatidylserine and GAS6", "TREATMENT", 42, 69], ["TAM receptors", "TREATMENT", 71, 84], ["type I interferon receptor", "TREATMENT", 124, 150]]], ["This leads to activation of IFNAR signalling, which triggers nuclear translocation of signal transducer and activator of transcription 1 (STAT1) and the subsequent transcription of suppressor of cytokine signalling 1 (SOCS1) and SOCS3, which encode proteins that contribute to the pleiotropic inhibition of inflammatory cytokines and of TLR signalling58.", [["nuclear", "ANATOMY", 61, 68], ["IFNAR", "GENE_OR_GENE_PRODUCT", 28, 33], ["nuclear", "CELLULAR_COMPONENT", 61, 68], ["signal transducer and activator of transcription 1", "GENE_OR_GENE_PRODUCT", 86, 136], ["STAT1", "GENE_OR_GENE_PRODUCT", 138, 143], ["suppressor of cytokine signalling 1", "GENE_OR_GENE_PRODUCT", 181, 216], ["SOCS1", "GENE_OR_GENE_PRODUCT", 218, 223], ["SOCS3", "GENE_OR_GENE_PRODUCT", 229, 234], ["TLR", "GENE_OR_GENE_PRODUCT", 337, 340], ["IFNAR", "PROTEIN", 28, 33], ["signal transducer and activator of transcription 1", "PROTEIN", 86, 136], ["STAT1", "PROTEIN", 138, 143], ["cytokine signalling 1", "PROTEIN", 195, 216], ["SOCS1", "PROTEIN", 218, 223], ["SOCS3", "PROTEIN", 229, 234], ["inflammatory cytokines", "PROTEIN", 307, 329], ["TLR", "PROTEIN", 337, 340], ["IFNAR signalling", "PROBLEM", 28, 44], ["cytokine signalling", "PROBLEM", 195, 214], ["SOCS3", "PROBLEM", 229, 234], ["inflammatory cytokines", "PROBLEM", 307, 329], ["TLR signalling", "TEST", 337, 351], ["inflammatory", "OBSERVATION_MODIFIER", 307, 319]]], ["The major question that arises from these findings is whether virus-mediated activation of phosphatidylserine receptors also dampens the innate immune response to potentiate infection.Viral immune evasionA recent study suggests that TAM ligands complexed to pseudotyped lentiviral particles are 'super TAM agonists' that disable host immune responses and facilitate virus spread14.", [["phosphatidylserine", "CHEMICAL", 91, 109], ["infection", "DISEASE", 174, 183], ["TAM", "CHEMICAL", 233, 236], ["TAM", "CHEMICAL", 302, 305], ["phosphatidylserine", "CHEMICAL", 91, 109], ["TAM", "CHEMICAL", 233, 236], ["TAM", "CHEMICAL", 302, 305], ["phosphatidylserine receptors", "GENE_OR_GENE_PRODUCT", 91, 119], ["TAM", "SIMPLE_CHEMICAL", 233, 236], ["pseudotyped lentiviral particles", "ORGANISM", 258, 290], ["spread14", "GENE_OR_GENE_PRODUCT", 372, 380], ["phosphatidylserine receptors", "PROTEIN", 91, 119], ["virus", "PROBLEM", 62, 67], ["phosphatidylserine receptors", "TREATMENT", 91, 119], ["infection", "PROBLEM", 174, 183], ["Viral immune evasionA", "TEST", 184, 205], ["recent study", "TEST", 206, 218], ["TAM ligands", "PROBLEM", 233, 244], ["pseudotyped lentiviral particles", "TREATMENT", 258, 290], ["'super TAM agonists", "TREATMENT", 295, 314], ["disable host immune responses", "PROBLEM", 321, 350], ["facilitate virus spread14", "PROBLEM", 355, 380], ["infection", "OBSERVATION", 174, 183]]], ["It was shown that TAM-mediated inhibition of type I interferon (IFN) signalling enhances viral infection14.", [["TAM", "CHEMICAL", 18, 21], ["TAM", "CHEMICAL", 18, 21], ["TAM", "SIMPLE_CHEMICAL", 18, 21], ["type I interferon", "GENE_OR_GENE_PRODUCT", 45, 62], ["IFN", "GENE_OR_GENE_PRODUCT", 64, 67], ["viral", "ORGANISM", 89, 94], ["type I interferon", "PROTEIN", 45, 62], ["IFN", "PROTEIN", 64, 67], ["TAM", "TEST", 18, 21], ["type I interferon (IFN", "TREATMENT", 45, 67], ["signalling enhances viral infection14", "PROBLEM", 69, 106], ["viral infection14", "OBSERVATION", 89, 106]]], ["Experiments in bone marrow-derived dendritic cells (BMDCs) from knockout mice lacking all three TAM receptors showed that pseudotyped lentiviral particles containing phosphatidylserine on the viral surface produced a strong antiviral response, with high levels of Ifna4, Ifnb and Socs1 mRNAs compared with levels in infected BMDCs from wild-type mice.", [["bone marrow-derived dendritic cells", "ANATOMY", 15, 50], ["BMDCs", "ANATOMY", 52, 57], ["surface", "ANATOMY", 198, 205], ["BMDCs", "ANATOMY", 325, 330], ["TAM", "CHEMICAL", 96, 99], ["phosphatidylserine", "CHEMICAL", 166, 184], ["TAM", "CHEMICAL", 96, 99], ["phosphatidylserine", "CHEMICAL", 166, 184], ["bone marrow-derived dendritic cells", "CELL", 15, 50], ["BMDCs", "CELL", 52, 57], ["mice", "ORGANISM", 73, 77], ["pseudotyped lentiviral particles", "ORGANISM", 122, 154], ["phosphatidylserine", "AMINO_ACID", 166, 184], ["Ifna4", "GENE_OR_GENE_PRODUCT", 264, 269], ["Ifnb", "GENE_OR_GENE_PRODUCT", 271, 275], ["Socs1", "GENE_OR_GENE_PRODUCT", 280, 285], ["BMDCs", "CELL", 325, 330], ["mice", "ORGANISM", 346, 350], ["bone marrow-derived dendritic cells", "CELL_TYPE", 15, 50], ["BMDCs", "CELL_TYPE", 52, 57], ["TAM receptors", "PROTEIN", 96, 109], ["Ifna4, Ifnb and Socs1 mRNAs", "RNA", 264, 291], ["BMDCs", "CELL_TYPE", 325, 330], ["mice", "SPECIES", 73, 77], ["mice", "SPECIES", 346, 350], ["mice", "SPECIES", 73, 77], ["mice", "SPECIES", 346, 350], ["Experiments in bone marrow", "TEST", 0, 26], ["dendritic cells", "PROBLEM", 35, 50], ["knockout mice", "TREATMENT", 64, 77], ["all three TAM receptors", "TEST", 86, 109], ["pseudotyped lentiviral particles", "PROBLEM", 122, 154], ["the viral surface", "TEST", 188, 205], ["high levels of Ifna4", "PROBLEM", 249, 269], ["Ifnb and Socs1 mRNAs", "PROBLEM", 271, 291], ["bone marrow", "ANATOMY", 15, 26], ["dendritic cells", "OBSERVATION", 35, 50], ["pseudotyped lentiviral particles", "OBSERVATION", 122, 154], ["viral surface", "OBSERVATION_MODIFIER", 192, 205], ["strong", "OBSERVATION_MODIFIER", 217, 223], ["antiviral response", "OBSERVATION", 224, 242], ["Socs1 mRNAs", "OBSERVATION", 280, 291], ["infected", "OBSERVATION_MODIFIER", 316, 324], ["BMDCs", "OBSERVATION", 325, 330]]], ["Importantly, inclusion of antibodies against IFN\u03b1 and IFN\u03b2 proteins restored the level of infection in TAM triple-knockout BMDCs from the reduced level caused by the antiviral response to that seen in wild-type cells.", [["BMDCs", "ANATOMY", 123, 128], ["wild-type cells", "ANATOMY", 201, 216], ["infection", "DISEASE", 90, 99], ["TAM", "CHEMICAL", 103, 106], ["TAM", "CHEMICAL", 103, 106], ["antibodies against IFN\u03b1", "GENE_OR_GENE_PRODUCT", 26, 49], ["IFN\u03b2", "GENE_OR_GENE_PRODUCT", 54, 58], ["TAM", "SIMPLE_CHEMICAL", 103, 106], ["BMDCs", "CELL", 123, 128], ["cells", "CELL", 211, 216], ["antibodies", "PROTEIN", 26, 36], ["IFN\u03b1", "PROTEIN", 45, 49], ["IFN\u03b2 proteins", "PROTEIN", 54, 67], ["TAM triple-knockout BMDCs", "CELL_LINE", 103, 128], ["wild-type cells", "CELL_TYPE", 201, 216], ["antibodies", "TREATMENT", 26, 36], ["IFN", "TREATMENT", 45, 48], ["IFN\u03b2 proteins", "TEST", 54, 67], ["infection", "PROBLEM", 90, 99], ["knockout BMDCs", "PROBLEM", 114, 128], ["the reduced level", "PROBLEM", 134, 151], ["infection", "OBSERVATION", 90, 99], ["knockout BMDCs", "OBSERVATION", 114, 128], ["antiviral response", "OBSERVATION", 166, 184]]], ["Therefore, these data indicate that inhibition of the antiviral type I IFN response is the primary mechanism of TAM-mediated enhancement of lentiviral infection (Fig. 3).Viral immune evasionInterestingly, expression of CD300a (also known as CLM8), a recently identified direct phosphatidylserine receptor expressed mainly on myeloid and mast cells59,60, has been shown to increase the binding of pseudotyped lentiviral particles to host cells, but without any change in transduction efficiency52.", [["myeloid", "ANATOMY", 325, 332], ["mast cells", "ANATOMY", 337, 347], ["cells", "ANATOMY", 437, 442], ["TAM", "CHEMICAL", 112, 115], ["lentiviral infection", "DISEASE", 140, 160], ["phosphatidylserine", "CHEMICAL", 277, 295], ["TAM", "CHEMICAL", 112, 115], ["phosphatidylserine", "CHEMICAL", 277, 295], ["type I IFN", "GENE_OR_GENE_PRODUCT", 64, 74], ["TAM", "SIMPLE_CHEMICAL", 112, 115], ["lentiviral", "ORGANISM", 140, 150], ["CD300a", "GENE_OR_GENE_PRODUCT", 219, 225], ["CLM8", "GENE_OR_GENE_PRODUCT", 241, 245], ["phosphatidylserine receptor", "GENE_OR_GENE_PRODUCT", 277, 304], ["myeloid", "CELL", 325, 332], ["mast cells59,60", "CELL", 337, 352], ["lentiviral", "ORGANISM", 408, 418], ["host cells", "CELL", 432, 442], ["IFN", "PROTEIN", 71, 74], ["CD300a", "PROTEIN", 219, 225], ["CLM8", "PROTEIN", 241, 245], ["phosphatidylserine receptor", "PROTEIN", 277, 304], ["myeloid and mast cells59,60", "CELL_LINE", 325, 352], ["host cells", "CELL_TYPE", 432, 442], ["these data", "TEST", 11, 21], ["the antiviral type I IFN response", "TREATMENT", 50, 83], ["TAM", "PROBLEM", 112, 115], ["lentiviral infection", "PROBLEM", 140, 160], ["Viral immune evasion", "PROBLEM", 170, 190], ["direct phosphatidylserine receptor", "TREATMENT", 270, 304], ["mast cells", "TEST", 337, 347], ["pseudotyped lentiviral particles", "TREATMENT", 396, 428], ["any change in transduction efficiency", "PROBLEM", 456, 493], ["lentiviral infection", "OBSERVATION", 140, 160], ["immune evasion", "OBSERVATION", 176, 190], ["myeloid", "ANATOMY", 325, 332], ["mast cells", "OBSERVATION", 337, 347], ["host cells", "OBSERVATION", 432, 442], ["without", "UNCERTAINTY", 448, 455]]], ["Of note, engagement of CD300a by apoptotic cells does not promote their clearance; instead, on binding to phosphatidylserine, the cytoplasmic immunoreceptor tyrosine-based inhibition motif (ITIM) of CD300a recruits the phosphatase SHP1 (also known as PTPN6), which blocks the release of inflammatory cytokines and chemokines61.", [["cells", "ANATOMY", 43, 48], ["cytoplasmic", "ANATOMY", 130, 141], ["phosphatidylserine", "CHEMICAL", 106, 124], ["tyrosine", "CHEMICAL", 157, 165], ["phosphatidylserine", "CHEMICAL", 106, 124], ["tyrosine", "CHEMICAL", 157, 165], ["CD300a", "GENE_OR_GENE_PRODUCT", 23, 29], ["cells", "CELL", 43, 48], ["phosphatidylserine", "SIMPLE_CHEMICAL", 106, 124], ["cytoplasmic", "ORGANISM_SUBSTANCE", 130, 141], ["tyrosine", "AMINO_ACID", 157, 165], ["CD300a", "GENE_OR_GENE_PRODUCT", 199, 205], ["SHP1", "GENE_OR_GENE_PRODUCT", 231, 235], ["PTPN6", "GENE_OR_GENE_PRODUCT", 251, 256], ["CD300a", "PROTEIN", 23, 29], ["apoptotic cells", "CELL_TYPE", 33, 48], ["cytoplasmic immunoreceptor tyrosine-based inhibition motif", "PROTEIN", 130, 188], ["ITIM", "PROTEIN", 190, 194], ["CD300a", "PROTEIN", 199, 205], ["phosphatase", "PROTEIN", 219, 230], ["SHP1", "PROTEIN", 231, 235], ["PTPN6", "PROTEIN", 251, 256], ["inflammatory cytokines", "PROTEIN", 287, 309], ["chemokines61", "PROTEIN", 314, 326], ["apoptotic cells", "PROBLEM", 33, 48], ["phosphatidylserine", "TREATMENT", 106, 124], ["the cytoplasmic immunoreceptor tyrosine", "TREATMENT", 126, 165], ["the phosphatase SHP1", "TEST", 215, 235], ["inflammatory cytokines", "PROBLEM", 287, 309], ["chemokines", "TEST", 314, 324], ["inflammatory cytokines", "OBSERVATION", 287, 309]]], ["Thus, it is plausible that binding of a virus to CD300a modulates the inflammatory and innate immune responses of the host rather than facilitating viral uptake by endocytosis.Viral immune evasionAlthough direct evidence for using apoptotic mimicry to dampen the host immune response is thus far limited to pseudotyped lentiviruses, similarities have been noted between immunosuppression during apoptotic cell clearance and that during in vivo VACV infections; VACV infections lead to the upregulation of anti-inflammatory cytokines, including transforming growth factor-\u03b2 (TGF\u03b2) and interleukin-10 (IL-10), which prevent macrophage infiltration and inhibit T cell maturation62.", [["cell", "ANATOMY", 405, 409], ["macrophage", "ANATOMY", 622, 632], ["T cell", "ANATOMY", 658, 664], ["infections", "DISEASE", 449, 459], ["VACV infections", "DISEASE", 461, 476], ["CD300a", "GENE_OR_GENE_PRODUCT", 49, 55], ["pseudotyped", "ORGANISM", 307, 318], ["lentiviruses", "ORGANISM", 319, 331], ["cell", "CELL", 405, 409], ["VACV", "ORGANISM", 444, 448], ["VACV", "ORGANISM", 461, 465], ["transforming growth factor-\u03b2", "GENE_OR_GENE_PRODUCT", 544, 572], ["TGF\u03b2", "GENE_OR_GENE_PRODUCT", 574, 578], ["interleukin-10", "GENE_OR_GENE_PRODUCT", 584, 598], ["IL-10", "GENE_OR_GENE_PRODUCT", 600, 605], ["macrophage", "CELL", 622, 632], ["T cell", "CELL", 658, 664], ["CD300a", "PROTEIN", 49, 55], ["anti-inflammatory cytokines", "PROTEIN", 505, 532], ["TGF\u03b2", "PROTEIN", 574, 578], ["interleukin-10 (IL-10", "PROTEIN", 584, 605], ["VACV", "SPECIES", 444, 448], ["VACV", "SPECIES", 461, 465], ["a virus", "PROBLEM", 38, 45], ["Viral immune evasion", "PROBLEM", 176, 196], ["apoptotic mimicry", "TREATMENT", 231, 248], ["pseudotyped lentiviruses", "PROBLEM", 307, 331], ["immunosuppression", "TREATMENT", 370, 387], ["apoptotic cell clearance", "TREATMENT", 395, 419], ["vivo VACV infections", "PROBLEM", 439, 459], ["VACV infections", "PROBLEM", 461, 476], ["anti-inflammatory cytokines", "TREATMENT", 505, 532], ["transforming growth factor", "TEST", 544, 570], ["TGF", "TEST", 574, 577], ["interleukin", "TEST", 584, 595], ["IL", "TEST", 600, 602], ["macrophage infiltration", "PROBLEM", 622, 645], ["T cell maturation62", "PROBLEM", 658, 677], ["inflammatory", "OBSERVATION_MODIFIER", 70, 82], ["viral uptake", "OBSERVATION", 148, 160], ["apoptotic cell clearance", "OBSERVATION", 395, 419], ["anti-inflammatory cytokines", "OBSERVATION", 505, 532], ["prevent", "UNCERTAINTY", 614, 621], ["macrophage infiltration", "OBSERVATION", 622, 645]]], ["It has been proposed that the suppression of innate immunity facilitates unchecked viral replication, but whether this is due to the engagement of phosphatidylserine receptors \u2014 and hence to apoptotic mimicry \u2014 remains to be determined.Viral immune evasionThese studies do suggest that phosphatidylserine receptors are activated by viruses during binding and/or entry to modulate innate immunity, but additional studies are required to determine the exact molecular mechanisms involved and to extend the findings to other viral systems.", [["phosphatidylserine", "CHEMICAL", 147, 165], ["phosphatidylserine", "CHEMICAL", 286, 304], ["phosphatidylserine", "CHEMICAL", 147, 165], ["phosphatidylserine", "CHEMICAL", 286, 304], ["phosphatidylserine receptors", "GENE_OR_GENE_PRODUCT", 147, 175], ["phosphatidylserine receptors", "GENE_OR_GENE_PRODUCT", 286, 314], ["phosphatidylserine receptors", "PROTEIN", 147, 175], ["phosphatidylserine receptors", "PROTEIN", 286, 314], ["innate immunity", "TREATMENT", 45, 60], ["unchecked viral replication", "TREATMENT", 73, 100], ["phosphatidylserine receptors", "TREATMENT", 147, 175], ["Viral immune evasion", "TREATMENT", 236, 256], ["These studies", "TEST", 256, 269], ["phosphatidylserine receptors", "TREATMENT", 286, 314], ["viruses", "PROBLEM", 332, 339], ["additional studies", "TEST", 401, 419], ["immune evasion", "OBSERVATION", 242, 256]]], ["In addition, the concept of viral apoptotic mimicry being a means of immune evasion has to date been reported only in infection studies performed with mouse BMDCs and awaits confirmation in additional cell types and, more importantly, in vivo.", [["BMDCs", "ANATOMY", 157, 162], ["cell", "ANATOMY", 201, 205], ["infection", "DISEASE", 118, 127], ["mouse", "ORGANISM", 151, 156], ["BMDCs", "CELL", 157, 162], ["cell", "CELL", 201, 205], ["mouse BMDCs", "CELL_TYPE", 151, 162], ["mouse", "SPECIES", 151, 156], ["mouse", "SPECIES", 151, 156], ["viral apoptotic mimicry", "PROBLEM", 28, 51], ["immune evasion", "PROBLEM", 69, 83], ["infection studies", "TEST", 118, 135], ["mouse BMDCs", "TREATMENT", 151, 162], ["viral apoptotic mimicry", "OBSERVATION", 28, 51]]], ["Furthermore, as several viruses can engage both direct and indirect phosphatidylserine receptors, whether apoptotic mimicry for the purpose of immune evasion can be extended to direct phosphatidylserine receptors, such as TIMs, should be explored.PerspectivesApoptotic cell death and clearance are essential functions within all multicellular organisms63,64.", [["cell", "ANATOMY", 269, 273], ["phosphatidylserine", "CHEMICAL", 68, 86], ["phosphatidylserine", "CHEMICAL", 184, 202], ["phosphatidylserine", "CHEMICAL", 68, 86], ["phosphatidylserine", "CHEMICAL", 184, 202], ["phosphatidylserine receptors", "GENE_OR_GENE_PRODUCT", 68, 96], ["phosphatidylserine receptors", "GENE_OR_GENE_PRODUCT", 184, 212], ["TIMs", "GENE_OR_GENE_PRODUCT", 222, 226], ["Apoptotic cell", "CELL", 259, 273], ["phosphatidylserine receptors", "PROTEIN", 68, 96], ["phosphatidylserine receptors", "PROTEIN", 184, 212], ["TIMs", "PROTEIN", 222, 226], ["several viruses", "PROBLEM", 16, 31], ["indirect phosphatidylserine receptors", "TREATMENT", 59, 96], ["apoptotic mimicry", "PROBLEM", 106, 123], ["immune evasion", "TREATMENT", 143, 157], ["direct phosphatidylserine receptors", "TREATMENT", 177, 212], ["TIMs", "TREATMENT", 222, 226], ["Apoptotic cell death", "PROBLEM", 259, 279], ["all multicellular organisms", "TEST", 325, 352], ["Apoptotic cell death", "OBSERVATION", 259, 279]]], ["Owing to their importance in the maintenance of tissue homeostasis, defects in these processes often result in disease.", [["tissue", "ANATOMY", 48, 54], ["tissue", "TISSUE", 48, 54], ["tissue homeostasis", "PROBLEM", 48, 66], ["defects in these processes", "PROBLEM", 68, 94], ["disease", "PROBLEM", 111, 118], ["tissue homeostasis", "OBSERVATION", 48, 66], ["defects", "OBSERVATION", 68, 75], ["disease", "OBSERVATION", 111, 118]]], ["Like many other indispensible host processes, apoptosis is subverted by viruses1, and recent studies have shown that viruses disguised as apoptotic debris hijack the apoptotic clearance machinery.", [["apoptosis", "PROBLEM", 46, 55], ["recent studies", "TEST", 86, 100], ["viruses", "PROBLEM", 117, 124], ["host processes", "OBSERVATION", 30, 44], ["apoptosis", "OBSERVATION", 46, 55], ["viruses", "OBSERVATION", 117, 124], ["apoptotic clearance", "OBSERVATION", 166, 185]]], ["In the past few years, the list of enveloped viruses that use apoptotic mimicry has expanded (Table 1).", [["enveloped viruses", "PROBLEM", 35, 52], ["apoptotic mimicry", "PROBLEM", 62, 79], ["viruses", "OBSERVATION", 45, 52]]], ["Experimental evidence indicates that phosphatidylserine is displayed on the external leaflet of viral membranes and is required for binding, endocytosis or infectivity.", [["external leaflet", "ANATOMY", 76, 92], ["membranes", "ANATOMY", 102, 111], ["phosphatidylserine", "CHEMICAL", 37, 55], ["phosphatidylserine", "CHEMICAL", 37, 55], ["phosphatidylserine", "SIMPLE_CHEMICAL", 37, 55], ["external leaflet", "CELLULAR_COMPONENT", 76, 92], ["viral membranes", "CELLULAR_COMPONENT", 96, 111], ["phosphatidylserine", "PROBLEM", 37, 55], ["viral membranes", "PROBLEM", 96, 111], ["binding", "PROBLEM", 132, 139], ["endocytosis", "PROBLEM", 141, 152], ["infectivity", "PROBLEM", 156, 167], ["phosphatidylserine", "OBSERVATION", 37, 55], ["external leaflet", "ANATOMY", 76, 92], ["viral membranes", "OBSERVATION", 96, 111]]], ["The broad use of viral apoptotic mimicry strategies to enhance entry and infection suggests that it is a general mechanism that is exploited by many enveloped viruses.PerspectivesAs the field of viral apoptotic mimicry is still young, many important questions have not yet been answered.", [["infection", "DISEASE", 73, 82], ["viral apoptotic mimicry strategies", "TREATMENT", 17, 51], ["infection", "PROBLEM", 73, 82], ["a general mechanism", "PROBLEM", 103, 122], ["broad", "OBSERVATION_MODIFIER", 4, 9], ["viral apoptotic mimicry", "OBSERVATION", 17, 40], ["infection", "OBSERVATION", 73, 82], ["enveloped", "OBSERVATION_MODIFIER", 149, 158], ["viruses", "OBSERVATION", 159, 166], ["viral apoptotic mimicry", "OBSERVATION", 195, 218]]], ["For many of the enveloped viruses described, we still do not know how they acquire phosphatidylserine in their membrane nor whether this is an active process.", [["membrane", "ANATOMY", 111, 119], ["phosphatidylserine", "CHEMICAL", 83, 101], ["phosphatidylserine", "CHEMICAL", 83, 101], ["phosphatidylserine", "SIMPLE_CHEMICAL", 83, 101], ["membrane", "CELLULAR_COMPONENT", 111, 119], ["the enveloped viruses", "PROBLEM", 12, 33], ["an active process", "PROBLEM", 140, 157], ["enveloped", "OBSERVATION_MODIFIER", 16, 25], ["viruses", "OBSERVATION", 26, 33], ["active", "OBSERVATION_MODIFIER", 143, 149], ["process", "OBSERVATION", 150, 157]]], ["For viruses that bud from the plasma membrane, timed induction of apoptosis or modulation of cellular ATP-dependent phospholipid flippases5 could possibly provide a means of enriching phosphatidylserine on the membrane before virion exit from the cell.", [["bud", "ANATOMY", 17, 20], ["plasma membrane", "ANATOMY", 30, 45], ["cellular", "ANATOMY", 93, 101], ["membrane", "ANATOMY", 210, 218], ["virion", "ANATOMY", 226, 232], ["cell", "ANATOMY", 247, 251], ["ATP", "CHEMICAL", 102, 105], ["phosphatidylserine", "CHEMICAL", 184, 202], ["ATP", "CHEMICAL", 102, 105], ["phosphatidylserine", "CHEMICAL", 184, 202], ["plasma membrane", "CELLULAR_COMPONENT", 30, 45], ["cellular", "CELL", 93, 101], ["ATP", "SIMPLE_CHEMICAL", 102, 105], ["phospholipid flippases5", "SIMPLE_CHEMICAL", 116, 139], ["phosphatidylserine", "SIMPLE_CHEMICAL", 184, 202], ["membrane", "CELLULAR_COMPONENT", 210, 218], ["virion", "CELLULAR_COMPONENT", 226, 232], ["cell", "CELL", 247, 251], ["viruses", "PROBLEM", 4, 11], ["the plasma membrane", "TREATMENT", 26, 45], ["apoptosis", "PROBLEM", 66, 75], ["cellular ATP", "PROBLEM", 93, 105], ["dependent phospholipid flippases5", "PROBLEM", 106, 139], ["enriching phosphatidylserine on the membrane", "TREATMENT", 174, 218], ["viruses", "OBSERVATION", 4, 11], ["plasma membrane", "ANATOMY", 30, 45], ["cellular ATP", "OBSERVATION", 93, 105]]], ["Once a virus displays phosphatidylserine, does the distribution or concentration of this phospholipid in the viral membrane dictate binding to a distinct phosphatidylserine receptor and, by extension, the cell type specificity of the virus?", [["membrane", "ANATOMY", 115, 123], ["cell", "ANATOMY", 205, 209], ["phosphatidylserine", "CHEMICAL", 22, 40], ["phosphatidylserine", "CHEMICAL", 154, 172], ["phosphatidylserine", "CHEMICAL", 22, 40], ["phosphatidylserine", "CHEMICAL", 154, 172], ["phosphatidylserine", "AMINO_ACID", 22, 40], ["phospholipid", "SIMPLE_CHEMICAL", 89, 101], ["viral membrane", "CELLULAR_COMPONENT", 109, 123], ["phosphatidylserine receptor", "GENE_OR_GENE_PRODUCT", 154, 181], ["cell", "CELL", 205, 209], ["phosphatidylserine receptor", "PROTEIN", 154, 181], ["phosphatidylserine", "TREATMENT", 22, 40], ["this phospholipid", "PROBLEM", 84, 101], ["a distinct phosphatidylserine receptor", "TREATMENT", 143, 181], ["the virus", "PROBLEM", 230, 239], ["viral membrane", "OBSERVATION", 109, 123]]], ["To better understand viral apoptotic mimicry, it may be important to elucidate why some enveloped viruses, including herpes simplex virus 1 (HSV-1), severe acute respiratory syndrome coronavirus (SARS-CoV), influenza A virus and some arenaviruses, do not use apoptotic mimicry for infection17,19 and why some phosphatidylserine receptors, such as brain-specific angiogenesis inhibitor 1 (BAI1) and receptor for advanced glycosylation end products (RAGE), do not mediate virus entry52.", [["brain", "ANATOMY", 347, 352], ["herpes simplex virus", "DISEASE", 117, 137], ["acute respiratory syndrome coronavirus", "DISEASE", 156, 194], ["SARS-CoV)", "DISEASE", 196, 205], ["influenza A virus", "DISEASE", 207, 224], ["arenaviruses", "DISEASE", 234, 246], ["infection", "DISEASE", 281, 290], ["phosphatidylserine", "CHEMICAL", 309, 327], ["phosphatidylserine", "CHEMICAL", 309, 327], ["enveloped viruses", "ORGANISM", 88, 105], ["herpes simplex virus 1", "ORGANISM", 117, 139], ["HSV-1", "ORGANISM", 141, 146], ["severe acute respiratory syndrome coronavirus", "ORGANISM", 149, 194], ["SARS-CoV", "ORGANISM", 196, 204], ["influenza A virus", "ORGANISM", 207, 224], ["phosphatidylserine receptors", "GENE_OR_GENE_PRODUCT", 309, 337], ["brain-specific angiogenesis inhibitor 1", "GENE_OR_GENE_PRODUCT", 347, 386], ["BAI1", "GENE_OR_GENE_PRODUCT", 388, 392], ["receptor for advanced glycosylation end products", "GENE_OR_GENE_PRODUCT", 398, 446], ["RAGE", "GENE_OR_GENE_PRODUCT", 448, 452], ["phosphatidylserine receptors", "PROTEIN", 309, 337], ["brain-specific angiogenesis inhibitor 1 (BAI1) and receptor for advanced glycosylation end products", "PROTEIN", 347, 446], ["RAGE", "PROTEIN", 448, 452], ["herpes simplex virus 1", "SPECIES", 117, 139], ["HSV-1", "SPECIES", 141, 146], ["influenza A virus", "SPECIES", 207, 224], ["herpes simplex virus 1", "SPECIES", 117, 139], ["HSV-1", "SPECIES", 141, 146], ["severe acute respiratory syndrome coronavirus", "SPECIES", 149, 194], ["SARS-CoV", "SPECIES", 196, 204], ["influenza A virus", "SPECIES", 207, 224], ["some enveloped viruses", "PROBLEM", 83, 105], ["herpes simplex virus", "PROBLEM", 117, 137], ["HSV", "TEST", 141, 144], ["severe acute respiratory syndrome coronavirus (SARS-CoV)", "PROBLEM", 149, 205], ["influenza A virus", "PROBLEM", 207, 224], ["some arenaviruses", "PROBLEM", 229, 246], ["infection", "PROBLEM", 281, 290], ["some phosphatidylserine receptors", "PROBLEM", 304, 337], ["specific angiogenesis inhibitor", "TREATMENT", 353, 384], ["receptor", "TREATMENT", 398, 406], ["advanced glycosylation end products", "TREATMENT", 411, 446], ["viruses", "OBSERVATION", 98, 105], ["severe", "OBSERVATION_MODIFIER", 149, 155], ["acute", "OBSERVATION_MODIFIER", 156, 161], ["respiratory syndrome coronavirus", "OBSERVATION", 162, 194], ["brain", "ANATOMY", 347, 352]]], ["Also, the possibility that viruses using apoptotic mimicry simultaneously engage different phosphatidylserine receptors to promote virus entry and modulate the immune response at the same time should be investigated.PerspectivesIn addition, the in vivo relevance of viral apoptotic mimicry needs to be explored.", [["phosphatidylserine", "CHEMICAL", 91, 109], ["phosphatidylserine", "CHEMICAL", 91, 109], ["phosphatidylserine receptors", "GENE_OR_GENE_PRODUCT", 91, 119], ["phosphatidylserine receptors", "PROTEIN", 91, 119], ["viruses", "PROBLEM", 27, 34], ["apoptotic mimicry", "TREATMENT", 41, 58], ["different phosphatidylserine receptors", "TREATMENT", 81, 119], ["virus entry", "TREATMENT", 131, 142], ["viral apoptotic mimicry", "TREATMENT", 266, 289], ["viruses", "OBSERVATION", 27, 34], ["viral apoptotic", "OBSERVATION", 266, 281]]], ["Established mouse pathogenesis models exist for several of the viruses described in this article, and knockout mice are available for TIM and TAM receptors, as well as for the integrins that bind the bridging molecule MFGE8.", [["TAM", "CHEMICAL", 142, 145], ["TAM", "CHEMICAL", 142, 145], ["mouse", "ORGANISM", 12, 17], ["mice", "ORGANISM", 111, 115], ["TIM", "GENE_OR_GENE_PRODUCT", 134, 137], ["TAM receptors", "GENE_OR_GENE_PRODUCT", 142, 155], ["integrins", "GENE_OR_GENE_PRODUCT", 176, 185], ["MFGE8", "GENE_OR_GENE_PRODUCT", 218, 223], ["TIM", "PROTEIN", 134, 137], ["TAM receptors", "PROTEIN", 142, 155], ["integrins", "PROTEIN", 176, 185], ["bridging molecule", "PROTEIN", 200, 217], ["MFGE8", "PROTEIN", 218, 223], ["mouse", "SPECIES", 12, 17], ["mice", "SPECIES", 111, 115], ["mouse", "SPECIES", 12, 17], ["mice", "SPECIES", 111, 115], ["the viruses", "PROBLEM", 59, 70], ["TIM and TAM receptors", "TREATMENT", 134, 155], ["viruses", "OBSERVATION", 63, 70]]], ["At the clinical level, it could be interesting to evaluate cohorts of patients infected with these viruses, to determine whether any correlation exists between disease severity and polymorphisms in phosphatidylserine receptors or phosphatidylserine-bridging molecules.PerspectivesFinally, and perhaps most importantly, can viral apoptotic mimicry be targeted therapeutically?", [["phosphatidylserine", "CHEMICAL", 198, 216], ["phosphatidylserine", "CHEMICAL", 230, 248], ["phosphatidylserine", "CHEMICAL", 198, 216], ["phosphatidylserine", "CHEMICAL", 230, 248], ["patients", "ORGANISM", 70, 78], ["phosphatidylserine receptors", "GENE_OR_GENE_PRODUCT", 198, 226], ["phosphatidylserine", "SIMPLE_CHEMICAL", 230, 248], ["phosphatidylserine receptors", "PROTEIN", 198, 226], ["phosphatidylserine-bridging molecules", "PROTEIN", 230, 267], ["patients", "SPECIES", 70, 78], ["these viruses", "PROBLEM", 93, 106], ["disease severity", "PROBLEM", 160, 176], ["polymorphisms in phosphatidylserine receptors", "PROBLEM", 181, 226], ["phosphatidylserine-bridging molecules", "TREATMENT", 230, 267], ["bridging molecules", "OBSERVATION", 249, 267]]], ["Treatment of PICV infection with a humanized antibody against phosphatidylserine showed a protective effect against viral infection in vivo, indicating that targeting of phosphatidylserine may hold promise as an effective antiviral strategy31.", [["infection", "DISEASE", 18, 27], ["phosphatidylserine", "CHEMICAL", 62, 80], ["viral infection", "DISEASE", 116, 131], ["phosphatidylserine", "CHEMICAL", 170, 188], ["phosphatidylserine", "CHEMICAL", 62, 80], ["phosphatidylserine", "CHEMICAL", 170, 188], ["PICV", "CANCER", 13, 17], ["phosphatidylserine", "SIMPLE_CHEMICAL", 62, 80], ["phosphatidylserine", "SIMPLE_CHEMICAL", 170, 188], ["humanized antibody", "PROTEIN", 35, 53], ["PICV", "SPECIES", 13, 17], ["PICV infection", "PROBLEM", 13, 27], ["a humanized antibody", "TREATMENT", 33, 53], ["phosphatidylserine", "TREATMENT", 62, 80], ["viral infection in vivo", "PROBLEM", 116, 139], ["phosphatidylserine", "TREATMENT", 170, 188], ["an effective antiviral strategy", "TREATMENT", 209, 240], ["infection", "OBSERVATION", 18, 27], ["infection", "OBSERVATION", 122, 131]]], ["Several small-compound inhibitors and TAM decoy receptors directed against AXL and MER are in various stages of preclinical development as cancer therapeutics65,66.", [["cancer", "ANATOMY", 139, 145], ["TAM", "CHEMICAL", 38, 41], ["cancer", "DISEASE", 139, 145], ["TAM", "CHEMICAL", 38, 41], ["TAM", "SIMPLE_CHEMICAL", 38, 41], ["AXL", "GENE_OR_GENE_PRODUCT", 75, 78], ["MER", "SIMPLE_CHEMICAL", 83, 86], ["cancer", "CANCER", 139, 145], ["TAM decoy receptors", "PROTEIN", 38, 57], ["AXL", "PROTEIN", 75, 78], ["MER", "PROTEIN", 83, 86], ["Several small-compound inhibitors", "TREATMENT", 0, 33], ["TAM decoy receptors", "TREATMENT", 38, 57], ["cancer therapeutics", "TREATMENT", 139, 158], ["small", "OBSERVATION_MODIFIER", 8, 13], ["-compound inhibitors", "OBSERVATION_MODIFIER", 13, 33]]], ["In light of the use of these receptors by highly pathogenic viruses, including EBOV and DENV, these compounds should be tested for their potential antiviral efficacy.", [["EBOV", "ORGANISM", 79, 83], ["DENV", "ORGANISM", 88, 92], ["EBOV", "SPECIES", 79, 83], ["DENV", "SPECIES", 88, 92], ["these receptors", "TREATMENT", 23, 38], ["highly pathogenic viruses", "PROBLEM", 42, 67], ["EBOV", "PROBLEM", 79, 83], ["DENV", "PROBLEM", 88, 92]]], ["In support of this, a recent report showed that AXL-specific antibodies increased innate immune responses and could attenuate influenza virus and respiratory syncytial virus (RSV) lethality in vivo67.", [["influenza virus", "DISEASE", 126, 141], ["respiratory syncytial virus (RSV) lethality", "DISEASE", 146, 189], ["AXL", "GENE_OR_GENE_PRODUCT", 48, 51], ["influenza virus", "ORGANISM", 126, 141], ["respiratory syncytial virus", "ORGANISM", 146, 173], ["RSV", "ORGANISM", 175, 178], ["AXL", "PROTEIN", 48, 51], ["specific antibodies", "PROTEIN", 52, 71], ["influenza virus", "SPECIES", 126, 141], ["respiratory syncytial virus", "SPECIES", 146, 173], ["influenza virus", "SPECIES", 126, 141], ["respiratory syncytial virus", "SPECIES", 146, 173], ["RSV", "SPECIES", 175, 178], ["AXL", "TEST", 48, 51], ["influenza virus", "PROBLEM", 126, 141], ["respiratory syncytial virus", "PROBLEM", 146, 173], ["lethality", "PROBLEM", 180, 189], ["syncytial virus", "OBSERVATION", 158, 173]]], ["Although these particular viruses do not use apoptotic mimicry, this study serves as a proof of concept for the therapeutic potential of in vivo AXL targeting.", [["AXL", "SIMPLE_CHEMICAL", 145, 148], ["AXL", "PROTEIN", 145, 148], ["this study", "TEST", 64, 74], ["viruses", "OBSERVATION", 26, 33]]], ["Conversely, it was demonstrated that TIM receptors on virus-producing cells can capture HIV-1 virions through phosphatidylserine exposed on the HIV-1 membrane, thus restricting virion release and spread of infection68.", [["cells", "ANATOMY", 70, 75], ["HIV-1 membrane", "ANATOMY", 144, 158], ["virion", "ANATOMY", 177, 183], ["phosphatidylserine", "CHEMICAL", 110, 128], ["phosphatidylserine", "CHEMICAL", 110, 128], ["TIM receptors", "GENE_OR_GENE_PRODUCT", 37, 50], ["cells", "CELL", 70, 75], ["HIV-1 virions", "ORGANISM", 88, 101], ["phosphatidylserine", "AMINO_ACID", 110, 128], ["HIV-1", "ORGANISM", 144, 149], ["membrane", "CELLULAR_COMPONENT", 150, 158], ["virion", "CELLULAR_COMPONENT", 177, 183], ["TIM receptors", "PROTEIN", 37, 50], ["virus-producing cells", "CELL_TYPE", 54, 75], ["HIV-1", "SPECIES", 88, 93], ["HIV-1", "SPECIES", 144, 149], ["HIV-1", "SPECIES", 88, 93], ["HIV-1", "SPECIES", 144, 149], ["TIM receptors", "PROBLEM", 37, 50], ["virus", "TEST", 54, 59], ["HIV", "TEST", 88, 91], ["restricting virion release", "TREATMENT", 165, 191], ["infection68", "PROBLEM", 206, 217], ["virion release", "OBSERVATION", 177, 191], ["spread", "OBSERVATION_MODIFIER", 196, 202]]], ["Perhaps for some viruses, therapeutic overexpression (rather than inhibition) of phosphatidylserine receptors could be considered.", [["phosphatidylserine", "CHEMICAL", 81, 99], ["phosphatidylserine", "CHEMICAL", 81, 99], ["phosphatidylserine receptors", "GENE_OR_GENE_PRODUCT", 81, 109], ["phosphatidylserine receptors", "PROTEIN", 81, 109], ["some viruses", "PROBLEM", 12, 24], ["therapeutic overexpression", "PROBLEM", 26, 52], ["phosphatidylserine receptors", "TREATMENT", 81, 109], ["viruses", "OBSERVATION", 17, 24]]], ["Collectively, these results suggest that future efforts should be directed at exploiting viral apoptotic mimicry, phosphatidylserine exposure and phosphatidylserine receptors for the development of antiviral therapies.", [["phosphatidylserine", "CHEMICAL", 114, 132], ["phosphatidylserine", "CHEMICAL", 146, 164], ["phosphatidylserine", "CHEMICAL", 114, 132], ["phosphatidylserine", "CHEMICAL", 146, 164], ["phosphatidylserine", "SIMPLE_CHEMICAL", 114, 132], ["phosphatidylserine receptors", "GENE_OR_GENE_PRODUCT", 146, 174], ["phosphatidylserine receptors", "PROTEIN", 146, 174], ["viral apoptotic mimicry", "TREATMENT", 89, 112], ["phosphatidylserine exposure", "TREATMENT", 114, 141], ["phosphatidylserine receptors", "TREATMENT", 146, 174], ["antiviral therapies", "TREATMENT", 198, 217], ["antiviral therapies", "OBSERVATION", 198, 217]]]], "PMC6430905": [["INTRODUCTIONNeonatal calf diarrhea (NCD) is 1 of the most common diseases with serious financial and animal welfare implications in dairy and beef herds worldwide.1 Apart from calf death, economic losses arise from the cost of treatment as well as impaired calf growth and future performance.2, 3 NCD can be caused by infectious and noninfectious causes.", [["calf diarrhea", "DISEASE", 21, 34], ["NCD", "DISEASE", 36, 39], ["death", "DISEASE", 181, 186], ["NCD", "DISEASE", 297, 300], ["calf", "ORGANISM_SUBDIVISION", 21, 25], ["dairy", "ORGANISM_SUBDIVISION", 132, 137], ["calf", "ORGANISM_SUBDIVISION", 176, 180], ["calf", "ORGANISM_SUBDIVISION", 257, 261], ["calf", "SPECIES", 21, 25], ["beef", "SPECIES", 142, 146], ["calf", "SPECIES", 176, 180], ["calf", "SPECIES", 257, 261], ["beef", "SPECIES", 142, 146], ["INTRODUCTIONNeonatal calf diarrhea", "PROBLEM", 0, 34], ["calf death", "PROBLEM", 176, 186], ["economic losses", "PROBLEM", 188, 203], ["treatment", "TREATMENT", 227, 236], ["impaired calf growth", "PROBLEM", 248, 268], ["infectious and noninfectious causes", "PROBLEM", 318, 353], ["calf", "ANATOMY", 21, 25], ["diarrhea", "OBSERVATION", 26, 34], ["most common", "OBSERVATION_MODIFIER", 53, 64], ["diseases", "OBSERVATION", 65, 73], ["calf", "ANATOMY", 176, 180], ["death", "OBSERVATION", 181, 186], ["economic", "OBSERVATION_MODIFIER", 188, 196], ["losses", "OBSERVATION", 197, 203], ["calf", "ANATOMY", 257, 261], ["growth", "OBSERVATION_MODIFIER", 262, 268], ["can be caused by", "UNCERTAINTY", 301, 317], ["infectious", "OBSERVATION", 318, 328], ["noninfectious", "OBSERVATION", 333, 346]]], ["Enterotoxigenic Escherichia coli (ETEC) F5, rota\u2010 and coronavirus, and Cryptosporidium parvum (C. parvum) are the 4 most important enteropathogens associated with NCD.", [["Cryptosporidium parvum", "DISEASE", 71, 93], ["NCD", "DISEASE", 163, 166], ["Enterotoxigenic Escherichia coli", "ORGANISM", 0, 32], ["ETEC) F5", "ORGANISM", 34, 42], ["rota\u2010", "GENE_OR_GENE_PRODUCT", 44, 49], ["coronavirus", "ORGANISM", 54, 65], ["Cryptosporidium parvum", "ORGANISM", 71, 93], ["C. parvum", "ORGANISM", 95, 104], ["Escherichia coli", "SPECIES", 16, 32], ["coronavirus", "SPECIES", 54, 65], ["Cryptosporidium parvum", "SPECIES", 71, 93], ["C. parvum", "SPECIES", 95, 104], ["Escherichia coli", "SPECIES", 16, 32], ["ETEC", "SPECIES", 34, 38], ["Cryptosporidium parvum", "SPECIES", 71, 93], ["C. parvum", "SPECIES", 95, 104], ["Enterotoxigenic Escherichia coli (ETEC) F5", "TEST", 0, 42], ["rota\u2010", "TEST", 44, 49], ["coronavirus", "PROBLEM", 54, 65], ["Cryptosporidium parvum (C. parvum", "PROBLEM", 71, 104], ["Escherichia coli", "OBSERVATION", 16, 32], ["coronavirus", "ANATOMY", 54, 65], ["Cryptosporidium parvum", "OBSERVATION", 71, 93], ["enteropathogens", "OBSERVATION", 131, 146]]], ["In field conditions, the majority of diarrheic calves are concurrently infected with >1 pathogen.", [["diarrheic", "DISEASE", 37, 46], ["calves", "ORGANISM", 47, 53], ["calves", "SPECIES", 47, 53], ["diarrheic calves", "PROBLEM", 37, 53], ["diarrheic calves", "OBSERVATION", 37, 53]]], ["These enteropathogens primarily induce damage to the intestinal mucosa, involving villous atrophy and enterocyte mass reduction.", [["intestinal mucosa", "ANATOMY", 53, 70], ["villous", "ANATOMY", 82, 89], ["enterocyte", "ANATOMY", 102, 112], ["damage to the intestinal mucosa", "DISEASE", 39, 70], ["villous atrophy", "DISEASE", 82, 97], ["intestinal mucosa", "MULTI-TISSUE_STRUCTURE", 53, 70], ["villous", "MULTI-TISSUE_STRUCTURE", 82, 89], ["enterocyte", "CELLULAR_COMPONENT", 102, 112], ["These enteropathogens", "PROBLEM", 0, 21], ["damage to the intestinal mucosa", "PROBLEM", 39, 70], ["villous atrophy", "PROBLEM", 82, 97], ["enterocyte mass reduction", "TREATMENT", 102, 127], ["enteropathogens", "OBSERVATION", 6, 21], ["damage", "OBSERVATION", 39, 45], ["intestinal mucosa", "ANATOMY", 53, 70], ["villous", "ANATOMY_MODIFIER", 82, 89], ["atrophy", "OBSERVATION", 90, 97], ["enterocyte", "ANATOMY", 102, 112], ["mass", "OBSERVATION", 113, 117]]], ["The clinical consequences of inflammation and loss of mucosal integrity primarily in the small bowel include diarrhea, dehydration, malnutrition, potentially systemic inflammatory response syndrome (SIRS) or sepsis, and even death.1, 4, 5", [["mucosal", "ANATOMY", 54, 61], ["small bowel", "ANATOMY", 89, 100], ["inflammation", "DISEASE", 29, 41], ["diarrhea", "DISEASE", 109, 117], ["dehydration", "DISEASE", 119, 130], ["malnutrition", "DISEASE", 132, 144], ["systemic inflammatory response syndrome", "DISEASE", 158, 197], ["SIRS", "DISEASE", 199, 203], ["sepsis", "DISEASE", 208, 214], ["death", "DISEASE", 225, 230], ["mucosal", "MULTI-TISSUE_STRUCTURE", 54, 61], ["bowel", "ORGAN", 95, 100], ["inflammation", "PROBLEM", 29, 41], ["loss of mucosal integrity", "PROBLEM", 46, 71], ["diarrhea", "PROBLEM", 109, 117], ["dehydration", "PROBLEM", 119, 130], ["malnutrition", "PROBLEM", 132, 144], ["systemic inflammatory response syndrome", "PROBLEM", 158, 197], ["SIRS", "PROBLEM", 199, 203], ["sepsis", "PROBLEM", 208, 214], ["inflammation", "OBSERVATION", 29, 41], ["loss", "OBSERVATION_MODIFIER", 46, 50], ["mucosal integrity", "OBSERVATION", 54, 71], ["small bowel", "ANATOMY", 89, 100], ["diarrhea", "OBSERVATION", 109, 117], ["dehydration", "OBSERVATION_MODIFIER", 119, 130], ["malnutrition", "OBSERVATION", 132, 144], ["potentially", "UNCERTAINTY", 146, 157], ["systemic", "OBSERVATION_MODIFIER", 158, 166], ["inflammatory response syndrome", "OBSERVATION", 167, 197], ["sepsis", "OBSERVATION", 208, 214]]]], "09a6fad7371956e64e6f1c58d848268c84948557": [["IntroductionThe pathophysiology of SARS-CoV2 is becoming clearer with a number of recent reports in the literature after the fast viral outbreak in the city of Wuhan in China and more recently in other countries worldwide [1] .", [["SARS", "DISEASE", 35, 39], ["SARS-CoV2", "GENE_OR_GENE_PRODUCT", 35, 44], ["SARS", "PROBLEM", 35, 39], ["the fast viral outbreak", "PROBLEM", 121, 144], ["SARS", "OBSERVATION", 35, 39]]], ["The major symptom of SARS-CoV2 is severe acute respiratory syndrome due to virus interaction with cells expressing angiotensin-converting enzyme 2 (ACE2) and TMPRSS2, such as epithelial cells, endothelial cells, alveolar macrophages, triggering important immune response with the generation of cytokines and chemokines, which attract monocytes, macrophages and T cells promoting further inflammation [2] .", [["cells", "ANATOMY", 98, 103], ["epithelial cells", "ANATOMY", 175, 191], ["endothelial cells", "ANATOMY", 193, 210], ["alveolar macrophages", "ANATOMY", 212, 232], ["monocytes", "ANATOMY", 334, 343], ["macrophages", "ANATOMY", 345, 356], ["T cells", "ANATOMY", 361, 368], ["SARS-CoV2", "DISEASE", 21, 30], ["acute respiratory syndrome", "DISEASE", 41, 67], ["angiotensin", "CHEMICAL", 115, 126], ["inflammation", "DISEASE", 387, 399], ["cells", "CELL", 98, 103], ["angiotensin-converting enzyme 2", "GENE_OR_GENE_PRODUCT", 115, 146], ["ACE2", "GENE_OR_GENE_PRODUCT", 148, 152], ["TMPRSS2", "GENE_OR_GENE_PRODUCT", 158, 165], ["epithelial cells", "CELL", 175, 191], ["endothelial cells", "CELL", 193, 210], ["alveolar macrophages", "CELL", 212, 232], ["monocytes", "CELL", 334, 343], ["macrophages", "CELL", 345, 356], ["T cells", "CELL", 361, 368], ["angiotensin-converting enzyme 2", "PROTEIN", 115, 146], ["ACE2", "PROTEIN", 148, 152], ["TMPRSS2", "PROTEIN", 158, 165], ["epithelial cells", "CELL_TYPE", 175, 191], ["endothelial cells", "CELL_TYPE", 193, 210], ["alveolar macrophages", "CELL_TYPE", 212, 232], ["cytokines", "PROTEIN", 294, 303], ["chemokines", "PROTEIN", 308, 318], ["monocytes", "CELL_TYPE", 334, 343], ["macrophages", "CELL_TYPE", 345, 356], ["T cells", "CELL_TYPE", 361, 368], ["SARS", "PROBLEM", 21, 25], ["severe acute respiratory syndrome", "PROBLEM", 34, 67], ["virus interaction", "PROBLEM", 75, 92], ["angiotensin", "TEST", 115, 126], ["converting enzyme", "TEST", 127, 144], ["ACE2", "TEST", 148, 152], ["TMPRSS2", "TEST", 158, 165], ["epithelial cells", "PROBLEM", 175, 191], ["endothelial cells", "PROBLEM", 193, 210], ["alveolar macrophages", "PROBLEM", 212, 232], ["cytokines and chemokines", "TREATMENT", 294, 318], ["monocytes", "TEST", 334, 343], ["further inflammation", "PROBLEM", 379, 399], ["severe", "OBSERVATION_MODIFIER", 34, 40], ["acute", "OBSERVATION_MODIFIER", 41, 46], ["respiratory syndrome", "OBSERVATION", 47, 67], ["epithelial cells", "OBSERVATION", 175, 191], ["endothelial cells", "OBSERVATION", 193, 210], ["alveolar macrophages", "OBSERVATION", 212, 232]]], ["This may lead to further accumulation of immune cells in the lungs, with overproduction of pro-inflammatory cytokines and activation of complement and coagulation systems in lung microcirculation [3, 4] .", [["immune cells", "ANATOMY", 41, 53], ["lungs", "ANATOMY", 61, 66], ["lung", "ANATOMY", 174, 178], ["immune cells", "CELL", 41, 53], ["lungs", "ORGAN", 61, 66], ["lung", "ORGAN", 174, 178], ["immune cells", "CELL_TYPE", 41, 53], ["pro-inflammatory cytokines", "PROTEIN", 91, 117], ["further accumulation of immune cells in the lungs", "PROBLEM", 17, 66], ["pro-inflammatory cytokines", "PROBLEM", 91, 117], ["coagulation systems", "TEST", 151, 170], ["may lead to", "UNCERTAINTY", 5, 16], ["immune cells", "OBSERVATION", 41, 53], ["lungs", "ANATOMY", 61, 66], ["pro-inflammatory cytokines", "OBSERVATION", 91, 117], ["lung", "ANATOMY", 174, 178]]], ["During the course of the disease, this important immune response attracts virusspecific T cells to the site of infection, where they can eliminate the infected cells.", [["virusspecific T cells", "ANATOMY", 74, 95], ["cells", "ANATOMY", 160, 165], ["infection", "DISEASE", 111, 120], ["virusspecific T cells", "CELL", 74, 95], ["cells", "CELL", 160, 165], ["virusspecific T cells", "CELL_TYPE", 74, 95], ["infected cells", "CELL_TYPE", 151, 165], ["the disease", "PROBLEM", 21, 32], ["infection", "PROBLEM", 111, 120], ["the infected cells", "PROBLEM", 147, 165], ["disease", "OBSERVATION", 25, 32], ["infection", "OBSERVATION", 111, 120], ["infected cells", "OBSERVATION", 151, 165]]], ["Alveolar macrophages can then recognize neutralized viruses and apoptotic cells and clear them by phagocytosis.", [["Alveolar macrophages", "ANATOMY", 0, 20], ["cells", "ANATOMY", 74, 79], ["Alveolar macrophages", "CELL", 0, 20], ["cells", "CELL", 74, 79], ["Alveolar macrophages", "CELL_TYPE", 0, 20], ["apoptotic cells", "CELL_TYPE", 64, 79], ["Alveolar macrophages", "PROBLEM", 0, 20], ["neutralized viruses", "PROBLEM", 40, 59], ["apoptotic cells", "PROBLEM", 64, 79], ["macrophages", "OBSERVATION", 9, 20], ["neutralized viruses", "OBSERVATION", 40, 59], ["apoptotic cells", "OBSERVATION", 64, 79]]], ["Altogether, these processes lead to clearance of the virus and minimal lung and other organ damage, resulting in recovery [5] .IntroductionDespite these pathophysiological mechanisms are under continuous investigation, and the results of clinical studies presented in the literature on the effects of different therapeutical approaches on the SARS-CoV2 infection, there are only a few reports on the clinical course during the recovery phase of the disease.", [["lung", "ANATOMY", 71, 75], ["organ", "ANATOMY", 86, 91], ["lung and other organ damage", "DISEASE", 71, 98], ["SARS-CoV2 infection", "DISEASE", 343, 362], ["lung", "ORGAN", 71, 75], ["organ", "ORGAN", 86, 91], ["SARS-CoV2", "ORGANISM", 343, 352], ["the virus", "PROBLEM", 49, 58], ["minimal lung and other organ damage", "PROBLEM", 63, 98], ["continuous investigation", "TEST", 193, 217], ["clinical studies", "TEST", 238, 254], ["different therapeutical approaches", "TREATMENT", 301, 335], ["the SARS", "PROBLEM", 339, 347], ["CoV2 infection", "PROBLEM", 348, 362], ["the disease", "PROBLEM", 445, 456], ["virus", "OBSERVATION", 53, 58], ["minimal", "OBSERVATION_MODIFIER", 63, 70], ["lung", "ANATOMY", 71, 75], ["organ", "ANATOMY", 86, 91], ["damage", "OBSERVATION", 92, 98], ["infection", "OBSERVATION", 353, 362], ["few", "OBSERVATION_MODIFIER", 381, 384], ["disease", "OBSERVATION", 449, 456]]], ["Recent investigations [6, 7] show that lung abnormalities on chest computerized tomography (CT)Introductionshow the greatest severity approximately 6-11 days after the initial onset of symptoms, while in the following weeks' recovery occurs consistently and in around 30 days lung tissue lesions are almost absorbed [8] .", [["lung", "ANATOMY", 39, 43], ["lung tissue lesions", "ANATOMY", 276, 295], ["lung abnormalities", "DISEASE", 39, 57], ["lung", "ORGAN", 39, 43], ["lung tissue lesions", "CANCER", 276, 295], ["Recent investigations", "TEST", 0, 21], ["lung abnormalities", "PROBLEM", 39, 57], ["chest computerized tomography", "TEST", 61, 90], ["CT", "TEST", 92, 94], ["symptoms", "PROBLEM", 185, 193], ["lung tissue lesions", "PROBLEM", 276, 295], ["lung", "ANATOMY", 39, 43], ["abnormalities", "OBSERVATION", 44, 57], ["chest", "ANATOMY", 61, 66], ["lung", "ANATOMY", 276, 280], ["tissue", "OBSERVATION_MODIFIER", 281, 287], ["lesions", "OBSERVATION", 288, 295]]], ["However, extended observation on COVID-19 patient during recovery are still object of investigation, with and without positive result for RT-PCR test.IntroductionDue to the large number of patients admitted to the Bolognini Hospital (ASST Bergamo Est company) in the Bergamo area, during the COVID-19 outbreak, we had the chance to review CT findings in a number of patients during the recovery from the disease.", [["patient", "ORGANISM", 42, 49], ["patients", "ORGANISM", 189, 197], ["patients", "ORGANISM", 366, 374], ["patient", "SPECIES", 42, 49], ["patients", "SPECIES", 189, 197], ["patients", "SPECIES", 366, 374], ["COVID", "TEST", 33, 38], ["RT-PCR test", "TEST", 138, 149], ["CT findings", "TEST", 339, 350], ["the disease", "PROBLEM", 400, 411], ["large", "OBSERVATION_MODIFIER", 173, 178], ["disease", "OBSERVATION", 404, 411]]], ["In particular in some of these patients, CT scans were used to investigate potential thrombotic events with and without the use of contrast media.", [["thrombotic", "DISEASE", 85, 95], ["patients", "ORGANISM", 31, 39], ["patients", "SPECIES", 31, 39], ["CT scans", "TEST", 41, 49], ["potential thrombotic events", "PROBLEM", 75, 102], ["contrast media", "TREATMENT", 131, 145], ["thrombotic", "OBSERVATION", 85, 95]]], ["We report here the results of these investigations, since the use of the contrast media allowed us to investigate the perfusion conditions of these organs using digital image processing.", [["organs", "ANATOMY", 148, 154], ["organs", "ORGAN", 148, 154], ["these investigations", "TEST", 30, 50], ["the contrast media", "TREATMENT", 69, 87], ["digital image processing", "TEST", 161, 185]]], ["We did identify perfusion defects in lungs of these patients, more than one month after remission of the symptoms, that deserve attention.Material and MethodsAll rights reserved.", [["lungs", "ANATOMY", 37, 42], ["perfusion defects", "DISEASE", 16, 33], ["lungs", "ORGAN", 37, 42], ["patients", "ORGANISM", 52, 60], ["patients", "SPECIES", 52, 60], ["perfusion defects in lungs", "PROBLEM", 16, 42], ["the symptoms", "PROBLEM", 101, 113], ["Material and Methods", "TREATMENT", 138, 158], ["perfusion defects", "OBSERVATION", 16, 33], ["lungs", "ANATOMY", 37, 42]]], ["No reuse allowed without permission.Material and Methods(which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.Material and MethodsThe copyright holder for this preprint this version posted June 3, 2020. . https://doi.org/10.1101/2020.05.29.20117143 doi: medRxiv preprintPatient populationDuring the period from 15 April and 30 April, 20 patients (12 male and 8 female; age range 35-86, mean age 58 +10 years) previously treated for pneumonia SARS-CoV-2, with negative swab, have been admitted to our department to assess the outcome of SARS-CoV-2 pneumonia.", [["pneumonia", "DISEASE", 513, 522], ["SARS", "DISEASE", 617, 621], ["pneumonia", "DISEASE", 628, 637], ["patients", "ORGANISM", 418, 426], ["SARS-CoV-2", "ORGANISM", 617, 627], ["patients", "SPECIES", 418, 426], ["SARS-CoV", "SPECIES", 617, 625], ["The copyright holder", "TREATMENT", 211, 231], ["pneumonia SARS", "PROBLEM", 513, 527], ["SARS", "PROBLEM", 617, 621], ["CoV", "PROBLEM", 622, 625], ["pneumonia", "PROBLEM", 628, 637], ["med", "ANATOMY", 135, 138], ["pneumonia", "OBSERVATION", 513, 522], ["pneumonia", "OBSERVATION", 628, 637]]], ["The follow up was performed by chest CT at an interval between 14 days and 60 days after remission of the fever (average 40 +13 days).", [["chest", "ANATOMY", 31, 36], ["fever", "DISEASE", 106, 111], ["chest CT", "TEST", 31, 39], ["the fever", "PROBLEM", 102, 111], ["chest", "ANATOMY", 31, 36], ["fever", "OBSERVATION", 106, 111]]], ["Twelve patients reported an almost complete resolution of the symptoms, while 8 patients The lung perfusion evaluation was performed by using PAA (Pulmonary Artery Analysis) Software installed on IntelliSpace Portal release 11 (Philips Medical Systems, Best, the Netherlands) [9] .", [["lung", "ANATOMY", 93, 97], ["PAA", "CHEMICAL", 142, 145], ["PAA", "CHEMICAL", 142, 145], ["patients", "ORGANISM", 7, 15], ["patients", "ORGANISM", 80, 88], ["lung", "ORGAN", 93, 97], ["patients", "SPECIES", 7, 15], ["patients", "SPECIES", 80, 88], ["the symptoms", "PROBLEM", 58, 70], ["The lung perfusion evaluation", "TEST", 89, 118], ["PAA (Pulmonary Artery Analysis", "TREATMENT", 142, 172], ["IntelliSpace Portal release", "TREATMENT", 196, 223], ["lung", "ANATOMY", 93, 97], ["Pulmonary Artery", "ANATOMY", 147, 163]]], ["PAA provides semi-automatic and manual tools to visualize and measure pulmonary embolism and provides a Hounsfield Units (HU)-based colormap visualization tool.", [["pulmonary", "ANATOMY", 70, 79], ["PAA", "CHEMICAL", 0, 3], ["pulmonary embolism", "DISEASE", 70, 88], ["PAA", "CHEMICAL", 0, 3], ["PAA", "SIMPLE_CHEMICAL", 0, 3], ["pulmonary", "ORGAN", 70, 79], ["semi-automatic and manual tools", "TEST", 13, 44], ["pulmonary embolism", "PROBLEM", 70, 88], ["a Hounsfield Units (HU)", "TREATMENT", 102, 125], ["based colormap visualization tool", "TEST", 126, 159], ["pulmonary", "ANATOMY", 70, 79], ["embolism", "OBSERVATION", 80, 88]]], ["In particular the default setting allows imaging tissue lung perfusion using color palette for HU ranging from -749 to -983.", [["tissue lung", "ANATOMY", 49, 60], ["tissue lung", "TISSUE", 49, 60], ["imaging tissue lung perfusion", "TEST", 41, 70], ["color palette", "TEST", 77, 90], ["HU", "TEST", 95, 97], ["lung", "ANATOMY", 56, 60]]], ["The threshold level identified for normal lung tissue perfusion in control subjects was in average equal to -890 HU.", [["lung tissue", "ANATOMY", 42, 53], ["lung tissue", "MULTI-TISSUE_STRUCTURE", 42, 53], ["The threshold level", "TEST", 0, 19], ["lung", "ANATOMY", 42, 46], ["tissue", "OBSERVATION_MODIFIER", 47, 53], ["perfusion", "OBSERVATION_MODIFIER", 54, 63], ["890 HU", "OBSERVATION_MODIFIER", 109, 115]]], ["Lower attenuation values can be considered areas of hypoperfusion.", [["hypoperfusion", "DISEASE", 52, 65], ["Lower attenuation values", "PROBLEM", 0, 24], ["hypoperfusion", "PROBLEM", 52, 65], ["attenuation", "OBSERVATION", 6, 17], ["hypoperfusion", "OBSERVATION", 52, 65]]], ["In order to precisely quantify the volume of lung tissue identified as low All rights reserved.", [["lung tissue", "ANATOMY", 45, 56], ["lung tissue", "TISSUE", 45, 56], ["lung tissue", "PROBLEM", 45, 56], ["volume", "OBSERVATION", 35, 41], ["lung", "ANATOMY", 45, 49], ["tissue", "OBSERVATION", 50, 56], ["low", "OBSERVATION_MODIFIER", 71, 74]]], ["No reuse allowed without permission.Patient population(which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.Patient populationThe copyright holder for this preprint this version posted June 3, 2020. . https://doi.org/10.1101/2020.05.29.20117143 doi: medRxiv preprint perfusion, independently by the amount of contrast media, we used the following method to assume the HU threshold value discriminating between normal and hypoperfused tissue.", [["hypoperfused tissue", "ANATOMY", 502, 521], ["hypoperfused tissue", "TISSUE", 502, 521], ["Patient", "SPECIES", 36, 43], ["Patient", "SPECIES", 189, 196], ["The copyright holder", "TREATMENT", 207, 227], ["medRxiv preprint perfusion", "TREATMENT", 331, 357], ["contrast media", "TREATMENT", 390, 404], ["the HU threshold value", "TEST", 445, 467], ["med", "ANATOMY", 133, 136], ["normal", "OBSERVATION", 491, 497], ["hypoperfused tissue", "OBSERVATION", 502, 521]]], ["We calculated, that the previously mentioned range of HU for hypoperfused tissue (HU lower than -890) in the control group was on average 13.3% of the total HU range, estimated from air to pulmonary artery.", [["hypoperfused tissue", "ANATOMY", 61, 80], ["pulmonary artery", "ANATOMY", 189, 205], ["hypoperfused tissue", "TISSUE", 61, 80], ["pulmonary artery", "MULTI-TISSUE_STRUCTURE", 189, 205], ["hypoperfused tissue", "PROBLEM", 61, 80], ["HU", "TEST", 82, 84], ["hypoperfused tissue", "OBSERVATION", 61, 80], ["total HU", "OBSERVATION_MODIFIER", 151, 159], ["air", "ANATOMY_MODIFIER", 182, 185], ["pulmonary artery", "ANATOMY", 189, 205]]], ["Assuming this percentage, we calculated the new threshold level for hypoperfused tissue at the single patient level, using estimation of the HU range from air to pulmonary artery, and considering 13.3% of this interval, starting from HU of the air (-749).", [["hypoperfused tissue", "ANATOMY", 68, 87], ["pulmonary artery", "ANATOMY", 162, 178], ["hypoperfused tissue", "TISSUE", 68, 87], ["patient", "ORGANISM", 102, 109], ["pulmonary artery", "MULTI-TISSUE_STRUCTURE", 162, 178], ["patient", "SPECIES", 102, 109], ["hypoperfused tissue", "PROBLEM", 68, 87], ["hypoperfused tissue", "OBSERVATION", 68, 87], ["pulmonary artery", "ANATOMY", 162, 178], ["air", "ANATOMY", 244, 247]]], ["We labeled each pixel inside the lung mask as low perfusion or normal perfusion based on these patient-specific thresholds using Python implementation of SimpleITK library (https://simpleitk.org/about.html) to operate on DICOM images.", [["lung", "ANATOMY", 33, 37], ["lung", "ORGAN", 33, 37], ["patient", "ORGANISM", 95, 102], ["SimpleITK library", "DNA", 154, 171], ["patient", "SPECIES", 95, 102], ["the lung mask", "TREATMENT", 29, 42], ["low perfusion", "PROBLEM", 46, 59], ["DICOM images", "TEST", 221, 233], ["lung", "ANATOMY", 33, 37], ["mask", "ANATOMY_MODIFIER", 38, 42], ["low perfusion", "OBSERVATION", 46, 59]]], ["To estimate the percentage of lung volume characterized by hypoperfusion, we initially segmented the lung volume of the CT scans by automatic lung segmentation using the u-net (R231) convolutional network [10] .", [["lung", "ANATOMY", 30, 34], ["lung", "ANATOMY", 101, 105], ["lung", "ANATOMY", 142, 146], ["hypoperfusion", "DISEASE", 59, 72], ["lung", "ORGAN", 30, 34], ["lung", "ORGAN", 101, 105], ["lung", "ORGAN", 142, 146], ["lung volume", "TEST", 30, 41], ["hypoperfusion", "PROBLEM", 59, 72], ["the CT scans", "TEST", 116, 128], ["automatic lung segmentation", "TEST", 132, 159], ["lung", "ANATOMY", 30, 34], ["volume", "OBSERVATION", 35, 41], ["hypoperfusion", "OBSERVATION", 59, 72], ["lung", "ANATOMY", 101, 105], ["volume", "OBSERVATION_MODIFIER", 106, 112], ["lung", "ANATOMY", 142, 146], ["segmentation", "ANATOMY_MODIFIER", 147, 159]]], ["This model was trained on a large dataset, including COVID-19 CT slices, that covers a wide range of visual variability.", [["COVID", "TEST", 53, 58], ["CT slices", "TEST", 62, 71], ["wide", "OBSERVATION_MODIFIER", 87, 91], ["visual variability", "OBSERVATION", 101, 119]]], ["Segmentation on individual slices allowed to extract the right and left lung mask separately.", [["slices", "ANATOMY", 27, 33], ["right", "ANATOMY", 57, 62], ["left lung", "ANATOMY", 67, 76], ["lung", "ORGAN", 72, 76], ["individual slices", "TEST", 16, 33], ["right", "ANATOMY_MODIFIER", 57, 62], ["left", "ANATOMY_MODIFIER", 67, 71], ["lung", "ANATOMY", 72, 76], ["mask", "ANATOMY_MODIFIER", 77, 81]]], ["The trachea was not included in the lung segmentation.", [["trachea", "ANATOMY", 4, 11], ["lung", "ANATOMY", 36, 40], ["trachea", "ORGAN", 4, 11], ["lung", "ORGAN", 36, 40], ["trachea", "ANATOMY", 4, 11], ["not included", "UNCERTAINTY", 16, 28], ["lung", "ANATOMY", 36, 40], ["segmentation", "ANATOMY_MODIFIER", 41, 53]]], ["The number of voxels with HU value in the range of hypoperfused tissue was visualized using DICOM Vision (www.dicom.vision) and the ratio of this voxel count over that of the total lung volume was calculated.ResultsOut of the 20 patients who underwent follow-up, 12 patients had almost complete resolution of symptoms, with complete regression of the thickening areas detected with chest CT scan at diagnosis of SARS-CoV-2 pneumonia in 4 patients, and persistence of fibrous stripes areas in the other 8 patients.", [["hypoperfused tissue", "ANATOMY", 51, 70], ["lung", "ANATOMY", 181, 185], ["fibrous stripes areas", "ANATOMY", 467, 488], ["SARS", "DISEASE", 412, 416], ["pneumonia", "DISEASE", 423, 432], ["hypoperfused tissue", "TISSUE", 51, 70], ["lung", "ORGAN", 181, 185], ["patients", "ORGANISM", 229, 237], ["patients", "ORGANISM", 266, 274], ["patients", "ORGANISM", 438, 446], ["patients", "ORGANISM", 504, 512], ["patients", "SPECIES", 229, 237], ["patients", "SPECIES", 266, 274], ["patients", "SPECIES", 438, 446], ["patients", "SPECIES", 504, 512], ["HU value", "TEST", 26, 34], ["hypoperfused tissue", "PROBLEM", 51, 70], ["this voxel count", "TEST", 141, 157], ["the total lung volume", "TEST", 171, 192], ["symptoms", "PROBLEM", 309, 317], ["the thickening areas", "PROBLEM", 347, 367], ["chest CT scan", "TEST", 382, 395], ["SARS", "PROBLEM", 412, 416], ["CoV", "PROBLEM", 417, 420], ["pneumonia", "PROBLEM", 423, 432], ["fibrous stripes areas", "PROBLEM", 467, 488], ["hypoperfused tissue", "OBSERVATION", 51, 70], ["lung", "ANATOMY", 181, 185], ["volume", "OBSERVATION", 186, 192], ["thickening", "OBSERVATION", 351, 361], ["chest", "ANATOMY", 382, 387], ["SARS", "OBSERVATION", 412, 416], ["pneumonia", "OBSERVATION", 423, 432], ["fibrous stripes", "OBSERVATION", 467, 482]]], ["In the remaining 8 patients, 5 reported dyspnea after prolonged effort, with 3 of them with complete remission of signs of interstitial pneumonia and 2 with only partial remission.", [["interstitial", "ANATOMY", 123, 135], ["dyspnea", "DISEASE", 40, 47], ["interstitial pneumonia", "DISEASE", 123, 145], ["patients", "ORGANISM", 19, 27], ["patients", "SPECIES", 19, 27], ["dyspnea", "PROBLEM", 40, 47], ["interstitial pneumonia", "PROBLEM", 123, 145], ["partial remission", "PROBLEM", 162, 179], ["interstitial", "ANATOMY_MODIFIER", 123, 135], ["pneumonia", "OBSERVATION", 136, 145], ["partial", "OBSERVATION_MODIFIER", 162, 169], ["remission", "OBSERVATION", 170, 179]]], ["While the 3 other patients reported dyspnea with minimal effort and showed a completely normal CT scan and remission of parenchymal opacity.", [["parenchymal", "ANATOMY", 120, 131], ["dyspnea", "DISEASE", 36, 43], ["parenchymal opacity", "DISEASE", 120, 139], ["patients", "ORGANISM", 18, 26], ["parenchymal opacity", "PATHOLOGICAL_FORMATION", 120, 139], ["patients", "SPECIES", 18, 26], ["dyspnea", "PROBLEM", 36, 43], ["parenchymal opacity", "PROBLEM", 120, 139], ["dyspnea", "OBSERVATION", 36, 43], ["parenchymal", "ANATOMY_MODIFIER", 120, 131], ["opacity", "OBSERVATION", 132, 139]]], ["Out of the total number of 20 patients, 5 patients have been studied with contrast media.", [["patients", "ORGANISM", 30, 38], ["patients", "ORGANISM", 42, 50], ["patients", "SPECIES", 30, 38], ["patients", "SPECIES", 42, 50], ["contrast media", "TREATMENT", 74, 88]]], ["Three of them were those that reported dyspnea with minimal effort, while 2 had no such symptom.", [["dyspnea", "DISEASE", 39, 46], ["dyspnea", "PROBLEM", 39, 46], ["such symptom", "PROBLEM", 83, 95], ["dyspnea", "OBSERVATION", 39, 46], ["minimal", "OBSERVATION_MODIFIER", 52, 59]]], ["At CT evaluation, in all these patients no signs of thromboembolism were present.", [["thromboembolism", "DISEASE", 52, 67], ["patients", "ORGANISM", 31, 39], ["patients", "SPECIES", 31, 39], ["CT evaluation", "TEST", 3, 16], ["thromboembolism", "PROBLEM", 52, 67], ["no signs of", "UNCERTAINTY", 40, 51], ["thromboembolism", "OBSERVATION", 52, 67]]], ["At variance, in the three patients affected by dyspnea color map representation, as shown in Figure 1 , showed diffuse signs of hypoperfused areas (dark red/violet color) and the distribution of these areas was not uniform between the left and right lung.", [["left", "ANATOMY", 235, 239], ["right lung", "ANATOMY", 244, 254], ["dyspnea", "DISEASE", 47, 54], ["patients", "ORGANISM", 26, 34], ["lung", "ORGAN", 250, 254], ["patients", "SPECIES", 26, 34], ["dyspnea color map representation", "PROBLEM", 47, 79], ["diffuse signs of hypoperfused areas", "PROBLEM", 111, 146], ["dark red/violet color", "PROBLEM", 148, 169], ["diffuse", "OBSERVATION_MODIFIER", 111, 118], ["hypoperfused", "OBSERVATION_MODIFIER", 128, 140], ["areas", "OBSERVATION_MODIFIER", 141, 146], ["dark", "OBSERVATION_MODIFIER", 148, 152], ["violet color", "OBSERVATION", 157, 169], ["distribution", "OBSERVATION_MODIFIER", 179, 191], ["uniform", "OBSERVATION_MODIFIER", 215, 222], ["left", "ANATOMY_MODIFIER", 235, 239], ["right", "ANATOMY_MODIFIER", 244, 249], ["lung", "ANATOMY", 250, 254]]], ["Quantification of hypoperfused volumes are reported in Table 1 .", [["hypoperfused volumes", "PROBLEM", 18, 38], ["hypoperfused volumes", "OBSERVATION", 18, 38]]], ["Lungs from 3 out of 5 COVID-19 patients exceeded this threshold, reaching in one patient about 20% and 30% in the left and right lung.", [["Lungs", "ANATOMY", 0, 5], ["left", "ANATOMY", 114, 118], ["right lung", "ANATOMY", 123, 133], ["Lungs", "ORGAN", 0, 5], ["patients", "ORGANISM", 31, 39], ["patient", "ORGANISM", 81, 88], ["lung", "ORGAN", 129, 133], ["patients", "SPECIES", 31, 39], ["patient", "SPECIES", 81, 88], ["COVID", "TEST", 22, 27], ["left", "ANATOMY_MODIFIER", 114, 118], ["right", "ANATOMY_MODIFIER", 123, 128], ["lung", "ANATOMY", 129, 133]]], ["Of interest, tissue lung perfusion was normal in the two patients without dyspnea (see Table 1 and Figure 1 ).", [["tissue lung", "ANATOMY", 13, 24], ["dyspnea", "DISEASE", 74, 81], ["tissue lung", "MULTI-TISSUE_STRUCTURE", 13, 24], ["patients", "ORGANISM", 57, 65], ["patients", "SPECIES", 57, 65], ["tissue lung perfusion", "TEST", 13, 34], ["dyspnea", "PROBLEM", 74, 81], ["lung", "ANATOMY", 20, 24], ["perfusion", "OBSERVATION_MODIFIER", 25, 34], ["normal", "OBSERVATION", 39, 45]]], ["No evident sign of hypoperfused regions were present in CT of normal controls, and the hypoperfused tissue was present in less than 7% of lung volume.", [["hypoperfused tissue", "ANATOMY", 87, 106], ["lung", "ANATOMY", 138, 142], ["hypoperfused tissue", "TISSUE", 87, 106], ["lung", "ORGAN", 138, 142], ["hypoperfused regions", "PROBLEM", 19, 39], ["CT", "TEST", 56, 58], ["the hypoperfused tissue", "PROBLEM", 83, 106], ["evident sign of", "UNCERTAINTY", 3, 18], ["hypoperfused", "OBSERVATION", 19, 31], ["normal", "OBSERVATION", 62, 68], ["hypoperfused tissue", "OBSERVATION", 87, 106], ["less than 7", "OBSERVATION_MODIFIER", 122, 133], ["lung", "ANATOMY", 138, 142], ["volume", "OBSERVATION", 143, 149]]], ["No reuse allowed without permission.Results(which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.ResultsThe copyright holder for this preprint this version posted June 3, 2020. . https://doi.org/10.1101/2020.05.29.20117143 doi: medRxiv preprintDiscussionAs mentioned previously, the lung tissue inflammation induced in COVID-19 patients by accumulation of immune cells, overproduction of pro-inflammatory cytokines and activation of complement and coagulation system in the microcirculation is the reason for the observed focal or diffuse damage to the lungs, as observed during the course of the disease.", [["lung tissue", "ANATOMY", 364, 375], ["immune cells", "ANATOMY", 437, 449], ["lungs", "ANATOMY", 634, 639], ["inflammation", "DISEASE", 376, 388], ["lung tissue", "TISSUE", 364, 375], ["patients", "ORGANISM", 409, 417], ["immune cells", "CELL", 437, 449], ["lungs", "ORGAN", 634, 639], ["immune cells", "CELL_TYPE", 437, 449], ["pro-inflammatory cytokines", "PROTEIN", 469, 495], ["patients", "SPECIES", 409, 417], ["medRxiv preprintDiscussionAs", "TREATMENT", 309, 337], ["the lung tissue inflammation", "PROBLEM", 360, 388], ["immune cells", "PROBLEM", 437, 449], ["overproduction of pro-inflammatory cytokines", "PROBLEM", 451, 495], ["coagulation system", "TEST", 529, 547], ["diffuse damage to the lungs", "PROBLEM", 612, 639], ["the disease", "PROBLEM", 674, 685], ["med", "ANATOMY", 122, 125], ["lung tissue", "ANATOMY", 364, 375], ["inflammation", "OBSERVATION", 376, 388], ["immune cells", "OBSERVATION", 437, 449], ["pro-inflammatory cytokines", "OBSERVATION", 469, 495], ["focal", "OBSERVATION_MODIFIER", 603, 608], ["diffuse", "OBSERVATION_MODIFIER", 612, 619], ["damage", "OBSERVATION", 620, 626], ["lungs", "ANATOMY", 634, 639], ["disease", "OBSERVATION", 678, 685]]], ["This acute lung damage correlates with the initial appearance of areas of increased density with the \"ground glass\" appearance, which gradually tends to change into areas of consolidation, preferentially located in the peripheral subpleural area.", [["lung", "ANATOMY", 11, 15], ["peripheral subpleural area", "ANATOMY", 219, 245], ["lung damage", "DISEASE", 11, 22], ["lung", "ORGAN", 11, 15], ["peripheral subpleural area", "MULTI-TISSUE_STRUCTURE", 219, 245], ["This acute lung damage", "PROBLEM", 0, 22], ["increased density", "PROBLEM", 74, 91], ["the \"ground glass\" appearance", "PROBLEM", 97, 126], ["consolidation", "PROBLEM", 174, 187], ["acute", "OBSERVATION_MODIFIER", 5, 10], ["lung", "ANATOMY", 11, 15], ["damage", "OBSERVATION", 16, 22], ["areas", "OBSERVATION_MODIFIER", 65, 70], ["increased", "OBSERVATION_MODIFIER", 74, 83], ["density", "OBSERVATION", 84, 91], ["ground glass\"", "OBSERVATION", 102, 115], ["areas", "OBSERVATION_MODIFIER", 165, 170], ["consolidation", "OBSERVATION", 174, 187], ["peripheral", "ANATOMY_MODIFIER", 219, 229], ["subpleural", "ANATOMY_MODIFIER", 230, 240], ["area", "ANATOMY_MODIFIER", 241, 245]]], ["Four stages of infection were recently proposed: early, progression, peak, and resolution [11] .", [["infection", "DISEASE", 15, 24], ["infection", "PROBLEM", 15, 24], ["infection", "OBSERVATION", 15, 24]]], ["In the later stages of the infection, the pattern referred to as \"crazy paving\" and \"reversed halo sign\" have been found more frequently [11] .DiscussionOur retrospective analysis, in negative RT-PCR test patients recovering from COVID-19, more than 60% of patients without symptoms chest CT, one month after the resolution of the disease, displayed an incomplete regression of the lung opacities, with the persistence of mild fibrous stripes in interstitial areas, while in patients who reported residual dyspnea, an almost complete regression of the parenchymal thickening was observed.", [["lung opacities", "ANATOMY", 382, 396], ["fibrous stripes", "ANATOMY", 427, 442], ["interstitial areas", "ANATOMY", 446, 464], ["parenchymal", "ANATOMY", 552, 563], ["infection", "DISEASE", 27, 36], ["lung opacities", "DISEASE", 382, 396], ["dyspnea", "DISEASE", 506, 513], ["patients", "ORGANISM", 205, 213], ["patients", "ORGANISM", 257, 265], ["lung", "ORGAN", 382, 386], ["fibrous stripes", "PATHOLOGICAL_FORMATION", 427, 442], ["interstitial areas", "PATHOLOGICAL_FORMATION", 446, 464], ["patients", "ORGANISM", 475, 483], ["parenchymal", "TISSUE", 552, 563], ["patients", "SPECIES", 205, 213], ["patients", "SPECIES", 257, 265], ["patients", "SPECIES", 475, 483], ["the infection", "PROBLEM", 23, 36], ["retrospective analysis", "TEST", 157, 179], ["PCR test", "TEST", 196, 204], ["COVID", "TEST", 230, 235], ["symptoms", "PROBLEM", 274, 282], ["chest CT", "TEST", 283, 291], ["the disease", "PROBLEM", 327, 338], ["the lung opacities", "PROBLEM", 378, 396], ["mild fibrous stripes in interstitial areas", "PROBLEM", 422, 464], ["residual dyspnea", "PROBLEM", 497, 513], ["the parenchymal thickening", "PROBLEM", 548, 574], ["infection", "OBSERVATION", 27, 36], ["chest", "ANATOMY", 283, 288], ["disease", "OBSERVATION", 331, 338], ["incomplete", "OBSERVATION_MODIFIER", 353, 363], ["regression", "OBSERVATION_MODIFIER", 364, 374], ["lung", "ANATOMY", 382, 386], ["opacities", "OBSERVATION", 387, 396], ["mild", "OBSERVATION_MODIFIER", 422, 426], ["fibrous stripes", "OBSERVATION", 427, 442], ["interstitial", "ANATOMY_MODIFIER", 446, 458], ["areas", "OBSERVATION_MODIFIER", 459, 464], ["residual", "OBSERVATION_MODIFIER", 497, 505], ["dyspnea", "OBSERVATION", 506, 513], ["almost", "OBSERVATION_MODIFIER", 518, 524], ["complete", "OBSERVATION_MODIFIER", 525, 533], ["regression", "OBSERVATION_MODIFIER", 534, 544], ["parenchymal", "ANATOMY_MODIFIER", 552, 563], ["thickening", "OBSERVATION", 564, 574]]], ["At variance, our quantitative evaluations by volumetric image processing, show that in symptomatic patients (dyspnea), despite the absence of pulmonary fibrous stripes residues, there were hypoperfused areas of lung parenchyma, not symmetrical in the two lungs.", [["pulmonary fibrous stripes", "ANATOMY", 142, 167], ["lung parenchyma", "ANATOMY", 211, 226], ["lungs", "ANATOMY", 255, 260], ["dyspnea", "DISEASE", 109, 116], ["patients", "ORGANISM", 99, 107], ["lung parenchyma", "MULTI-TISSUE_STRUCTURE", 211, 226], ["lungs", "ORGAN", 255, 260], ["patients", "SPECIES", 99, 107], ["our quantitative evaluations", "TEST", 13, 41], ["volumetric image processing", "TEST", 45, 72], ["dyspnea", "PROBLEM", 109, 116], ["pulmonary fibrous stripes residues", "PROBLEM", 142, 176], ["hypoperfused areas of lung parenchyma", "PROBLEM", 189, 226], ["symptomatic", "OBSERVATION_MODIFIER", 87, 98], ["pulmonary", "ANATOMY", 142, 151], ["fibrous stripes", "OBSERVATION", 152, 167], ["hypoperfused", "OBSERVATION_MODIFIER", 189, 201], ["areas", "OBSERVATION_MODIFIER", 202, 207], ["lung", "ANATOMY", 211, 215], ["parenchyma", "ANATOMY_MODIFIER", 216, 226], ["not", "UNCERTAINTY", 228, 231], ["symmetrical", "OBSERVATION_MODIFIER", 232, 243], ["two", "ANATOMY_MODIFIER", 251, 254], ["lungs", "ANATOMY", 255, 260]]], ["These findings suggest that during the recovery of COVID-19 rather than ventilatory dysfunction, defect in lung blood perfusion of the microcirculation may persist.DiscussionTo our knowledge, this is the first report on quantitative estimation of lung perfusion indicating the presence of microvasculature defect in recovering COVID-19 patients, without thromboembolism, and with normal pulmonary ventilation.", [["lung blood", "ANATOMY", 107, 117], ["lung", "ANATOMY", 247, 251], ["microvasculature", "ANATOMY", 289, 305], ["pulmonary", "ANATOMY", 387, 396], ["ventilatory dysfunction", "DISEASE", 72, 95], ["thromboembolism", "DISEASE", 354, 369], ["COVID-19", "GENE_OR_GENE_PRODUCT", 51, 59], ["lung blood", "MULTI-TISSUE_STRUCTURE", 107, 117], ["lung", "ORGAN", 247, 251], ["microvasculature", "TISSUE", 289, 305], ["patients", "ORGANISM", 336, 344], ["pulmonary", "ORGAN", 387, 396], ["patients", "SPECIES", 336, 344], ["COVID", "TEST", 51, 56], ["ventilatory dysfunction", "PROBLEM", 72, 95], ["defect in lung blood perfusion of the microcirculation", "PROBLEM", 97, 151], ["lung perfusion", "TEST", 247, 261], ["microvasculature defect", "PROBLEM", 289, 312], ["thromboembolism", "PROBLEM", 354, 369], ["ventilatory dysfunction", "OBSERVATION", 72, 95], ["defect", "OBSERVATION", 97, 103], ["lung", "ANATOMY", 107, 111], ["blood perfusion", "OBSERVATION", 112, 127], ["microcirculation", "ANATOMY", 135, 151], ["may persist", "UNCERTAINTY", 152, 163], ["lung", "ANATOMY", 247, 251], ["microvasculature defect", "OBSERVATION", 289, 312], ["without", "UNCERTAINTY", 346, 353], ["thromboembolism", "OBSERVATION", 354, 369], ["normal", "OBSERVATION", 380, 386], ["pulmonary ventilation", "OBSERVATION", 387, 408]]], ["Our results suggest that in COVID-19 patients incomplete healing of alveolar parenchyma microcirculation may occur or persist during recovery.", [["alveolar parenchyma", "ANATOMY", 68, 87], ["patients", "ORGANISM", 37, 45], ["alveolar parenchyma", "MULTI-TISSUE_STRUCTURE", 68, 87], ["patients", "SPECIES", 37, 45], ["alveolar parenchyma microcirculation", "PROBLEM", 68, 104], ["healing", "OBSERVATION_MODIFIER", 57, 64], ["alveolar", "ANATOMY_MODIFIER", 68, 76], ["parenchyma", "ANATOMY_MODIFIER", 77, 87]]], ["Thus, while the lung tissue damage related to interstitial fluid accumulation and impairment of ventilation is almost completely recovered within one month, a persistent defect of the microcirculation may remain, likely due to residual of viralinduced inflammation, with immune cell accumulation, platelet adhesion and micro-disseminated thrombi.DiscussionWhether also fibrosis may be responsible for these microcirculation perfusion defects is worth to investigate.", [["lung tissue", "ANATOMY", 16, 27], ["interstitial fluid", "ANATOMY", 46, 64], ["immune cell", "ANATOMY", 271, 282], ["platelet", "ANATOMY", 297, 305], ["micro-disseminated thrombi", "ANATOMY", 319, 345], ["inflammation", "DISEASE", 252, 264], ["thrombi", "DISEASE", 338, 345], ["fibrosis", "DISEASE", 369, 377], ["lung tissue", "TISSUE", 16, 27], ["interstitial", "IMMATERIAL_ANATOMICAL_ENTITY", 46, 58], ["fluid", "ORGANISM_SUBSTANCE", 59, 64], ["immune cell", "CELL", 271, 282], ["platelet", "CELL", 297, 305], ["the lung tissue damage", "PROBLEM", 12, 34], ["interstitial fluid accumulation", "PROBLEM", 46, 77], ["impairment of ventilation", "PROBLEM", 82, 107], ["a persistent defect of the microcirculation", "PROBLEM", 157, 200], ["viralinduced inflammation", "PROBLEM", 239, 264], ["immune cell accumulation", "PROBLEM", 271, 295], ["platelet adhesion", "PROBLEM", 297, 314], ["micro-disseminated thrombi", "PROBLEM", 319, 345], ["fibrosis", "PROBLEM", 369, 377], ["these microcirculation perfusion defects", "PROBLEM", 401, 441], ["lung", "ANATOMY", 16, 20], ["tissue", "OBSERVATION", 21, 27], ["interstitial", "ANATOMY_MODIFIER", 46, 58], ["fluid accumulation", "OBSERVATION", 59, 77], ["impairment", "OBSERVATION_MODIFIER", 82, 92], ["persistent", "OBSERVATION_MODIFIER", 159, 169], ["defect", "OBSERVATION", 170, 176], ["likely due to", "UNCERTAINTY", 213, 226], ["residual", "OBSERVATION_MODIFIER", 227, 235], ["viralinduced", "OBSERVATION_MODIFIER", 239, 251], ["inflammation", "OBSERVATION", 252, 264], ["immune cell accumulation", "OBSERVATION", 271, 295], ["platelet adhesion", "OBSERVATION", 297, 314], ["micro-disseminated", "OBSERVATION_MODIFIER", 319, 337], ["thrombi", "OBSERVATION", 338, 345], ["fibrosis", "OBSERVATION", 369, 377], ["may be responsible for", "UNCERTAINTY", 378, 400]]], ["While these complications of the disease are now well recognized during the acute phase of the infection [12, 13, 14] , it is important to notice that this impairment of the microcirculation, we have detected, may affect lung function even in the recovery phase and may last for a long time or even not be healed with time.", [["lung", "ANATOMY", 221, 225], ["infection", "DISEASE", 95, 104], ["lung", "ORGAN", 221, 225], ["the disease", "PROBLEM", 29, 40], ["the infection", "PROBLEM", 91, 104], ["this impairment of the microcirculation", "PROBLEM", 151, 190], ["complications", "OBSERVATION", 12, 25], ["disease", "OBSERVATION", 33, 40], ["infection", "OBSERVATION", 95, 104], ["healed", "OBSERVATION", 306, 312]]], ["This evidence should be carefully considered, due to the potential clinical relevance of the problem in the large number of patients affected by the SARS-CoV-2 infection during the recovery phase worldwide in this period.", [["SARS-CoV-2 infection", "DISEASE", 149, 169], ["patients", "ORGANISM", 124, 132], ["SARS-CoV-2", "ORGANISM", 149, 159], ["patients", "SPECIES", 124, 132], ["SARS-CoV", "SPECIES", 149, 157], ["the problem", "PROBLEM", 89, 100], ["the SARS-CoV-2 infection", "PROBLEM", 145, 169], ["large", "OBSERVATION_MODIFIER", 108, 113], ["number", "OBSERVATION_MODIFIER", 114, 120], ["infection", "OBSERVATION", 160, 169]]], ["No reuse allowed without permission.Discussion(which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.DiscussionThe copyright holder for this preprint this version posted June 3, 2020. . https://doi.org/10.1101/2020.05.29.20117143 doi: medRxiv preprintConclusionsIn summary, the first message from our observation is that these patients, if still reporting dyspnea during recovery, should be followed using chest CT, to identify and quantify the presence of lung perfusion dysfunction.", [["chest", "ANATOMY", 486, 491], ["lung", "ANATOMY", 537, 541], ["dyspnea", "DISEASE", 436, 443], ["lung perfusion dysfunction", "DISEASE", 537, 563], ["patients", "ORGANISM", 407, 415], ["chest", "ORGANISM_SUBDIVISION", 486, 491], ["lung", "ORGAN", 537, 541], ["patients", "SPECIES", 407, 415], ["medRxiv", "TREATMENT", 315, 322], ["dyspnea", "PROBLEM", 436, 443], ["chest CT", "TEST", 486, 494], ["lung perfusion dysfunction", "PROBLEM", 537, 563], ["med", "ANATOMY", 125, 128], ["lung", "ANATOMY", 537, 541], ["perfusion dysfunction", "OBSERVATION", 542, 563]]], ["This will be important not only for diagnosis, but also to determine whether this damage to the lung microcirculation resolves with time or if they will be chronically affected by these changes.", [["lung", "ANATOMY", 96, 100], ["lung", "ORGAN", 96, 100], ["this damage to the lung microcirculation", "PROBLEM", 77, 117], ["lung", "ANATOMY", 96, 100], ["microcirculation", "OBSERVATION", 101, 117]]], ["The second message of our observation is that the study of these patients may allow identification of the potential need for pharmacological interventions, to choose the correct drug treatment to adopt, and the duration for these treatments.", [["patients", "ORGANISM", 65, 73], ["patients", "SPECIES", 65, 73], ["the study", "TEST", 46, 55], ["pharmacological interventions", "TREATMENT", 125, 154], ["the correct drug treatment", "TREATMENT", 166, 192], ["these treatments", "TREATMENT", 224, 240]]], ["Deeper knowledge of these pathological processes will also improve the clinical outcome of this large patient population that is still increasing in size due to the ongoing SARS-CoV-2 outbreak.", [["patient", "ORGANISM", 102, 109], ["CoV-2", "ORGANISM", 178, 183], ["patient", "SPECIES", 102, 109], ["these pathological processes", "PROBLEM", 20, 48], ["this large patient population", "PROBLEM", 91, 120], ["the ongoing SARS", "PROBLEM", 161, 177], ["large", "OBSERVATION_MODIFIER", 96, 101], ["increasing", "OBSERVATION_MODIFIER", 135, 145], ["size", "OBSERVATION_MODIFIER", 149, 153]]], ["While more extensive investigation with CT in discharged COVID19 patients is progress by our center and by others, we believe it is urgent to draw attention to these lung complication.ContributorsGP, SP, FB and FC performed data collection, analysis and clinical observations, MR and SM implemented computational codes and performed image processing, AR analyzed the data, AR and GP interpreted the data and wrote the manuscript.", [["lung", "ANATOMY", 166, 170], ["patients", "ORGANISM", 65, 73], ["lung", "ORGAN", 166, 170], ["SP", "PROTEIN", 200, 202], ["FC", "PROTEIN", 211, 213], ["MR", "PROTEIN", 277, 279], ["SM", "PROTEIN", 284, 286], ["AR", "PROTEIN", 351, 353], ["AR", "PROTEIN", 373, 375], ["patients", "SPECIES", 65, 73], ["CT", "TEST", 40, 42], ["these lung complication", "PROBLEM", 160, 183], ["data collection", "TEST", 224, 239], ["analysis", "TEST", 241, 249], ["clinical observations", "TEST", 254, 275], ["MR", "TEST", 277, 279], ["image processing", "TEST", 333, 349], ["lung", "ANATOMY", 166, 170], ["complication", "OBSERVATION", 171, 183]]], ["All authors interpreted the findings, contributed to manuscript revision, and approved the final version for publication.Declaration of interestsWe declare no competing interests.Declaration of interestsAll rights reserved.", [["manuscript revision", "TREATMENT", 53, 72], ["revision", "OBSERVATION", 64, 72]]], ["No reuse allowed without permission.Declaration of interests(which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.Declaration of interestsThe copyright holder for this preprint this version posted June 3, 2020. . https://doi.org/10.1101/2020.05.29.20117143 doi: medRxiv preprintRepresentative images of lung perfusion map and CT in COVID-19 patients (Pt1-4) and in normal control (Ctrl2).", [["lung", "ANATOMY", 384, 388], ["Pt1-4", "ANATOMY", 432, 437], ["lung", "ORGAN", 384, 388], ["patients", "ORGANISM", 422, 430], ["Pt1-4", "CELL", 432, 437], ["patients", "SPECIES", 422, 430], ["The copyright holder", "TREATMENT", 219, 239], ["medRxiv", "TREATMENT", 343, 350], ["Representative images", "TEST", 359, 380], ["lung perfusion map", "TEST", 384, 402], ["CT", "TEST", 407, 409], ["COVID", "TEST", 413, 418], ["Pt1", "TEST", 432, 435], ["med", "ANATOMY", 139, 142], ["lung", "ANATOMY", 384, 388], ["normal", "OBSERVATION", 446, 452]]], ["Perfusion maps of Pt1, 2 and 3 that were not affected by dyspnea show areas of low perfusion, whilePt4 that was not affected by dyspnea shows normal perfusion map, comparable to normal control (Ctrl2).Representative images of lung perfusion map and CT in COVID-19 patients (Pt1-4) and in normal control (Ctrl2).", [["lung", "ANATOMY", 226, 230], ["Pt1-4", "ANATOMY", 274, 279], ["dyspnea", "DISEASE", 57, 64], ["dyspnea", "DISEASE", 128, 135], ["Pt4", "GENE_OR_GENE_PRODUCT", 99, 102], ["lung", "ORGAN", 226, 230], ["patients", "ORGANISM", 264, 272], ["Pt1-4", "CELL", 274, 279], ["Pt4", "PROTEIN", 99, 102], ["patients", "SPECIES", 264, 272], ["Perfusion maps", "TEST", 0, 14], ["Pt1", "TEST", 18, 21], ["dyspnea", "PROBLEM", 57, 64], ["low perfusion", "PROBLEM", 79, 92], ["dyspnea", "PROBLEM", 128, 135], ["Representative images", "TEST", 201, 222], ["lung perfusion map", "TEST", 226, 244], ["CT", "TEST", 249, 251], ["COVID", "TEST", 255, 260], ["Pt1", "TEST", 274, 277], ["low perfusion", "OBSERVATION", 79, 92], ["normal", "OBSERVATION", 142, 148], ["perfusion map", "OBSERVATION", 149, 162], ["normal", "OBSERVATION", 178, 184], ["lung", "ANATOMY", 226, 230], ["normal", "OBSERVATION", 288, 294]]], ["Perfusion maps of Pt1, 2 and 3 that were not affected by dyspnea show areas of low perfusion, whilePulmonary CT was normal in all CT scans.", [["Pulmonary", "ANATOMY", 99, 108], ["dyspnea", "DISEASE", 57, 64], ["Perfusion maps", "TEST", 0, 14], ["Pt1", "TEST", 18, 21], ["dyspnea", "PROBLEM", 57, 64], ["low perfusion", "PROBLEM", 79, 92], ["Pulmonary CT", "TEST", 99, 111], ["all CT scans", "TEST", 126, 138], ["not affected", "UNCERTAINTY", 41, 53], ["low perfusion", "OBSERVATION", 79, 92], ["Pulmonary", "ANATOMY", 99, 108], ["normal", "OBSERVATION", 116, 122]]]], "PMC7236743": [["Case description ::: IntroductionA previously healthy 70 year old woman presented to an urgent care with 5 days of fever, malaise, headache, and dry cough.", [["fever", "DISEASE", 115, 120], ["malaise", "DISEASE", 122, 129], ["headache", "DISEASE", 131, 139], ["dry cough", "DISEASE", 145, 154], ["woman", "ORGANISM", 66, 71], ["woman", "SPECIES", 66, 71], ["fever", "PROBLEM", 115, 120], ["malaise", "PROBLEM", 122, 129], ["headache", "PROBLEM", 131, 139], ["dry cough", "PROBLEM", 145, 154], ["fever", "OBSERVATION", 115, 120], ["malaise", "OBSERVATION", 122, 129], ["headache", "OBSERVATION", 131, 139], ["dry", "OBSERVATION_MODIFIER", 145, 148], ["cough", "OBSERVATION", 149, 154]]], ["Chest radiography revealed right lung airspace opacities.", [["right lung airspace", "ANATOMY", 27, 46], ["lung airspace", "MULTI-TISSUE_STRUCTURE", 33, 46], ["Chest radiography", "TEST", 0, 17], ["right lung airspace opacities", "PROBLEM", 27, 56], ["right", "ANATOMY_MODIFIER", 27, 32], ["lung", "ANATOMY", 33, 37], ["airspace", "ANATOMY_MODIFIER", 38, 46], ["opacities", "OBSERVATION", 47, 56]]], ["She was prescribed azithromycin and amoxicillin/clavulanic acid.", [["azithromycin", "CHEMICAL", 19, 31], ["amoxicillin/clavulanic acid", "CHEMICAL", 36, 63], ["azithromycin", "CHEMICAL", 19, 31], ["amoxicillin", "CHEMICAL", 36, 47], ["clavulanic acid", "CHEMICAL", 48, 63], ["azithromycin", "SIMPLE_CHEMICAL", 19, 31], ["amoxicillin/clavulanic acid", "SIMPLE_CHEMICAL", 36, 63], ["azithromycin", "TREATMENT", 19, 31], ["amoxicillin", "TREATMENT", 36, 47], ["clavulanic acid", "TREATMENT", 48, 63]]], ["Over the next day, her shortness of breath worsened and her viral PCR for SARS-CoV-2 returned positive.", [["shortness of breath", "DISEASE", 23, 42], ["SARS", "DISEASE", 74, 78], ["SARS-CoV-2", "GENE_OR_GENE_PRODUCT", 74, 84], ["SARS-CoV", "SPECIES", 74, 82], ["her shortness of breath", "PROBLEM", 19, 42], ["her viral PCR", "TEST", 56, 69], ["SARS", "TEST", 74, 78], ["CoV", "TEST", 79, 82]]], ["She presented for a scheduled hospital admission, where she was febrile to 103.7F and tachypneic.", [["febrile", "DISEASE", 64, 71], ["febrile", "PROBLEM", 64, 71], ["tachypneic", "PROBLEM", 86, 96]]], ["Absolute lymphocyte count was 710, interleukin-6 31 pg/mL, ferritin 1,222 ng/mL, C-reactive protein (CRP) 3.4 mg/dL, and procalcitonin 0.53 ng/mL.", [["lymphocyte", "ANATOMY", 9, 19], ["lymphocyte", "CELL", 9, 19], ["interleukin-6", "GENE_OR_GENE_PRODUCT", 35, 48], ["ferritin", "GENE_OR_GENE_PRODUCT", 59, 67], ["C-reactive protein", "GENE_OR_GENE_PRODUCT", 81, 99], ["CRP", "GENE_OR_GENE_PRODUCT", 101, 104], ["interleukin", "PROTEIN", 35, 46], ["ferritin", "PROTEIN", 59, 67], ["C-reactive protein", "PROTEIN", 81, 99], ["CRP", "PROTEIN", 101, 104], ["Absolute lymphocyte count", "TEST", 0, 25], ["interleukin", "TEST", 35, 46], ["pg", "TEST", 52, 54], ["ferritin", "TEST", 59, 67], ["ng/mL", "TEST", 74, 79], ["C-reactive protein", "TEST", 81, 99], ["CRP", "TEST", 101, 104], ["procalcitonin", "TREATMENT", 121, 134], ["lymphocyte count", "OBSERVATION", 9, 25]]], ["Renal function demonstrated impairment above her baseline (estimated glomerular filtration rate 52mL/min/1.73m2.)", [["Renal", "ANATOMY", 0, 5], ["glomerular", "ANATOMY", 69, 79], ["Renal", "ORGAN", 0, 5], ["glomerular", "TISSUE", 69, 79], ["Renal function", "TEST", 0, 14], ["impairment", "PROBLEM", 28, 38], ["glomerular filtration rate", "TEST", 69, 95], ["impairment", "OBSERVATION", 28, 38]]], ["Aspartate aminotransferase and alanine aminotransferase were mildly elevated at 112 and 139 units/L, respectively.", [["Aspartate", "CHEMICAL", 0, 9], ["alanine", "CHEMICAL", 31, 38], ["Aspartate", "CHEMICAL", 0, 9], ["alanine", "CHEMICAL", 31, 38], ["Aspartate aminotransferase", "GENE_OR_GENE_PRODUCT", 0, 26], ["alanine", "AMINO_ACID", 31, 38], ["aminotransferase", "AMINO_ACID", 39, 55], ["Aspartate aminotransferase", "PROTEIN", 0, 26], ["Aspartate aminotransferase", "TEST", 0, 26], ["alanine aminotransferase", "TEST", 31, 55], ["mildly elevated", "PROBLEM", 61, 76]]], ["Her initial QTc was 397 ms.Case description ::: IntroductionShe was treated with 5 days of ceftriaxone and azithromycin due to concern for bacterial coinfection and 10 days of remdesivir as a part of trial for treatment of COVID-19.", [["ceftriaxone", "CHEMICAL", 91, 102], ["azithromycin", "CHEMICAL", 107, 119], ["bacterial coinfection", "DISEASE", 139, 160], ["remdesivir", "CHEMICAL", 176, 186], ["ceftriaxone", "CHEMICAL", 91, 102], ["azithromycin", "CHEMICAL", 107, 119], ["remdesivir", "CHEMICAL", 176, 186], ["She", "ORGANISM", 60, 63], ["ceftriaxone", "SIMPLE_CHEMICAL", 91, 102], ["azithromycin", "SIMPLE_CHEMICAL", 107, 119], ["Her initial QTc", "TEST", 0, 15], ["ceftriaxone", "TREATMENT", 91, 102], ["azithromycin", "TREATMENT", 107, 119], ["bacterial coinfection", "PROBLEM", 139, 160], ["remdesivir", "TREATMENT", 176, 186], ["treatment", "TREATMENT", 210, 219], ["COVID", "TEST", 223, 228], ["bacterial", "OBSERVATION_MODIFIER", 139, 148], ["coinfection", "OBSERVATION", 149, 160]]], ["She was transferred to the ICU for worsening hypoxic respiratory failure on admission day 3 and intubated on admission day 4.", [["respiratory", "ANATOMY", 53, 64], ["hypoxic respiratory failure", "DISEASE", 45, 72], ["worsening hypoxic respiratory failure", "PROBLEM", 35, 72], ["worsening", "OBSERVATION_MODIFIER", 35, 44], ["hypoxic", "OBSERVATION_MODIFIER", 45, 52], ["respiratory failure", "OBSERVATION", 53, 72]]], ["While she was briefly extubated on day 26, she required reintubation on the same day.Case description ::: IntroductionTo facilitate mechanical ventilation and combat significant agitation, patient received numerous sedative drips, including dexmedetomidine, hydromorphone, propofol, midazolam, and ketamine, as well oxycodone (up to 60 mg daily) and chlordiazepoxide (up to 30 mg daily).", [["agitation", "DISEASE", 178, 187], ["dexmedetomidine", "CHEMICAL", 241, 256], ["hydromorphone", "CHEMICAL", 258, 271], ["propofol", "CHEMICAL", 273, 281], ["midazolam", "CHEMICAL", 283, 292], ["ketamine", "CHEMICAL", 298, 306], ["oxycodone", "CHEMICAL", 316, 325], ["chlordiazepoxide", "CHEMICAL", 350, 366], ["dexmedetomidine", "CHEMICAL", 241, 256], ["hydromorphone", "CHEMICAL", 258, 271], ["propofol", "CHEMICAL", 273, 281], ["midazolam", "CHEMICAL", 283, 292], ["ketamine", "CHEMICAL", 298, 306], ["oxycodone", "CHEMICAL", 316, 325], ["chlordiazepoxide", "CHEMICAL", 350, 366], ["patient", "ORGANISM", 189, 196], ["dexmedetomidine", "SIMPLE_CHEMICAL", 241, 256], ["hydromorphone", "SIMPLE_CHEMICAL", 258, 271], ["propofol", "SIMPLE_CHEMICAL", 273, 281], ["midazolam", "SIMPLE_CHEMICAL", 283, 292], ["ketamine", "SIMPLE_CHEMICAL", 298, 306], ["oxycodone", "SIMPLE_CHEMICAL", 316, 325], ["chlordiazepoxide", "SIMPLE_CHEMICAL", 350, 366], ["patient", "SPECIES", 189, 196], ["reintubation", "TREATMENT", 56, 68], ["mechanical ventilation", "TREATMENT", 132, 154], ["combat significant agitation", "PROBLEM", 159, 187], ["numerous sedative drips", "TREATMENT", 206, 229], ["dexmedetomidine", "TREATMENT", 241, 256], ["hydromorphone", "TREATMENT", 258, 271], ["propofol", "TREATMENT", 273, 281], ["midazolam", "TREATMENT", 283, 292], ["ketamine", "TREATMENT", 298, 306], ["oxycodone", "TREATMENT", 316, 325], ["chlordiazepoxide", "TREATMENT", 350, 366], ["mechanical ventilation", "OBSERVATION", 132, 154]]], ["Other psychotropic agents used by her primary team included quetiapine (up to 175 mg daily) and melatonin 5 mg nightly.", [["quetiapine", "CHEMICAL", 60, 70], ["melatonin", "CHEMICAL", 96, 105], ["quetiapine", "CHEMICAL", 60, 70], ["melatonin", "CHEMICAL", 96, 105], ["quetiapine", "SIMPLE_CHEMICAL", 60, 70], ["melatonin", "SIMPLE_CHEMICAL", 96, 105], ["Other psychotropic agents", "TREATMENT", 0, 25], ["quetiapine", "TREATMENT", 60, 70], ["melatonin", "TREATMENT", 96, 105]]], ["She remained restless and agitated.Case description ::: IntroductionPsychiatry was consulted on admission day 29 to assist with management of agitation, one day prior to tracheostomy placement on hospital day 30.", [["restless and agitated", "DISEASE", 13, 34], ["agitation", "DISEASE", 142, 151], ["restless", "PROBLEM", 13, 21], ["agitated", "PROBLEM", 26, 34], ["management", "TREATMENT", 128, 138], ["agitation", "PROBLEM", 142, 151], ["tracheostomy placement", "TREATMENT", 170, 192], ["restless", "OBSERVATION", 13, 21]]], ["Due to strict COVID-19 infection control policies, patient was assessed virtually, by chart review, and via discussions with her nurses, ICU team, and family.", [["infection", "DISEASE", 23, 32], ["patient", "ORGANISM", 51, 58], ["patient", "SPECIES", 51, 58], ["strict COVID-19 infection control policies", "TREATMENT", 7, 49]]], ["The diagnosis of delirium was made according to the Diagnostic and Statistical Manual of Mental Disorders, 5th Edition (DSM-5), based on acute onset of disturbance of attention and awareness, impaired cognition, agitation, and sleep-wake cycle dysregulation in context of medical illness (8), and confirmed by the Confusion Assessment Method for the ICU (CAM-ICU) (9) and the Stanford Proxy Test for Delirium (S-PTD) (10,11).Case description ::: IntroductionUnder the psychiatry\u2019s recommendations, melatonin was increased to 15 mg nightly to regulate sleep-wake cycle and for the antioxidant and anti-inflammatory effects and suvorexant, an orexin antagonist, was added at 20 mg, for sleep-wake cycle regulation.", [["delirium", "DISEASE", 17, 25], ["disturbance of attention and awareness", "DISEASE", 152, 190], ["impaired cognition", "DISEASE", 192, 210], ["agitation", "DISEASE", 212, 221], ["Confusion", "DISEASE", 314, 323], ["Delirium", "DISEASE", 400, 408], ["melatonin", "CHEMICAL", 498, 507], ["suvorexant", "CHEMICAL", 626, 636], ["melatonin", "CHEMICAL", 498, 507], ["suvorexant", "CHEMICAL", 626, 636], ["melatonin", "SIMPLE_CHEMICAL", 498, 507], ["suvorexant", "SIMPLE_CHEMICAL", 626, 636], ["orexin", "GENE_OR_GENE_PRODUCT", 641, 647], ["delirium", "PROBLEM", 17, 25], ["Mental Disorders", "PROBLEM", 89, 105], ["disturbance of attention", "PROBLEM", 152, 176], ["impaired cognition", "PROBLEM", 192, 210], ["agitation", "PROBLEM", 212, 221], ["sleep-wake cycle dysregulation", "PROBLEM", 227, 257], ["medical illness", "PROBLEM", 272, 287], ["Delirium", "PROBLEM", 400, 408], ["melatonin", "TREATMENT", 498, 507], ["the antioxidant", "TREATMENT", 576, 591], ["anti-inflammatory effects", "TREATMENT", 596, 621], ["suvorexant", "TREATMENT", 626, 636], ["an orexin antagonist", "TREATMENT", 638, 658], ["delirium", "OBSERVATION", 17, 25], ["acute", "OBSERVATION_MODIFIER", 137, 142]]], ["Guanfacine, an alpha-2 agonist, was started at 0.5 mg twice daily and titrated to 1 mg thrice daily to reduce sympathetic outflow, manage agitation, and assist in weaning intravenous sedatives.", [["intravenous", "ANATOMY", 171, 182], ["Guanfacine", "CHEMICAL", 0, 10], ["agitation", "DISEASE", 138, 147], ["Guanfacine", "CHEMICAL", 0, 10], ["Guanfacine", "SIMPLE_CHEMICAL", 0, 10], ["alpha-2", "GENE_OR_GENE_PRODUCT", 15, 22], ["intravenous", "IMMATERIAL_ANATOMICAL_ENTITY", 171, 182], ["Guanfacine", "TREATMENT", 0, 10], ["an alpha-2 agonist", "TREATMENT", 12, 30], ["sympathetic outflow", "PROBLEM", 110, 129], ["agitation", "PROBLEM", 138, 147], ["weaning intravenous sedatives", "TREATMENT", 163, 192], ["sympathetic outflow", "ANATOMY", 110, 129]]], ["Intravenous valproic acid (VPA; titrated to 1250 mg per day) was also started for management of agitation and symptoms of hyperactive delirium and to facilitate tapering of multiple other sedative deliriogenic medications.", [["valproic acid", "CHEMICAL", 12, 25], ["VPA", "CHEMICAL", 27, 30], ["agitation", "DISEASE", 96, 105], ["hyperactive delirium", "DISEASE", 122, 142], ["valproic acid", "CHEMICAL", 12, 25], ["VPA", "CHEMICAL", 27, 30], ["valproic acid", "SIMPLE_CHEMICAL", 12, 25], ["VPA", "SIMPLE_CHEMICAL", 27, 30], ["Intravenous valproic acid", "TREATMENT", 0, 25], ["VPA", "TREATMENT", 27, 30], ["management", "TREATMENT", 82, 92], ["agitation", "PROBLEM", 96, 105], ["symptoms", "PROBLEM", 110, 118], ["hyperactive delirium", "PROBLEM", 122, 142], ["multiple other sedative deliriogenic medications", "TREATMENT", 173, 221], ["hyperactive", "OBSERVATION_MODIFIER", 122, 133], ["delirium", "OBSERVATION", 134, 142]]], ["Quetiapine was initially titrated to 250 mg distributed throughout the day, but due to its ineffectiveness, it was discontinued on day 3 of psychiatric consultation and instead intravenous haloperidol (titrated to 8 mg per day) was used to manage symptoms of hyperactive delirium.", [["intravenous", "ANATOMY", 177, 188], ["Quetiapine", "CHEMICAL", 0, 10], ["psychiatric", "DISEASE", 140, 151], ["haloperidol", "CHEMICAL", 189, 200], ["hyperactive delirium", "DISEASE", 259, 279], ["Quetiapine", "CHEMICAL", 0, 10], ["haloperidol", "CHEMICAL", 189, 200], ["Quetiapine", "SIMPLE_CHEMICAL", 0, 10], ["intravenous", "IMMATERIAL_ANATOMICAL_ENTITY", 177, 188], ["haloperidol", "SIMPLE_CHEMICAL", 189, 200], ["Quetiapine", "TREATMENT", 0, 10], ["intravenous haloperidol", "TREATMENT", 177, 200], ["symptoms", "PROBLEM", 247, 255], ["hyperactive delirium", "PROBLEM", 259, 279], ["hyperactive", "OBSERVATION_MODIFIER", 259, 270], ["delirium", "OBSERVATION", 271, 279]]], ["Of note, nursing staff was educated and asked to examine for extrapyramidal side effects of antipsychotics during their regular patient evaluation and care.Case description ::: IntroductionOver the following five days, the patient tolerated discontinuation of all sedative drips with gradual tapering of chlordiazepoxide (discontinued on day 6 of psychiatric consultation) and oxycodone (discontinued on day 7 of psychiatric consultation).", [["chlordiazepoxide", "CHEMICAL", 304, 320], ["psychiatric", "DISEASE", 347, 358], ["oxycodone", "CHEMICAL", 377, 386], ["psychiatric", "DISEASE", 413, 424], ["chlordiazepoxide", "CHEMICAL", 304, 320], ["oxycodone", "CHEMICAL", 377, 386], ["patient", "ORGANISM", 128, 135], ["patient", "ORGANISM", 223, 230], ["chlordiazepoxide", "SIMPLE_CHEMICAL", 304, 320], ["oxycodone", "SIMPLE_CHEMICAL", 377, 386], ["patient", "SPECIES", 128, 135], ["patient", "SPECIES", 223, 230], ["extrapyramidal side effects", "PROBLEM", 61, 88], ["antipsychotics", "TREATMENT", 92, 106], ["their regular patient evaluation", "TEST", 114, 146], ["all sedative drips", "TREATMENT", 260, 278], ["gradual tapering of chlordiazepoxide", "TREATMENT", 284, 320], ["oxycodone", "TREATMENT", 377, 386]]], ["She had ongoing medical complications, including fevers and pneumothorax, during this phase of her treatment.", [["fevers", "DISEASE", 49, 55], ["pneumothorax", "DISEASE", 60, 72], ["ongoing medical complications", "PROBLEM", 8, 37], ["fevers", "PROBLEM", 49, 55], ["pneumothorax", "PROBLEM", 60, 72], ["her treatment", "TREATMENT", 95, 108], ["complications", "OBSERVATION", 24, 37], ["fevers", "OBSERVATION", 49, 55], ["pneumothorax", "OBSERVATION", 60, 72]]], ["VPA was discontinued on day 5 of consultation, and haloperidol was discontinued on day 11 of consultation.", [["VPA", "CHEMICAL", 0, 3], ["haloperidol", "CHEMICAL", 51, 62], ["VPA", "CHEMICAL", 0, 3], ["haloperidol", "CHEMICAL", 51, 62], ["VPA", "SIMPLE_CHEMICAL", 0, 3], ["haloperidol", "SIMPLE_CHEMICAL", 51, 62], ["VPA", "TREATMENT", 0, 3], ["haloperidol", "TREATMENT", 51, 62]]], ["On day 10 of psychiatric consultation, , the patient was fully cognizant, awake, alert, oriented, following simple and complex commands, communicative via the use of mouthing and writing (assessed virtually), and displayed no evidence of ongoing delirium on assessment by a psychiatry team and according to the DSM-5.", [["psychiatric", "DISEASE", 13, 24], ["delirium", "DISEASE", 246, 254], ["patient", "ORGANISM", 45, 52], ["patient", "SPECIES", 45, 52], ["ongoing delirium", "PROBLEM", 238, 254], ["assessment", "TEST", 258, 268], ["no evidence of", "UNCERTAINTY", 223, 237], ["delirium", "OBSERVATION", 246, 254]]], ["She was discharged on day 52 after her initial hospitalization to a long-term acute care facility.Case description ::: IntroductionThe patient provided verbal consent for the case report, but was unable to physically sign associated documentation due to infection control measures.Pathophysiology ::: DiscussionNeuropsychiatric presentations of COVID-19 are increasingly described in the literature.", [["infection", "DISEASE", 254, 263], ["patient", "ORGANISM", 135, 142], ["patient", "SPECIES", 135, 142], ["a long-term acute care facility", "TREATMENT", 66, 97], ["infection control measures", "TREATMENT", 254, 280], ["COVID", "TEST", 345, 350], ["infection", "OBSERVATION", 254, 263]]], ["A retrospective case series of 214 hospitalized patients in China demonstrated that 24.8% had central nervous system (CNS) manifestations (e.g., dizziness, impaired consciousness, acute cerebrovascular disease, seizures), 8.9% had peripheral nervous system manifestations (taste, smell, and/or vision impairment), and 10.7% - skeletal muscular injury manifestations (10.7%) (6).", [["central nervous system", "ANATOMY", 94, 116], ["CNS", "ANATOMY", 118, 121], ["cerebrovascular", "ANATOMY", 186, 201], ["peripheral nervous system", "ANATOMY", 231, 256], ["skeletal muscular", "ANATOMY", 326, 343], ["central nervous system (CNS) manifestations", "DISEASE", 94, 137], ["dizziness", "DISEASE", 145, 154], ["impaired consciousness", "DISEASE", 156, 178], ["acute cerebrovascular disease", "DISEASE", 180, 209], ["seizures", "DISEASE", 211, 219], ["peripheral nervous system manifestations", "DISEASE", 231, 271], ["taste, smell, and/or vision impairment", "DISEASE", 273, 311], ["skeletal muscular injury", "DISEASE", 326, 350], ["patients", "ORGANISM", 48, 56], ["nervous system", "ANATOMICAL_SYSTEM", 102, 116], ["CNS", "ANATOMICAL_SYSTEM", 118, 121], ["nervous system", "ANATOMICAL_SYSTEM", 242, 256], ["taste", "ORGANISM_SUBDIVISION", 273, 278], ["skeletal muscular", "ORGANISM_SUBDIVISION", 326, 343], ["patients", "SPECIES", 48, 56], ["A retrospective case series", "TEST", 0, 27], ["central nervous system (CNS) manifestations (e.g.", "PROBLEM", 94, 143], ["dizziness", "PROBLEM", 145, 154], ["impaired consciousness", "PROBLEM", 156, 178], ["acute cerebrovascular disease", "PROBLEM", 180, 209], ["seizures", "PROBLEM", 211, 219], ["peripheral nervous system manifestations", "PROBLEM", 231, 271], ["smell", "PROBLEM", 280, 285], ["vision impairment", "PROBLEM", 294, 311], ["skeletal muscular injury manifestations", "PROBLEM", 326, 365], ["central", "ANATOMY_MODIFIER", 94, 101], ["nervous system", "ANATOMY", 102, 116], ["acute", "OBSERVATION_MODIFIER", 180, 185], ["cerebrovascular", "ANATOMY", 186, 201], ["disease", "OBSERVATION", 202, 209], ["peripheral", "ANATOMY_MODIFIER", 231, 241], ["nervous system", "ANATOMY", 242, 256], ["skeletal muscular", "ANATOMY", 326, 343], ["injury", "OBSERVATION", 344, 350]]], ["Neurological abnormalities were observed in 45.5% of those severely ill with COVID-19 as compared to those less severely ill (P=0.02), including impaired consciousness (14.8% versus 2.4%, P < .001) (6).Pathophysiology ::: DiscussionIn general, delirium is present in up to 82% of ICU intubated patients (7).", [["Neurological", "ANATOMY", 0, 12], ["Neurological abnormalities", "DISEASE", 0, 26], ["ill", "DISEASE", 68, 71], ["ill", "DISEASE", 121, 124], ["impaired consciousness", "DISEASE", 145, 167], ["delirium", "DISEASE", 244, 252], ["patients", "ORGANISM", 294, 302], ["patients", "SPECIES", 294, 302], ["Neurological abnormalities", "PROBLEM", 0, 26], ["COVID", "TEST", 77, 82], ["impaired consciousness", "PROBLEM", 145, 167], ["delirium", "PROBLEM", 244, 252], ["impaired", "OBSERVATION_MODIFIER", 145, 153]]], ["Not surprisingly, ICU patients with COVID-19 and ARDS are similarly expected to have a high delirium incidence.", [["ARDS", "DISEASE", 49, 53], ["delirium", "DISEASE", 92, 100], ["patients", "ORGANISM", 22, 30], ["patients", "SPECIES", 22, 30], ["COVID", "TEST", 36, 41], ["ARDS", "PROBLEM", 49, 53], ["a high delirium incidence", "PROBLEM", 85, 110], ["ARDS", "OBSERVATION", 49, 53], ["high", "OBSERVATION_MODIFIER", 87, 91], ["delirium", "OBSERVATION", 92, 100]]], ["Helms and colleagues 12 reported on 58 severely ill COVID-19 patients with 69% agitated when weaning off sedation, and 65% of those able to participate in the CAM-ICU scoring positively, suggesting delirium.Pathophysiology ::: DiscussionThe differential diagnosis of neuropsychiatric symptoms, including delirium, in patients with COVID-19 is extensive.", [["COVID", "DISEASE", 52, 57], ["delirium", "DISEASE", 198, 206], ["neuropsychiatric symptoms", "DISEASE", 267, 292], ["delirium", "DISEASE", 304, 312], ["patients", "ORGANISM", 61, 69], ["CAM", "MULTI-TISSUE_STRUCTURE", 159, 162], ["patients", "ORGANISM", 317, 325], ["patients", "SPECIES", 61, 69], ["patients", "SPECIES", 317, 325], ["69% agitated", "PROBLEM", 75, 87], ["sedation", "TREATMENT", 105, 113], ["delirium", "PROBLEM", 198, 206], ["neuropsychiatric symptoms", "PROBLEM", 267, 292], ["delirium", "PROBLEM", 304, 312], ["COVID", "TEST", 331, 336], ["delirium", "OBSERVATION", 198, 206], ["extensive", "OBSERVATION_MODIFIER", 343, 352]]], ["Cases of encephalitis and meningitis have been documented with specific SARS-CoV-2 RNA detected in cerebral spinal fluid (13).", [["cerebral spinal fluid", "ANATOMY", 99, 120], ["encephalitis", "DISEASE", 9, 21], ["meningitis", "DISEASE", 26, 36], ["SARS-CoV-2", "GENE_OR_GENE_PRODUCT", 72, 82], ["cerebral spinal fluid", "MULTI-TISSUE_STRUCTURE", 99, 120], ["SARS-CoV-2 RNA", "RNA", 72, 86], ["encephalitis", "PROBLEM", 9, 21], ["meningitis", "PROBLEM", 26, 36], ["specific SARS", "TEST", 63, 76], ["CoV", "TEST", 77, 80], ["2 RNA", "PROBLEM", 81, 86], ["cerebral spinal fluid", "TEST", 99, 120], ["encephalitis", "OBSERVATION", 9, 21], ["meningitis", "OBSERVATION", 26, 36], ["cerebral spinal", "ANATOMY", 99, 114], ["fluid", "OBSERVATION", 115, 120]]], ["In addition, patients with COVID-19 might have elevated D-dimer and impaired platelet functioning, thus placing them at risk for acute cerebrovascular accidents (14).", [["platelet", "ANATOMY", 77, 85], ["cerebrovascular", "ANATOMY", 135, 150], ["impaired platelet functioning", "DISEASE", 68, 97], ["acute cerebrovascular accidents", "DISEASE", 129, 160], ["patients", "ORGANISM", 13, 21], ["D-dimer", "GENE_OR_GENE_PRODUCT", 56, 63], ["platelet", "CELL", 77, 85], ["D-dimer", "PROTEIN", 56, 63], ["patients", "SPECIES", 13, 21], ["COVID", "TEST", 27, 32], ["elevated D-dimer", "PROBLEM", 47, 63], ["impaired platelet functioning", "PROBLEM", 68, 97], ["acute cerebrovascular accidents", "PROBLEM", 129, 160], ["elevated", "OBSERVATION_MODIFIER", 47, 55], ["D-dimer", "OBSERVATION_MODIFIER", 56, 63], ["impaired", "OBSERVATION_MODIFIER", 68, 76], ["platelet functioning", "OBSERVATION", 77, 97], ["acute", "OBSERVATION_MODIFIER", 129, 134], ["cerebrovascular", "ANATOMY", 135, 150]]], ["Non-convulsive seizures should also be entertained on the differential, based on the clinical picture.Pathophysiology ::: DiscussionVarious pathophysiological mechanisms for delirium development and propagation have been proposed (18), many of which co-exist in patients with COVID-19.", [["seizures", "DISEASE", 15, 23], ["delirium", "DISEASE", 174, 182], ["COVID-19", "CHEMICAL", 276, 284], ["patients", "ORGANISM", 262, 270], ["patients", "SPECIES", 262, 270], ["Non-convulsive seizures", "PROBLEM", 0, 23], ["delirium development", "PROBLEM", 174, 194], ["COVID", "TEST", 276, 281]]], ["Some of these are unique to individual patients (i.e., substrates), some are related to the treatment environment (e.g., ICU, sedatives), and others are related to the acute effects of the virus and its comorbidities (i.e., precipitants).", [["patients", "ORGANISM", 39, 47], ["patients", "SPECIES", 39, 47], ["sedatives", "TREATMENT", 126, 135], ["the virus", "PROBLEM", 185, 194], ["its comorbidities", "PROBLEM", 199, 216], ["acute", "OBSERVATION_MODIFIER", 168, 173]]], ["However, there are unique considerations in COVID-19 patients, including CNS viral effects, COVID-19 specific treatment side effects, and environmental factors.Pathophysiology ::: DiscussionEvidence suggests that direct CNS invasion of the SARS-CoV-2 is possible, which might lead to deleterious neuropsychiatric effects.", [["CNS", "ANATOMY", 73, 76], ["CNS", "ANATOMY", 220, 223], ["SARS", "DISEASE", 240, 244], ["patients", "ORGANISM", 53, 61], ["CNS", "ANATOMICAL_SYSTEM", 73, 76], ["CNS", "ANATOMICAL_SYSTEM", 220, 223], ["SARS-CoV-2", "GENE_OR_GENE_PRODUCT", 240, 250], ["patients", "SPECIES", 53, 61], ["COVID", "TEST", 44, 49], ["CNS viral effects", "PROBLEM", 73, 90], ["COVID", "TEST", 92, 97], ["specific treatment side effects", "TREATMENT", 101, 132], ["direct CNS invasion", "PROBLEM", 213, 232], ["the SARS", "PROBLEM", 236, 244], ["deleterious neuropsychiatric effects", "PROBLEM", 284, 320], ["CNS", "ANATOMY", 73, 76], ["viral effects", "OBSERVATION", 77, 90]]], ["In fact, animal studies have demonstrated that SARS-CoV-2 is neuro-invasive, likely entering the brain parenchyma via ascending olfactory nerves, then spreading to the thalamus and brainstem (5).Pathophysiology ::: DiscussionAdditionally, a subset of COVID-19 patients experience a cytokine storm (15).", [["brain parenchyma", "ANATOMY", 97, 113], ["olfactory nerves", "ANATOMY", 128, 144], ["thalamus", "ANATOMY", 168, 176], ["brainstem", "ANATOMY", 181, 190], ["SARS", "DISEASE", 47, 51], ["SARS-CoV-2", "GENE_OR_GENE_PRODUCT", 47, 57], ["brain parenchyma", "MULTI-TISSUE_STRUCTURE", 97, 113], ["olfactory nerves", "MULTI-TISSUE_STRUCTURE", 128, 144], ["thalamus", "MULTI-TISSUE_STRUCTURE", 168, 176], ["brainstem", "ORGAN", 181, 190], ["patients", "ORGANISM", 260, 268], ["cytokine", "PROTEIN", 282, 290], ["patients", "SPECIES", 260, 268], ["SARS-CoV", "SPECIES", 47, 55], ["animal studies", "TEST", 9, 23], ["SARS", "TEST", 47, 51], ["CoV", "TEST", 52, 55], ["neuro-invasive", "PROBLEM", 61, 75], ["brain", "ANATOMY", 97, 102], ["parenchyma", "ANATOMY_MODIFIER", 103, 113], ["ascending", "ANATOMY_MODIFIER", 118, 127], ["olfactory nerves", "ANATOMY", 128, 144], ["thalamus", "ANATOMY", 168, 176], ["brainstem", "ANATOMY_MODIFIER", 181, 190]]], ["While an immune response is important to fight the infection, an excessive and dysregulated immune overactivation is likely to contribute to the development of ARDS and multi-organ failure, including \u201cbrain failure\u201d or delirium (16).", [["multi-organ", "ANATOMY", 169, 180], ["brain", "ANATOMY", 201, 206], ["infection", "DISEASE", 51, 60], ["ARDS", "DISEASE", 160, 164], ["multi-organ failure", "DISEASE", 169, 188], ["brain failure", "DISEASE", 201, 214], ["delirium", "DISEASE", 219, 227], ["multi-organ", "ORGAN", 169, 180], ["brain", "ORGAN", 201, 206], ["the infection", "PROBLEM", 47, 60], ["an excessive and dysregulated immune overactivation", "PROBLEM", 62, 113], ["ARDS", "PROBLEM", 160, 164], ["multi-organ failure", "PROBLEM", 169, 188], ["\u201cbrain failure", "PROBLEM", 200, 214], ["delirium", "PROBLEM", 219, 227], ["infection", "OBSERVATION", 51, 60], ["dysregulated immune overactivation", "OBSERVATION", 79, 113], ["ARDS", "OBSERVATION", 160, 164], ["multi-organ failure", "OBSERVATION", 169, 188], ["brain", "ANATOMY", 201, 206], ["failure", "OBSERVATION", 207, 214]]], ["Many pro-inflammatory cytokines (e.g., interleukin-6, interleukin-8, interleukin-1 \u03b2) and chemokines (e.g., CCL2, CCL-5) have been linked to the development of ARDS, a frequent cause of mortality in patients with COVID-19 (15); the same have been associated with the development of delirium16.", [["ARDS", "DISEASE", 160, 164], ["delirium16", "CHEMICAL", 282, 292], ["delirium16", "CHEMICAL", 282, 292], ["interleukin-6", "GENE_OR_GENE_PRODUCT", 39, 52], ["interleukin-8", "GENE_OR_GENE_PRODUCT", 54, 67], ["interleukin-1 \u03b2", "GENE_OR_GENE_PRODUCT", 69, 84], ["CCL2", "GENE_OR_GENE_PRODUCT", 108, 112], ["CCL-5", "GENE_OR_GENE_PRODUCT", 114, 119], ["patients", "ORGANISM", 199, 207], ["delirium16", "GENE_OR_GENE_PRODUCT", 282, 292], ["pro-inflammatory cytokines", "PROTEIN", 5, 31], ["interleukin-6", "PROTEIN", 39, 52], ["interleukin-8", "PROTEIN", 54, 67], ["interleukin-1 \u03b2", "PROTEIN", 69, 84], ["chemokines", "PROTEIN", 90, 100], ["CCL2", "PROTEIN", 108, 112], ["CCL", "PROTEIN", 114, 117], ["patients", "SPECIES", 199, 207], ["Many pro-inflammatory cytokines", "TEST", 0, 31], ["interleukin", "TEST", 39, 50], ["interleukin", "TEST", 54, 65], ["interleukin", "TEST", 69, 80], ["chemokines", "TEST", 90, 100], ["CCL2", "TEST", 108, 112], ["CCL", "TEST", 114, 117], ["ARDS", "PROBLEM", 160, 164], ["COVID", "TEST", 213, 218], ["delirium16", "PROBLEM", 282, 292], ["pro-inflammatory cytokines", "OBSERVATION", 5, 31], ["ARDS", "OBSERVATION", 160, 164]]], ["Specifically, Qin et al described extensive dysregulation of the immune response in patients with COVID-19 (17).", [["COVID-19", "CHEMICAL", 98, 106], ["patients", "ORGANISM", 84, 92], ["patients", "SPECIES", 84, 92], ["COVID", "TEST", 98, 103], ["extensive", "OBSERVATION_MODIFIER", 34, 43], ["dysregulation", "OBSERVATION", 44, 57], ["immune response", "OBSERVATION", 65, 80]]], ["Moreover, cytokine storm is fueled by the release of catecholamines by immune cells via a self-amplifying circuit (18).", [["immune cells", "ANATOMY", 71, 83], ["catecholamines", "CHEMICAL", 53, 67], ["catecholamines", "CHEMICAL", 53, 67], ["catecholamines", "SIMPLE_CHEMICAL", 53, 67], ["immune cells", "CELL", 71, 83], ["cytokine", "PROTEIN", 10, 18], ["immune cells", "CELL_TYPE", 71, 83], ["a self-amplifying circuit", "TREATMENT", 88, 113]]], ["Catecholamines, such as norepinephrine, might also be elevated in hyperactive delirium contributing to its pathophysiology and symptomology (16).", [["norepinephrine", "CHEMICAL", 24, 38], ["hyperactive delirium", "DISEASE", 66, 86], ["Catecholamines", "CHEMICAL", 0, 14], ["norepinephrine", "CHEMICAL", 24, 38], ["Catecholamines", "SIMPLE_CHEMICAL", 0, 14], ["norepinephrine", "SIMPLE_CHEMICAL", 24, 38], ["Catecholamines", "TREATMENT", 0, 14], ["norepinephrine", "TREATMENT", 24, 38], ["hyperactive delirium", "PROBLEM", 66, 86], ["symptomology", "PROBLEM", 127, 139], ["hyperactive", "OBSERVATION_MODIFIER", 66, 77], ["delirium", "OBSERVATION", 78, 86]]], ["Our patient\u2019s course was characterized by significant agitation, requiring use of multiple high-dose sedatives.", [["agitation", "DISEASE", 54, 63], ["patient", "ORGANISM", 4, 11], ["patient", "SPECIES", 4, 11], ["significant agitation", "PROBLEM", 42, 63], ["multiple high-dose sedatives", "TREATMENT", 82, 110], ["significant", "OBSERVATION_MODIFIER", 42, 53], ["agitation", "OBSERVATION", 54, 63]]], ["This agitation, along with ARDS, might be one presentation of the cytokine storm and catecholamine release in this patient population.Pathophysiology ::: DiscussionAmong specific patient\u2019s characteristics, older age among COVID-19 patients is associated with higher morbidity and mortality rates (19).", [["agitation", "DISEASE", 5, 14], ["ARDS", "DISEASE", 27, 31], ["catecholamine", "CHEMICAL", 85, 98], ["catecholamine", "CHEMICAL", 85, 98], ["catecholamine", "SIMPLE_CHEMICAL", 85, 98], ["patient", "ORGANISM", 115, 122], ["patient", "ORGANISM", 179, 186], ["patients", "ORGANISM", 231, 239], ["cytokine", "PROTEIN", 66, 74], ["patient", "SPECIES", 115, 122], ["patient", "SPECIES", 179, 186], ["patients", "SPECIES", 231, 239], ["This agitation", "PROBLEM", 0, 14], ["ARDS", "PROBLEM", 27, 31], ["the cytokine storm", "TREATMENT", 62, 80], ["catecholamine release", "TREATMENT", 85, 106], ["higher morbidity", "PROBLEM", 259, 275], ["mortality rates", "TEST", 280, 295], ["ARDS", "OBSERVATION", 27, 31], ["cytokine storm", "OBSERVATION", 66, 80]]], ["Similarly, older age and associated medical comorbidities are recognized as major risk factors for delirium development (16).", [["delirium", "DISEASE", 99, 107], ["associated medical comorbidities", "PROBLEM", 25, 57], ["delirium development", "PROBLEM", 99, 119]]], ["In addition, patients with pneumonia and respiratory failure might experience CNS hypoxia and increasing anaerobic metabolism in the mitochondria of brain cells.", [["respiratory", "ANATOMY", 41, 52], ["CNS", "ANATOMY", 78, 81], ["mitochondria", "ANATOMY", 133, 145], ["brain cells", "ANATOMY", 149, 160], ["pneumonia", "DISEASE", 27, 36], ["respiratory failure", "DISEASE", 41, 60], ["hypoxia", "DISEASE", 82, 89], ["patients", "ORGANISM", 13, 21], ["CNS", "ANATOMICAL_SYSTEM", 78, 81], ["mitochondria", "CELLULAR_COMPONENT", 133, 145], ["brain cells", "CELL", 149, 160], ["brain cells", "CELL_TYPE", 149, 160], ["patients", "SPECIES", 13, 21], ["pneumonia", "PROBLEM", 27, 36], ["respiratory failure", "PROBLEM", 41, 60], ["CNS hypoxia", "PROBLEM", 78, 89], ["increasing anaerobic metabolism in the mitochondria of brain cells", "PROBLEM", 94, 160], ["pneumonia", "OBSERVATION", 27, 36], ["respiratory failure", "OBSERVATION", 41, 60], ["increasing", "OBSERVATION_MODIFIER", 94, 104], ["anaerobic metabolism", "OBSERVATION", 105, 125], ["brain cells", "OBSERVATION", 149, 160]]], ["This can then lead to cerebral vasodilation, brain cell and interstitial edema, and obstruction of cerebral blood flow (14).", [["cerebral", "ANATOMY", 22, 30], ["brain cell", "ANATOMY", 45, 55], ["interstitial edema", "ANATOMY", 60, 78], ["cerebral blood", "ANATOMY", 99, 113], ["cerebral vasodilation", "DISEASE", 22, 43], ["interstitial edema", "DISEASE", 60, 78], ["obstruction of cerebral blood flow", "DISEASE", 84, 118], ["cerebral", "MULTI-TISSUE_STRUCTURE", 22, 30], ["brain cell", "CELL", 45, 55], ["interstitial edema", "PATHOLOGICAL_FORMATION", 60, 78], ["cerebral", "MULTI-TISSUE_STRUCTURE", 99, 107], ["blood", "ORGANISM_SUBSTANCE", 108, 113], ["cerebral vasodilation", "PROBLEM", 22, 43], ["brain cell", "PROBLEM", 45, 55], ["interstitial edema", "PROBLEM", 60, 78], ["obstruction of cerebral blood flow", "PROBLEM", 84, 118], ["cerebral", "ANATOMY", 22, 30], ["vasodilation", "OBSERVATION", 31, 43], ["brain", "ANATOMY", 45, 50], ["cell", "ANATOMY_MODIFIER", 51, 55], ["interstitial", "ANATOMY_MODIFIER", 60, 72], ["edema", "OBSERVATION", 73, 78], ["obstruction", "OBSERVATION", 84, 95], ["cerebral blood", "ANATOMY", 99, 113], ["flow", "OBSERVATION_MODIFIER", 114, 118]]], ["These same mechanisms have been described as causative factors in delirium development (18).", [["delirium", "DISEASE", 66, 74], ["delirium development", "PROBLEM", 66, 86]]], ["Our patient was an older woman.Pathophysiology ::: DiscussionRegarding treatment-related factors, patients with severe COVID-19 often require management in ICU settings and/or ventilatory support.", [["patient", "ORGANISM", 4, 11], ["woman", "ORGANISM", 25, 30], ["patients", "ORGANISM", 98, 106], ["patient", "SPECIES", 4, 11], ["woman", "SPECIES", 25, 30], ["patients", "SPECIES", 98, 106], ["severe COVID", "PROBLEM", 112, 124], ["ICU settings", "TREATMENT", 156, 168], ["ventilatory support", "TREATMENT", 176, 195], ["ventilatory support", "OBSERVATION", 176, 195]]], ["Ventilated patients are frequently placed on combinations of CNS depressants to facilitate ventilatory compliance.", [["CNS", "ANATOMY", 61, 64], ["patients", "ORGANISM", 11, 19], ["patients", "SPECIES", 11, 19], ["Ventilated", "TREATMENT", 0, 10], ["CNS depressants", "TREATMENT", 61, 76], ["ventilatory compliance", "TREATMENT", 91, 113], ["ventilatory compliance", "OBSERVATION", 91, 113]]], ["Many of these sedatives are associated with an increased incidence of delirium (16).", [["delirium", "DISEASE", 70, 78], ["these sedatives", "TREATMENT", 8, 23], ["delirium", "PROBLEM", 70, 78], ["increased", "OBSERVATION_MODIFIER", 47, 56], ["delirium", "OBSERVATION", 70, 78]]], ["In fact, due to significant agitation in many COVID-19 ICU patients and the risk to patients and staff associated with patients dislodging lines and endotracheal tubes in context of high viral infectivity, patients have anecdotally required combinations of multiple sedatives with very high doses.", [["endotracheal tubes", "ANATOMY", 149, 167], ["agitation", "DISEASE", 28, 37], ["viral infectivity", "DISEASE", 187, 204], ["patients", "ORGANISM", 59, 67], ["patients", "ORGANISM", 84, 92], ["patients", "ORGANISM", 119, 127], ["lines", "CELL", 139, 144], ["endotracheal tubes", "MULTI-TISSUE_STRUCTURE", 149, 167], ["patients", "ORGANISM", 206, 214], ["patients", "SPECIES", 59, 67], ["patients", "SPECIES", 84, 92], ["patients", "SPECIES", 119, 127], ["patients", "SPECIES", 206, 214], ["significant agitation", "PROBLEM", 16, 37], ["patients dislodging lines", "TREATMENT", 119, 144], ["endotracheal tubes", "TREATMENT", 149, 167], ["high viral infectivity", "PROBLEM", 182, 204], ["multiple sedatives", "TREATMENT", 257, 275], ["significant", "OBSERVATION_MODIFIER", 16, 27], ["agitation", "OBSERVATION", 28, 37], ["dislodging lines", "OBSERVATION", 128, 144], ["endotracheal tubes", "OBSERVATION", 149, 167], ["high", "OBSERVATION_MODIFIER", 182, 186], ["viral infectivity", "OBSERVATION", 187, 204]]], ["In our case, the patient had required propofol, opiods, and high-dose benzodiazepines, among other agents, which could have all further worsened her confusion and agitation.Pathophysiology ::: DiscussionIn addition, some medications that have been specifically used in the treatment of COVID-19 may themselves induce neuropsychiatric side effects.", [["propofol", "CHEMICAL", 38, 46], ["benzodiazepines", "CHEMICAL", 70, 85], ["confusion", "DISEASE", 149, 158], ["agitation", "DISEASE", 163, 172], ["COVID-19", "CHEMICAL", 286, 294], ["propofol", "CHEMICAL", 38, 46], ["benzodiazepines", "CHEMICAL", 70, 85], ["COVID-19", "CHEMICAL", 286, 294], ["patient", "ORGANISM", 17, 24], ["propofol", "SIMPLE_CHEMICAL", 38, 46], ["patient", "SPECIES", 17, 24], ["propofol", "TREATMENT", 38, 46], ["opiods", "TREATMENT", 48, 54], ["high-dose benzodiazepines", "TREATMENT", 60, 85], ["her confusion", "PROBLEM", 145, 158], ["agitation", "PROBLEM", 163, 172], ["some medications", "TREATMENT", 216, 232], ["COVID", "TREATMENT", 286, 291], ["neuropsychiatric side effects", "PROBLEM", 317, 346]]], ["For example, hydroxychloroquine has been known to cause such side effects, including delirium (20).", [["hydroxychloroquine", "CHEMICAL", 13, 31], ["delirium", "DISEASE", 85, 93], ["hydroxychloroquine", "CHEMICAL", 13, 31], ["hydroxychloroquine", "SIMPLE_CHEMICAL", 13, 31], ["hydroxychloroquine", "TREATMENT", 13, 31], ["such side effects", "PROBLEM", 56, 73], ["delirium", "PROBLEM", 85, 93]]], ["These effects may be exacerbated by a cytokine storm-mediated increase in blood-brain permeability.", [["blood", "ANATOMY", 74, 79], ["brain", "ANATOMY", 80, 85], ["blood", "ORGANISM_SUBSTANCE", 74, 79], ["brain", "ORGAN", 80, 85], ["cytokine", "PROTEIN", 38, 46], ["a cytokine storm", "PROBLEM", 36, 52], ["mediated increase in blood-brain permeability", "PROBLEM", 53, 98], ["may be", "UNCERTAINTY", 14, 20], ["cytokine storm", "OBSERVATION", 38, 52], ["increase", "OBSERVATION_MODIFIER", 62, 70], ["blood", "ANATOMY", 74, 79], ["brain", "ANATOMY", 80, 85], ["permeability", "OBSERVATION_MODIFIER", 86, 98]]], ["While our patient was not treated with hydroxychloroquine, it might be an important consideration for others.", [["hydroxychloroquine", "CHEMICAL", 39, 57], ["hydroxychloroquine", "CHEMICAL", 39, 57], ["patient", "ORGANISM", 10, 17], ["hydroxychloroquine", "SIMPLE_CHEMICAL", 39, 57], ["patient", "SPECIES", 10, 17], ["hydroxychloroquine", "TREATMENT", 39, 57]]], ["Moreover, secondary complications, such as renal failure and secondary infections, can contribute to or worsen delirium.Pathophysiology ::: DiscussionEnvironmental factors also increase the risk of delirium during these challenging times.", [["renal", "ANATOMY", 43, 48], ["renal failure", "DISEASE", 43, 56], ["infections", "DISEASE", 71, 81], ["delirium", "DISEASE", 111, 119], ["delirium", "DISEASE", 198, 206], ["renal", "ORGAN", 43, 48], ["secondary complications", "PROBLEM", 10, 33], ["renal failure", "PROBLEM", 43, 56], ["secondary infections", "PROBLEM", 61, 81], ["worsen delirium", "PROBLEM", 104, 119], ["delirium", "PROBLEM", 198, 206], ["secondary", "OBSERVATION_MODIFIER", 10, 19], ["complications", "OBSERVATION", 20, 33], ["renal", "ANATOMY", 43, 48], ["failure", "OBSERVATION", 49, 56], ["secondary", "OBSERVATION_MODIFIER", 61, 70], ["infections", "OBSERVATION", 71, 81], ["delirium", "OBSERVATION", 198, 206]]], ["Due to the high infectivity of this virus, shortage of personal protective equipment (PPE), and medical isolation to decrease virus transmission, COVID-19 patients might not have the benefit of conventional non-pharmacological prevention strategies or the support of loved ones (21).", [["patients", "ORGANISM", 155, 163], ["patients", "SPECIES", 155, 163], ["the high infectivity", "PROBLEM", 7, 27], ["this virus", "PROBLEM", 31, 41], ["personal protective equipment (PPE)", "TREATMENT", 55, 90], ["medical isolation", "TREATMENT", 96, 113], ["conventional non-pharmacological prevention strategies", "TREATMENT", 194, 248], ["high", "OBSERVATION_MODIFIER", 11, 15], ["infectivity", "OBSERVATION", 16, 27]]], ["The staff is unable to spend time and provide frequent re-orientation and cognitive stimulation for the patients, while family members are not allowed to visit and provide visual cues, reassurance, and practical support.", [["patients", "ORGANISM", 104, 112], ["patients", "SPECIES", 104, 112], ["frequent re-orientation", "TREATMENT", 46, 69], ["cognitive stimulation", "TREATMENT", 74, 95], ["reassurance", "TREATMENT", 185, 196], ["practical support", "TREATMENT", 202, 219]]], ["In addition, unusual configuration of the rooms, inability to recognize faces due to staff\u2019s extensive PPE, and potentially even the use of the virtual modalities to communicate (e.g., remote telemedicine and virtual visits with family members) as opposed to live visits, all might worsen patients\u2019 perception of the reality and contribute to disorientation and confusion.Evaluation and diagnosis ::: DiscussionThe diagnosis of delirium in patients with COVID-19 is challenging due to limited interactions between staff and patients due to isolation protocols.", [["disorientation", "DISEASE", 343, 357], ["confusion", "DISEASE", 362, 371], ["delirium", "DISEASE", 428, 436], ["patients", "ORGANISM", 289, 297], ["patients", "ORGANISM", 440, 448], ["patients", "ORGANISM", 524, 532], ["patients", "SPECIES", 289, 297], ["patients", "SPECIES", 440, 448], ["patients", "SPECIES", 524, 532], ["disorientation", "PROBLEM", 343, 357], ["confusion", "PROBLEM", 362, 371], ["Evaluation", "TEST", 372, 382], ["delirium", "PROBLEM", 428, 436], ["COVID", "TEST", 454, 459], ["isolation protocols", "TREATMENT", 540, 559], ["delirium", "OBSERVATION", 428, 436]]], ["A live neuropsychiatric evaluation (gold standard) might not be available and/or safe; thus screening tools, such as CAM-ICU (9) and the Intensive Care Delirium Screening Checklist (ICDSC) (22) might be especially useful.", [["Delirium", "DISEASE", 152, 160], ["A live neuropsychiatric evaluation", "TEST", 0, 34], ["screening tools", "TEST", 92, 107]]], ["Yet, up to 30% of patients might not be able to complete screening tools that require patient participation (9).", [["patients", "ORGANISM", 18, 26], ["patient", "ORGANISM", 86, 93], ["patients", "SPECIES", 18, 26], ["patient", "SPECIES", 86, 93], ["screening tools", "TEST", 57, 72]]], ["Thus, a novel tool, the S-PTD, might be particularly helpful as it relies on nursing report of patients\u2019 cognition and behaviors, rather than on patient\u2019s participation (10,11).", [["patients", "ORGANISM", 95, 103], ["patient", "ORGANISM", 145, 152], ["patients", "SPECIES", 95, 103], ["patient", "SPECIES", 145, 152]]], ["Our patient was initially evaluated remotely from outside of the room integrating review of the chart and descriptions of her behavior and mental status from her nursing and medical staff.", [["patient", "ORGANISM", 4, 11], ["patient", "SPECIES", 4, 11]]], ["CAM-ICU and S-PTD were also used in her evaluation and diagnosis.", [["CAM", "MULTI-TISSUE_STRUCTURE", 0, 3], ["S-PTD", "GENE_OR_GENE_PRODUCT", 12, 17], ["her evaluation", "TEST", 36, 50]]], ["As patient improved and was able to engage in an evaluation, she was interviewed virtually with the use of telemedicine.Work-up ::: DiscussionIn addition to usual infectious and metabolic work-up for delirium, pharmacological agents that can contribute to mental status alterations must be reviewed.", [["delirium", "DISEASE", 200, 208], ["patient", "ORGANISM", 3, 10], ["patient", "SPECIES", 3, 10], ["an evaluation", "TEST", 46, 59], ["delirium", "PROBLEM", 200, 208], ["pharmacological agents", "TREATMENT", 210, 232], ["mental status alterations", "PROBLEM", 256, 281]]], ["Our patient received significant amounts of deliriogenic medications (e.g., propofol, hydromorphone, oxycodone, chlordiazepoxide).", [["propofol", "CHEMICAL", 76, 84], ["hydromorphone", "CHEMICAL", 86, 99], ["oxycodone", "CHEMICAL", 101, 110], ["chlordiazepoxide", "CHEMICAL", 112, 128], ["propofol", "CHEMICAL", 76, 84], ["hydromorphone", "CHEMICAL", 86, 99], ["oxycodone", "CHEMICAL", 101, 110], ["chlordiazepoxide", "CHEMICAL", 112, 128], ["patient", "ORGANISM", 4, 11], ["propofol", "SIMPLE_CHEMICAL", 76, 84], ["hydromorphone", "SIMPLE_CHEMICAL", 86, 99], ["oxycodone", "SIMPLE_CHEMICAL", 101, 110], ["chlordiazepoxide", "SIMPLE_CHEMICAL", 112, 128], ["patient", "SPECIES", 4, 11], ["deliriogenic medications", "TREATMENT", 44, 68], ["propofol", "TREATMENT", 76, 84], ["hydromorphone", "TREATMENT", 86, 99], ["oxycodone", "TREATMENT", 101, 110], ["chlordiazepoxide", "TREATMENT", 112, 128]]], ["Based on the differential diagnosis, brain imaging, a lumbar puncture, and an electroencephalogram might be indicated.", [["brain", "ANATOMY", 37, 42], ["lumbar", "ANATOMY", 54, 60], ["brain", "ORGAN", 37, 42], ["brain imaging", "TEST", 37, 50], ["a lumbar puncture", "TEST", 52, 69], ["an electroencephalogram", "TEST", 75, 98], ["lumbar", "ANATOMY", 54, 60]]], ["Since our patient did not display focal neurologic deficits, abnormal movements or consistently depressed mental status, these studies were not indicated or pursued.", [["neurologic", "ANATOMY", 40, 50], ["neurologic deficits", "DISEASE", 40, 59], ["abnormal movements", "DISEASE", 61, 79], ["depressed", "DISEASE", 96, 105], ["patient", "ORGANISM", 10, 17], ["patient", "SPECIES", 10, 17], ["focal neurologic deficits", "PROBLEM", 34, 59], ["abnormal movements", "PROBLEM", 61, 79], ["consistently depressed mental status", "PROBLEM", 83, 119], ["these studies", "TEST", 121, 134], ["focal", "OBSERVATION_MODIFIER", 34, 39]]], ["Renal and liver function as well as QTc on electrocardiogram should be established to safely choose an appropriate pharmacological regimen.", [["Renal", "ANATOMY", 0, 5], ["liver", "ANATOMY", 10, 15], ["Renal", "MULTI-TISSUE_STRUCTURE", 0, 5], ["liver", "ORGAN", 10, 15], ["QTc", "TEST", 36, 39], ["electrocardiogram", "TEST", 43, 60], ["an appropriate pharmacological regimen", "TREATMENT", 100, 138], ["liver", "ANATOMY", 10, 15]]], ["Our patient had baseline elevated liver function tests (likely due to COVID-19 infection) and these were carefully monitored on daily basis while VPA was administered on short-term basis.Non-pharmacological ::: Delirium Management ::: DiscussionLaHue and colleagues have suggested practical non-pharmacological interventions to prevent delirium in patients with COVID-19, given the unique challenges (21).", [["liver", "ANATOMY", 34, 39], ["elevated liver function", "DISEASE", 25, 48], ["infection", "DISEASE", 79, 88], ["VPA", "CHEMICAL", 146, 149], ["Delirium", "DISEASE", 211, 219], ["delirium", "DISEASE", 336, 344], ["VPA", "CHEMICAL", 146, 149], ["patient", "ORGANISM", 4, 11], ["liver", "ORGAN", 34, 39], ["VPA", "SIMPLE_CHEMICAL", 146, 149], ["patients", "ORGANISM", 348, 356], ["patient", "SPECIES", 4, 11], ["patients", "SPECIES", 348, 356], ["baseline elevated liver function tests", "PROBLEM", 16, 54], ["COVID-19 infection", "PROBLEM", 70, 88], ["VPA", "TREATMENT", 146, 149], ["Delirium", "PROBLEM", 211, 219], ["practical non-pharmacological interventions", "TREATMENT", 281, 324], ["delirium", "PROBLEM", 336, 344], ["COVID", "TEST", 362, 367], ["elevated", "OBSERVATION", 25, 33], ["liver", "ANATOMY", 34, 39], ["infection", "OBSERVATION", 79, 88]]], ["Some practical non-pharmacological interventions in this population include maintaining light-dark environment consistent with the diurnal cycle; minimization of nighttime disruptions; re-orientation and cognitive stimulation of the patient whenever possible; encouragement of family photos, phone calls, and virtual visits; provision of physical mobilization whenever possible; ensuring availability of glasses, hearing aids, and communication devices.Medications and monitoring ::: Delirium Management ::: DiscussionDelirium-related agitation places the patient and healthcare providers at risk, thus medications should be available for acute management.", [["Delirium", "DISEASE", 484, 492], ["Delirium", "DISEASE", 518, 526], ["agitation", "DISEASE", 535, 544], ["patient", "ORGANISM", 233, 240], ["patient", "ORGANISM", 556, 563], ["patient", "SPECIES", 233, 240], ["patient", "SPECIES", 556, 563], ["Some practical non-pharmacological interventions", "TREATMENT", 0, 48], ["the diurnal cycle", "TREATMENT", 127, 144], ["nighttime disruptions", "PROBLEM", 162, 183], ["re-orientation", "TREATMENT", 185, 199], ["cognitive stimulation", "TREATMENT", 204, 225], ["physical mobilization", "TREATMENT", 338, 359], ["hearing aids", "TREATMENT", 413, 425], ["communication devices", "TREATMENT", 431, 452], ["Delirium", "PROBLEM", 484, 492], ["Delirium", "PROBLEM", 518, 526], ["agitation", "PROBLEM", 535, 544], ["medications", "TREATMENT", 603, 614], ["acute management", "TREATMENT", 639, 655]]], ["While no studies have demonstrated pharmacological efficacy in the management of delirium among COVID-19 patients, we provide a framework for choosing psychotropic medications to assist in achieving behavioral control in ICU patients.", [["delirium", "DISEASE", 81, 89], ["patients", "ORGANISM", 105, 113], ["patients", "ORGANISM", 225, 233], ["patients", "SPECIES", 105, 113], ["patients", "SPECIES", 225, 233], ["studies", "TEST", 9, 16], ["pharmacological efficacy", "PROBLEM", 35, 59], ["delirium", "PROBLEM", 81, 89], ["choosing psychotropic medications", "TREATMENT", 142, 175]]], ["Agents chosen to treat symptoms of delirium in our patient and included in Table 1were specifically selected due to their own low deliriogenic potential and with the goal to minimize the use of conventional sedatives which are associated with worsening delirium, longer recovery, and impaired long-term cognition.Medications and monitoring ::: Delirium Management ::: DiscussionAt our center, the following medications have been used in management of agitation in patients with COVID-19 ICU-associated hyperactive delirium, including the described patient, with following considerations.Medications and monitoring ::: Delirium Management ::: DiscussionHigh-dose melatonin is used for treatment of delirium and sleep-wake cycle regulation, and postulated to be useful in treatment of COVID-19 in general, given its anti-inflammatory and anti-oxidant effects (23).", [["delirium", "DISEASE", 35, 43], ["delirium", "DISEASE", 253, 261], ["impaired long-term cognition", "DISEASE", 284, 312], ["Delirium", "DISEASE", 344, 352], ["agitation", "DISEASE", 451, 460], ["COVID", "DISEASE", 478, 483], ["hyperactive delirium", "DISEASE", 502, 522], ["Delirium", "DISEASE", 618, 626], ["melatonin", "CHEMICAL", 662, 671], ["delirium", "DISEASE", 697, 705], ["COVID-19", "CHEMICAL", 783, 791], ["melatonin", "CHEMICAL", 662, 671], ["COVID-19", "CHEMICAL", 783, 791], ["patient", "ORGANISM", 51, 58], ["patients", "ORGANISM", 464, 472], ["patient", "ORGANISM", 548, 555], ["melatonin", "SIMPLE_CHEMICAL", 662, 671], ["patient", "SPECIES", 51, 58], ["patients", "SPECIES", 464, 472], ["patient", "SPECIES", 548, 555], ["Agents", "TREATMENT", 0, 6], ["symptoms", "PROBLEM", 23, 31], ["delirium", "PROBLEM", 35, 43], ["conventional sedatives", "TREATMENT", 194, 216], ["worsening delirium", "PROBLEM", 243, 261], ["impaired long-term cognition", "PROBLEM", 284, 312], ["Delirium", "PROBLEM", 344, 352], ["the following medications", "TREATMENT", 393, 418], ["agitation", "PROBLEM", 451, 460], ["COVID", "TEST", 478, 483], ["hyperactive delirium", "PROBLEM", 502, 522], ["Delirium", "PROBLEM", 618, 626], ["DiscussionHigh-dose melatonin", "TREATMENT", 642, 671], ["delirium", "PROBLEM", 697, 705], ["COVID", "TEST", 783, 788], ["its anti-inflammatory and anti-oxidant effects", "TREATMENT", 810, 856], ["delirium", "OBSERVATION", 35, 43], ["long-term cognition", "OBSERVATION_MODIFIER", 293, 312], ["hyperactive", "OBSERVATION_MODIFIER", 502, 513], ["delirium", "OBSERVATION", 514, 522], ["delirium", "OBSERVATION", 697, 705]]], ["We have maximized melatonin in this patient.Medications and monitoring ::: Delirium Management ::: DiscussionSuvorexant regulates sleep-wake cycle and assists in treatment of delirium, especially in combination with melatonin or melatonin receptor agonist (24, 25).", [["melatonin", "CHEMICAL", 18, 27], ["Delirium", "DISEASE", 75, 83], ["delirium", "DISEASE", 175, 183], ["melatonin", "CHEMICAL", 216, 225], ["melatonin", "CHEMICAL", 229, 238], ["melatonin", "CHEMICAL", 18, 27], ["melatonin", "CHEMICAL", 216, 225], ["melatonin", "CHEMICAL", 229, 238], ["melatonin", "SIMPLE_CHEMICAL", 18, 27], ["patient", "ORGANISM", 36, 43], ["melatonin", "SIMPLE_CHEMICAL", 216, 225], ["melatonin", "SIMPLE_CHEMICAL", 229, 238], ["patient", "SPECIES", 36, 43], ["melatonin", "TREATMENT", 18, 27], ["Delirium", "PROBLEM", 75, 83], ["delirium", "PROBLEM", 175, 183], ["melatonin", "TREATMENT", 216, 225], ["melatonin receptor agonist", "TREATMENT", 229, 255], ["delirium", "OBSERVATION", 175, 183]]], ["Thus, it was added for management of sleep-wake cycle in this patient with hyperactive COVID-19 associated delirium.Medications and monitoring ::: Delirium Management ::: DiscussionAlpha-2 agonists decrease noradrenergic upregulation secondary to cytokine storm.", [["delirium", "DISEASE", 107, 115], ["Delirium", "DISEASE", 147, 155], ["patient", "ORGANISM", 62, 69], ["DiscussionAlpha-2", "GENE_OR_GENE_PRODUCT", 171, 188], ["noradrenergic", "SIMPLE_CHEMICAL", 207, 220], ["cytokine", "PROTEIN", 247, 255], ["patient", "SPECIES", 62, 69], ["management", "TREATMENT", 23, 33], ["sleep", "TEST", 37, 42], ["hyperactive COVID", "PROBLEM", 75, 92], ["delirium", "PROBLEM", 107, 115], ["Delirium", "PROBLEM", 147, 155], ["DiscussionAlpha-2 agonists", "TREATMENT", 171, 197], ["noradrenergic upregulation", "TREATMENT", 207, 233], ["cytokine storm", "PROBLEM", 247, 261], ["cytokine storm", "OBSERVATION", 247, 261]]], ["While dexmedetomidine can be used for acute agitation and cycling at night, guanfacine can help taper off dexmedetomidine and other sedatives.", [["dexmedetomidine", "CHEMICAL", 6, 21], ["agitation", "DISEASE", 44, 53], ["guanfacine", "CHEMICAL", 76, 86], ["dexmedetomidine", "CHEMICAL", 106, 121], ["dexmedetomidine", "CHEMICAL", 6, 21], ["guanfacine", "CHEMICAL", 76, 86], ["dexmedetomidine", "CHEMICAL", 106, 121], ["dexmedetomidine", "SIMPLE_CHEMICAL", 6, 21], ["guanfacine", "SIMPLE_CHEMICAL", 76, 86], ["dexmedetomidine", "SIMPLE_CHEMICAL", 106, 121], ["dexmedetomidine", "TREATMENT", 6, 21], ["acute agitation", "PROBLEM", 38, 53], ["guanfacine", "TREATMENT", 76, 86], ["dexmedetomidine", "TREATMENT", 106, 121], ["other sedatives", "TREATMENT", 126, 141]]], ["Our patient had already been managed with dexmedetomidine.", [["dexmedetomidine", "CHEMICAL", 42, 57], ["dexmedetomidine", "CHEMICAL", 42, 57], ["patient", "ORGANISM", 4, 11], ["dexmedetomidine", "SIMPLE_CHEMICAL", 42, 57], ["patient", "SPECIES", 4, 11], ["dexmedetomidine", "TREATMENT", 42, 57]]], ["Addition of guanfacine appears to have facilitated tapering off her other sedative drips, including dexmedetomidine.Medications and monitoring ::: Delirium Management ::: DiscussionAntipsychotics can assist in delirium symptom control, while patients must be monitored for QTc prolongation and neurologic and sedative side effects.", [["neurologic", "ANATOMY", 294, 304], ["guanfacine", "CHEMICAL", 12, 22], ["dexmedetomidine", "CHEMICAL", 100, 115], ["Delirium", "DISEASE", 147, 155], ["delirium", "DISEASE", 210, 218], ["QTc prolongation", "DISEASE", 273, 289], ["guanfacine", "CHEMICAL", 12, 22], ["dexmedetomidine", "CHEMICAL", 100, 115], ["guanfacine", "SIMPLE_CHEMICAL", 12, 22], ["dexmedetomidine", "SIMPLE_CHEMICAL", 100, 115], ["patients", "ORGANISM", 242, 250], ["patients", "SPECIES", 242, 250], ["guanfacine", "TREATMENT", 12, 22], ["her other sedative drips", "TREATMENT", 64, 88], ["dexmedetomidine", "TREATMENT", 100, 115], ["Delirium", "PROBLEM", 147, 155], ["delirium symptom control", "PROBLEM", 210, 234], ["QTc prolongation", "PROBLEM", 273, 289], ["neurologic and sedative side effects", "TREATMENT", 294, 330], ["guanfacine", "OBSERVATION", 12, 22], ["tapering", "OBSERVATION_MODIFIER", 51, 59]]], ["Specifically in this patient population, antipsychotic agents must be carefully monitored, given the potential use of COVID-19 specific medications that may prolong QTc (e.g., hydroxychloroquine, azithromycin), leading to a potentially increased risk of torsade\u2019s de pointes (26), as well as rare cardiac manifestations of COVID-19.", [["cardiac", "ANATOMY", 297, 304], ["hydroxychloroquine", "CHEMICAL", 176, 194], ["azithromycin", "CHEMICAL", 196, 208], ["torsade\u2019s de pointes", "DISEASE", 254, 274], ["hydroxychloroquine", "CHEMICAL", 176, 194], ["azithromycin", "CHEMICAL", 196, 208], ["COVID-19", "CHEMICAL", 323, 331], ["patient", "ORGANISM", 21, 28], ["QTc", "SIMPLE_CHEMICAL", 165, 168], ["hydroxychloroquine", "SIMPLE_CHEMICAL", 176, 194], ["azithromycin", "SIMPLE_CHEMICAL", 196, 208], ["cardiac", "ORGAN", 297, 304], ["patient", "SPECIES", 21, 28], ["antipsychotic agents", "TREATMENT", 41, 61], ["COVID-19 specific medications", "TREATMENT", 118, 147], ["QTc", "TEST", 165, 168], ["hydroxychloroquine", "TREATMENT", 176, 194], ["azithromycin", "TREATMENT", 196, 208], ["torsade\u2019s de pointes", "PROBLEM", 254, 274], ["rare cardiac manifestations", "PROBLEM", 292, 319], ["COVID", "TEST", 323, 328], ["torsade", "OBSERVATION", 254, 261], ["cardiac", "ANATOMY", 297, 304], ["manifestations", "OBSERVATION", 305, 319]]], ["QTc was monitored on daily basis and did not demonstrate prolongation in our patient.", [["patient", "ORGANISM", 77, 84], ["patient", "SPECIES", 77, 84], ["QTc", "TEST", 0, 3], ["prolongation", "OBSERVATION", 57, 69]]], ["While increasing doses of quetiapine did not seem helpful in our patient, switching to haloperidol in combination with other interventions, was correlated with improvement in patient\u2019s mental status.", [["quetiapine", "CHEMICAL", 26, 36], ["haloperidol", "CHEMICAL", 87, 98], ["quetiapine", "CHEMICAL", 26, 36], ["haloperidol", "CHEMICAL", 87, 98], ["quetiapine", "SIMPLE_CHEMICAL", 26, 36], ["patient", "ORGANISM", 65, 72], ["haloperidol", "SIMPLE_CHEMICAL", 87, 98], ["patient", "ORGANISM", 175, 182], ["patient", "SPECIES", 65, 72], ["patient", "SPECIES", 175, 182], ["quetiapine", "TREATMENT", 26, 36], ["haloperidol", "TREATMENT", 87, 98], ["other interventions", "TREATMENT", 119, 138]]], ["Haloperidol might have been more helpful due to its more potent dopamine blockade and minimal antihistaminic and anticholinergic activity as compared to quetiapine.", [["Haloperidol", "CHEMICAL", 0, 11], ["dopamine", "CHEMICAL", 64, 72], ["quetiapine", "CHEMICAL", 153, 163], ["Haloperidol", "CHEMICAL", 0, 11], ["dopamine", "CHEMICAL", 64, 72], ["quetiapine", "CHEMICAL", 153, 163], ["Haloperidol", "SIMPLE_CHEMICAL", 0, 11], ["dopamine", "SIMPLE_CHEMICAL", 64, 72], ["quetiapine", "SIMPLE_CHEMICAL", 153, 163], ["Haloperidol", "TREATMENT", 0, 11], ["potent dopamine blockade", "TREATMENT", 57, 81], ["minimal antihistaminic", "TREATMENT", 86, 108], ["anticholinergic activity", "TREATMENT", 113, 137], ["quetiapine", "TREATMENT", 153, 163]]], ["In addition, haloperidol has been found to be an effective antagonist of Sigma-1 receptors, which, in theory, might potently protect against oxidative stress-related cell death (27).", [["cell", "ANATOMY", 166, 170], ["haloperidol", "CHEMICAL", 13, 24], ["death", "DISEASE", 171, 176], ["haloperidol", "CHEMICAL", 13, 24], ["haloperidol", "SIMPLE_CHEMICAL", 13, 24], ["Sigma-1 receptors", "GENE_OR_GENE_PRODUCT", 73, 90], ["cell", "CELL", 166, 170], ["Sigma-1 receptors", "PROTEIN", 73, 90], ["haloperidol", "TREATMENT", 13, 24], ["oxidative stress-related cell death", "PROBLEM", 141, 176]]], ["Nursing staff was educated on assessing for extrapyramidal side effects associated with antipsychotics, integrating this into their regular patient assessment and care.Medications and monitoring ::: Delirium Management ::: DiscussionVPA is used for management of hyperactive and/or mixed (i.e., fluctuating between agitation and hypoactivity) delirium, has potential anti-inflammatory and anti-oxidant effects, and might decrease transcription of interleukin-6 (28).", [["Delirium", "DISEASE", 199, 207], ["hyperactive", "DISEASE", 263, 274], ["agitation", "DISEASE", 315, 324], ["delirium", "DISEASE", 343, 351], ["patient", "ORGANISM", 140, 147], ["interleukin-6 (28)", "GENE_OR_GENE_PRODUCT", 447, 465], ["interleukin-6", "PROTEIN", 447, 460], ["patient", "SPECIES", 140, 147], ["extrapyramidal side effects", "PROBLEM", 44, 71], ["antipsychotics", "TREATMENT", 88, 102], ["patient assessment", "TEST", 140, 158], ["Delirium Management", "TREATMENT", 199, 218], ["management", "TREATMENT", 249, 259], ["hyperactive and/or mixed (i.e., fluctuating between agitation and hypoactivity)", "PROBLEM", 263, 342], ["delirium", "PROBLEM", 343, 351], ["anti-inflammatory and anti-oxidant effects", "TREATMENT", 367, 409], ["interleukin", "TEST", 447, 458], ["hyperactive", "OBSERVATION", 263, 274], ["anti-inflammatory", "OBSERVATION_MODIFIER", 367, 384]]], ["Evidence also suggests potential neuroprotective effects of VPA (28).", [["VPA", "CHEMICAL", 60, 63], ["VPA", "CHEMICAL", 60, 63], ["VPA", "SIMPLE_CHEMICAL", 60, 63], ["VPA", "TREATMENT", 60, 63], ["suggests potential", "UNCERTAINTY", 14, 32], ["neuroprotective", "OBSERVATION_MODIFIER", 33, 48]]], ["VPA might assist to minimize or taper off sedative agents, however, liver function tests and platelets must be closely monitored.", [["liver", "ANATOMY", 68, 73], ["platelets", "ANATOMY", 93, 102], ["VPA", "CHEMICAL", 0, 3], ["VPA", "CHEMICAL", 0, 3], ["VPA", "SIMPLE_CHEMICAL", 0, 3], ["liver", "ORGAN", 68, 73], ["platelets", "CELL", 93, 102], ["platelets", "CELL_TYPE", 93, 102], ["VPA", "TREATMENT", 0, 3], ["sedative agents", "TREATMENT", 42, 57], ["liver function tests", "TEST", 68, 88], ["platelets", "TEST", 93, 102], ["liver", "ANATOMY", 68, 73]]], ["Addition of VPA seemed crucial in decreasing agitation of the patient and assisting in tapering off multiple sedating drips and as well as benzodiazepines and opiates.ConclusionsThis case report discusses the proposed pathophysiology of COVID-19 associated ICU delirium.", [["VPA", "CHEMICAL", 12, 15], ["agitation", "DISEASE", 45, 54], ["benzodiazepines", "CHEMICAL", 139, 154], ["COVID-19", "CHEMICAL", 237, 245], ["ICU delirium", "DISEASE", 257, 269], ["VPA", "CHEMICAL", 12, 15], ["benzodiazepines", "CHEMICAL", 139, 154], ["VPA", "SIMPLE_CHEMICAL", 12, 15], ["patient", "ORGANISM", 62, 69], ["benzodiazepines", "SIMPLE_CHEMICAL", 139, 154], ["opiates", "SIMPLE_CHEMICAL", 159, 166], ["patient", "SPECIES", 62, 69], ["VPA", "TREATMENT", 12, 15], ["decreasing agitation", "PROBLEM", 34, 54], ["multiple sedating drips", "TREATMENT", 100, 123], ["benzodiazepines", "TREATMENT", 139, 154], ["opiates", "TREATMENT", 159, 166], ["COVID", "TEST", 237, 242], ["ICU delirium", "PROBLEM", 257, 269], ["decreasing", "OBSERVATION_MODIFIER", 34, 44], ["agitation", "OBSERVATION", 45, 54]]], ["Derived from the clinical complexity of the patient described, we provide a framework to delirium evaluation and management in similar patients.", [["delirium", "DISEASE", 89, 97], ["patient", "ORGANISM", 44, 51], ["patients", "ORGANISM", 135, 143], ["patient", "SPECIES", 44, 51], ["patients", "SPECIES", 135, 143], ["delirium evaluation", "TEST", 89, 108], ["management", "TREATMENT", 113, 123]]], ["As the number of cases of COVID-19 continues to increase, so will the hospital length of stay and inevitable incidence of delirium and agitation in these patients.", [["delirium", "DISEASE", 122, 130], ["agitation", "DISEASE", 135, 144], ["COVID-19", "CHEMICAL", 26, 34], ["patients", "ORGANISM", 154, 162], ["patients", "SPECIES", 154, 162], ["COVID", "TEST", 26, 31], ["delirium", "PROBLEM", 122, 130], ["agitation", "PROBLEM", 135, 144], ["delirium", "OBSERVATION", 122, 130]]], ["Thus, a systematic approach to delirium prophylaxis, screening, diagnosis, and treatment are paramount to patients\u2019 management and improved outcomes.ConclusionsThis research did not receive any specific grant from funding agencies in the public, commercial, orConclusionsnot-for-profit sectors.", [["delirium", "DISEASE", 31, 39], ["patients", "ORGANISM", 106, 114], ["patients", "SPECIES", 106, 114], ["a systematic approach", "TREATMENT", 6, 27], ["delirium prophylaxis", "TREATMENT", 31, 51], ["screening", "TEST", 53, 62], ["treatment", "TREATMENT", 79, 88], ["patients\u2019 management", "TREATMENT", 106, 126]]]], "13d72f82a139dfbdf64553e31df087199ee35284": [["The Work Under Consideration for Publication Section 2.", [["Publication Section", "TREATMENT", 33, 52]]]], "efef7b27628b4eb962473f2211371353fe422139": [["A pandemic of unprecedented magnitude has rocked the mankind.", [["unprecedented", "OBSERVATION_MODIFIER", 14, 27], ["magnitude", "OBSERVATION_MODIFIER", 28, 37]]], ["As per the reports and research the sight of origin of the outbreak of this pneumonia-like disease has been identified as Wuhan, Hubei province of China (Wang et al. 2020) .", [["pneumonia", "DISEASE", 76, 85], ["this pneumonia", "PROBLEM", 71, 85], ["disease", "PROBLEM", 91, 98], ["pneumonia", "OBSERVATION", 76, 85]]], ["The respiratory illness was found to be associated with a novel coronavirus which was later specifically named as \"acute respiratory syndrome coronavirus 2\" (SARS-CoV-2) by World Health Organization (WHO) (Lu et al. 2020) .", [["respiratory", "ANATOMY", 4, 15], ["respiratory illness", "DISEASE", 4, 23], ["coronavirus", "DISEASE", 64, 75], ["acute respiratory syndrome coronavirus", "DISEASE", 115, 153], ["coronavirus", "ORGANISM", 64, 75], ["The respiratory illness", "PROBLEM", 0, 23], ["a novel coronavirus", "PROBLEM", 56, 75], ["acute respiratory syndrome coronavirus", "PROBLEM", 115, 153], ["respiratory illness", "OBSERVATION", 4, 23], ["coronavirus", "OBSERVATION", 64, 75], ["acute", "OBSERVATION_MODIFIER", 115, 120], ["respiratory syndrome", "OBSERVATION", 121, 141]]], ["Millions of people around the globe have been infected, and several thousands have already perished.", [["people", "ORGANISM", 12, 18], ["globe", "ORGAN", 30, 35], ["people", "SPECIES", 12, 18], ["infected", "PROBLEM", 46, 54], ["people", "OBSERVATION", 12, 18], ["globe", "ANATOMY", 30, 35], ["infected", "OBSERVATION", 46, 54]]], ["Apart from direct infections, almost every human on earth is going to be affected by this pandemic in one way or the other.", [["infections", "DISEASE", 18, 28], ["human", "ORGANISM", 43, 48], ["human", "SPECIES", 43, 48], ["human", "SPECIES", 43, 48], ["direct infections", "PROBLEM", 11, 28], ["infections", "OBSERVATION", 18, 28]]], ["The pandemic is going to inflict huge economic damages and the impact will be far-reaching, which is very difficult to assess as of now.", [["huge economic damages", "PROBLEM", 33, 54], ["economic", "OBSERVATION_MODIFIER", 38, 46], ["damages", "OBSERVATION", 47, 54]]], ["In fact, this pandemic is going to have the biggest effect on mankind after the second world war catastrophe.", [["catastrophe", "OBSERVATION", 97, 108]]], ["Almost every country on the globe, except for a few island nations, have already been battered by the pandemic.", [["globe", "ANATOMY", 28, 33]]], ["However, looking at the magnitude of the situation, so far, no concrete scientific opinion is available to explain the original route of the transfer of coronavirus to humans.", [["coronavirus", "DISEASE", 153, 164], ["coronavirus", "ORGANISM", 153, 164], ["humans", "ORGANISM", 168, 174], ["humans", "SPECIES", 168, 174], ["humans", "SPECIES", 168, 174], ["coronavirus", "PROBLEM", 153, 164]]], ["Although the transfer route of the virus is not certain, one thing is assured that reservoir of coronavirus are some wild animals such as civets, bats, pangolins, etc. and most probably these are the source of this deadly virus to humans.", [["coronavirus", "DISEASE", 96, 107], ["coronavirus", "ORGANISM", 96, 107], ["pangolins", "GENE_OR_GENE_PRODUCT", 152, 161], ["humans", "ORGANISM", 231, 237], ["humans", "SPECIES", 231, 237], ["humans", "SPECIES", 231, 237], ["the virus", "PROBLEM", 31, 40], ["coronavirus", "PROBLEM", 96, 107]]], ["As per World Livestock 2013 report of United Nation's Food and Agriculture Organization (FAO), 70% of the novel pathogens/diseases emerging in humans are zoonotic in nature.", [["humans", "ORGANISM", 143, 149], ["humans", "SPECIES", 143, 149], ["humans", "SPECIES", 143, 149], ["the novel pathogens", "PROBLEM", 102, 121], ["diseases", "PROBLEM", 122, 130], ["diseases", "OBSERVATION", 122, 130], ["zoonotic", "OBSERVATION_MODIFIER", 154, 162]]], ["According to the available data consumption of animal meat is increasing by the day, and some exotic wild animals have become part of the human platter; particularly in some parts of the world their demand is increasing as important portion of the diet.", [["meat", "ANATOMY", 54, 58], ["meat", "ORGANISM_SUBDIVISION", 54, 58], ["human", "ORGANISM", 138, 143], ["human", "SPECIES", 138, 143], ["human", "SPECIES", 138, 143], ["increasing", "OBSERVATION_MODIFIER", 62, 72]]], ["With most of the novel pathogens coming from animal sources this pandemic has raised several questions for mankind and its future.", [["the novel pathogens", "PROBLEM", 13, 32], ["pathogens", "OBSERVATION", 23, 32]]]], "7d57b976c313c5ddda78e1251bccff4778650724": [["Year-to-year differences in PM 2.5 and impacts on reference year selection\u2026\u2026\u2026..\u2026\u2026\u2026\u2026.\u2026.9 The 27 RAMP sites were broken down into 4 categories: High Traffic (n = 3), Urban 96 Residential (n = 11), Suburban Residential (n = 8), and Industrial (n = 4).", [["RAMP sites", "DNA", 95, 105], ["The 27 RAMP sites", "TREATMENT", 88, 105]]], ["This breakdown only 97 equals 26 sites, the 27 th site was not included in any site group because it did not properly fit into 98 any category as it was a much more background, rural location.", [["27 th site", "DNA", 44, 54], ["This breakdown", "PROBLEM", 0, 14]]], ["It was however used to aid in 99 background correction calculations, so we include this RAMP in our network count.", [["RAMP", "PROTEIN", 88, 92], ["this RAMP", "TEST", 83, 92]]], ["Briefly, the Urban Residential sites were located within the city limits and had moderate traffic 112 density (below the 60th percentile) along with low restaurant density (within the first quartile).113Suburban Residential sites were those sites that were located outside of the city limits and 114 experienced low vehicle and restaurant densities (within the first quartile).", [["moderate traffic 112 density", "PROBLEM", 81, 109], ["moderate", "OBSERVATION_MODIFIER", 81, 89], ["112 density", "OBSERVATION_MODIFIER", 98, 109], ["low restaurant", "OBSERVATION_MODIFIER", 149, 163], ["density", "OBSERVATION", 164, 171], ["densities", "OBSERVATION", 339, 348]]], ["Two of the sites were within 1500 meters 118 of a steel mill and the remaining two were within 1500 meters of a metallurgical coke plant.119These sites were east, and therefore generally downwind of, the respective point sources.", [["a steel mill", "TREATMENT", 48, 60], ["a metallurgical coke plant", "TREATMENT", 110, 136], ["sites", "OBSERVATION_MODIFIER", 11, 16], ["metallurgical", "OBSERVATION", 112, 125], ["coke plant", "OBSERVATION", 126, 136], ["east", "OBSERVATION_MODIFIER", 157, 161]]], ["120 Figure S1 .", [["S1", "ANATOMY", 11, 13]]], ["The map (generated using a Google API and MATLAB) shows the locations of air quality monitoring sites within the city of Pittsburgh and the surrounding areas where the air quality monitoring sites used in this study are located.", [["The map", "TEST", 0, 7], ["the air quality monitoring sites", "TEST", 164, 196], ["this study", "TEST", 205, 215], ["air quality", "OBSERVATION", 73, 84], ["surrounding", "OBSERVATION_MODIFIER", 140, 151], ["areas", "OBSERVATION_MODIFIER", 152, 157], ["air quality", "OBSERVATION", 168, 179]]], ["The circles and two diamonds indicate locations of CO and PM 2.5 monitoring by RAMP monitors.", [["CO", "CHEMICAL", 51, 53], ["CO", "SIMPLE_CHEMICAL", 51, 53], ["RAMP", "SIMPLE_CHEMICAL", 79, 83], ["CO", "TEST", 51, 53], ["RAMP monitors", "TEST", 79, 92], ["circles", "OBSERVATION_MODIFIER", 4, 11], ["two", "OBSERVATION_MODIFIER", 16, 19], ["diamonds", "OBSERVATION_MODIFIER", 20, 28]]], ["The blue dots are the locations of the High Traffic sites (n = 3), the red dots and red diamonds are the Urban Residential sites (n = 11), the green dots are the background and Suburban Residential sites (n = 9), and the black dots are the Industrial sites (n = 4).", [["blue dots", "SIMPLE_CHEMICAL", 4, 13], ["The blue dots", "TREATMENT", 0, 13], ["the red dots and red diamonds", "PROBLEM", 67, 96], ["the green dots", "PROBLEM", 139, 153], ["the black dots", "TREATMENT", 217, 231], ["blue dots", "OBSERVATION", 4, 13], ["High", "OBSERVATION_MODIFIER", 39, 43], ["Traffic sites", "OBSERVATION", 44, 57], ["red diamonds", "OBSERVATION", 84, 96], ["green dots", "OBSERVATION", 143, 153]]], ["The five Suburban Residential sites with the lowest PM 2.5 concentrations were used to calculate background concentrations at the Industrial sites.", [["the lowest PM 2.5 concentrations", "TREATMENT", 41, 73], ["Industrial sites", "OBSERVATION", 130, 146]]], ["For the Urban Residential sites two locations are indicated by diamonds instead of circles because those two sites were operational throughout March 2020, but they were not running in March 2019.", [["diamonds", "OBSERVATION", 63, 71]]], ["Therefore, no data was available for those locations to determine changes in concentration for site specific calculations.", [["site specific calculations", "TEST", 95, 121]]], ["The two maroon stars indicate the two Allegheny County Health Department (ACHD) sites where NO 2 data was collected.", [["NO", "CHEMICAL", 92, 94], ["NO 2", "CHEMICAL", 92, 96], ["maroon stars", "OBSERVATION", 8, 20]]], ["CO and PM 2.5 measurements are different beyond the uncertainty of the measurements between the \"business as usual\" data to the post-closure data aside from the 25 th percentile of the CO data.", [["CO", "CHEMICAL", 0, 2], ["CO", "CHEMICAL", 185, 187], ["CO", "SIMPLE_CHEMICAL", 0, 2], ["CO and PM 2.5 measurements", "TEST", 0, 26], ["the post-closure data", "TEST", 124, 145], ["the CO data", "TEST", 181, 192]]], ["The diurnal patterns for the NO 2 measurements from the Allegheny County Health Department's two monitoring sites are shown.", [["NO", "CHEMICAL", 29, 31], ["NO 2", "CHEMICAL", 29, 33]]], ["The variation before the closures at the High Traffic site mirrors that of the CO concentrations at the RAMP High Traffic sites and there is a clear reduction in NO 2 concentrations post-closures similar to the CO concentrations.", [["NO", "CHEMICAL", 162, 164], ["CO", "CHEMICAL", 79, 81], ["NO 2", "CHEMICAL", 162, 166], ["CO", "CHEMICAL", 211, 213], ["CO", "SIMPLE_CHEMICAL", 79, 81], ["NO 2", "SIMPLE_CHEMICAL", 162, 166], ["CO", "SIMPLE_CHEMICAL", 211, 213], ["the closures", "TREATMENT", 21, 33], ["the CO concentrations", "PROBLEM", 75, 96], ["the CO concentrations", "PROBLEM", 207, 228], ["variation", "OBSERVATION_MODIFIER", 4, 13], ["High", "OBSERVATION_MODIFIER", 109, 113], ["Traffic sites", "OBSERVATION", 114, 127], ["clear", "OBSERVATION_MODIFIER", 143, 148], ["reduction", "OBSERVATION_MODIFIER", 149, 158]]], ["The Suburban site's NO 2 measurements similarly mimic the CO diurnal patterns observed at the RAMP Suburban Residential sites.", [["NO", "CHEMICAL", 20, 22], ["NO 2", "CHEMICAL", 20, 24], ["CO", "CHEMICAL", 58, 60], ["NO 2", "GENE_OR_GENE_PRODUCT", 20, 24], ["Suburban site", "DNA", 4, 17], ["the CO diurnal patterns", "PROBLEM", 54, 77]]], ["Although the NO 2 concentrations at the Suburban site start out lower than the measurements at the High Traffic site, they still experience a significant reduction in their absolute values and daily variation following the COVID-related closures.", [["NO", "CHEMICAL", 13, 15], ["NO 2", "CHEMICAL", 13, 17], ["NO 2", "GENE_OR_GENE_PRODUCT", 13, 17], ["Suburban site", "DNA", 40, 53], ["a significant reduction", "PROBLEM", 140, 163], ["the COVID-related closures", "TREATMENT", 219, 245], ["significant", "OBSERVATION_MODIFIER", 142, 153], ["reduction", "OBSERVATION_MODIFIER", 154, 163], ["absolute values", "OBSERVATION", 173, 188], ["closures", "OBSERVATION", 237, 245]]], ["The thirty-year average high and low temperatures as well as rainfall for March and April (1981-2020) are shown in the table alongside the rainfall and temperature bounds in March and April after the COVID-related closures (March 14 th , 2020 through April 30 th , 2020).", [["low temperatures", "PROBLEM", 33, 49], ["the COVID-related closures", "TREATMENT", 196, 222], ["low temperatures", "OBSERVATION_MODIFIER", 33, 49]]], ["The temperature bounds for our study period are not significantly different from the thirty-year temperature bounds, so we do not expect the temperature to affect the concentrations of pollutants post-COVID closures.", [["our study", "TEST", 27, 36], ["the temperature", "PROBLEM", 137, 152], ["pollutants post-COVID closures", "TREATMENT", 185, 215], ["significantly different", "OBSERVATION_MODIFIER", 52, 75]]], ["There was however more rainfall in the post-COVID closure period than the average expected rainfall for March-April.", [["more", "OBSERVATION_MODIFIER", 18, 22], ["rainfall", "OBSERVATION_MODIFIER", 23, 31], ["closure", "OBSERVATION", 50, 57]]], ["The rainfall received in March 2020 (0.18 inches/day) most closely matches the rainfall from March 2017 (0.16 inches/day) in recent years.", [["rainfall", "OBSERVATION_MODIFIER", 4, 12]]], ["Based on this comparison we found there was still a significant decrease in PM 2.5 concentration after the closures when compared to March 2017 (0.80\u00b5g/m 3 reduction across all sites and a reduction of 2.48\u03bcg/m 3 at the High Traffic, Parkway East site).", [["a reduction", "TREATMENT", 187, 198], ["significant", "OBSERVATION_MODIFIER", 52, 63], ["decrease", "OBSERVATION_MODIFIER", 64, 72]]], ["A sensitivity analysis was performed by selecting varying times as the background pre-morning rush-hour concentration.", [["A sensitivity analysis", "TEST", 0, 22]]], ["We show that although the determination of the morning rush-hour enhancement is dependent on the hour of the night used as the background the pattern of enhancement by site group remains the same.", [["enhancement", "OBSERVATION", 153, 164]]], ["The estimate of 141 restaurant activity reduction was approximately 60%.143For electricity we calculated the decrease in the metered hourly electricity load supplied by152The impacts of COVID-19 related shutdowns identified in this analysis could be influenced by 153 the selection of 2019 as the base case.", [["COVID", "PROTEIN", 186, 191], ["the metered hourly electricity load", "TREATMENT", 121, 156], ["COVID", "TEST", 186, 191], ["this analysis", "TEST", 227, 240], ["decrease", "OBSERVATION_MODIFIER", 109, 117]]], ["We believe that this is a minor source of uncertainty.155Long-term average pollutant concentrations have been relatively stable in Pittsburgh since 156~2012.", [["relatively", "OBSERVATION_MODIFIER", 110, 120], ["stable", "OBSERVATION_MODIFIER", 121, 127]]], ["Figure S6 shows the annual average PM 2.5 at all of the EPA AQS monitoring sites in Figure S7 .", [["EPA", "CHEMICAL", 56, 59], ["S6", "PROTEIN", 7, 9], ["Figure S7", "OBSERVATION", 84, 93]]], ["Empirical CDFs (ECDF) of hourly PM 2.5 measured at two RAMP locations.", [["Empirical CDFs (ECDF", "TREATMENT", 0, 20]]], ["The left panel shows an Urban Residential location, and the right panel shows an Industrial location.", [["The left panel", "TEST", 0, 14], ["the right panel", "TEST", 56, 71], ["left", "ANATOMY_MODIFIER", 4, 8], ["Urban", "OBSERVATION_MODIFIER", 24, 29], ["Residential location", "OBSERVATION", 30, 50], ["right", "ANATOMY_MODIFIER", 60, 65], ["Industrial location", "OBSERVATION", 81, 100]]], ["2020 data (green) have a different CDF in part because the dataset only covers January and February, whereas 2018 and 2019 data cover the entire year.", [["a different CDF", "PROBLEM", 23, 38]]], ["Figures S6 and S7 suggest that the overall conclusions of our analysis would be the same whether we used 2018, 2019, or an average of the two as the base case.", [["S6", "PROTEIN", 8, 10], ["S7", "PROTEIN", 15, 17], ["our analysis", "TEST", 58, 70]]], ["Short-term average pollutant concentrations (e.g., a one-or two-week average) can be impacted by meteorological factors such as boundary layer height or precipitation frequency.", [["Short-term average pollutant concentrations", "PROBLEM", 0, 43], ["precipitation frequency", "PROBLEM", 153, 176], ["pollutant", "OBSERVATION_MODIFIER", 19, 28], ["concentrations", "OBSERVATION_MODIFIER", 29, 43]]], ["For example, a simple comparison of the mean PM 2.5 concentration during the morning rush hour before and after the closures may be influenced by more frequent inversions or rain.", [["the closures", "TREATMENT", 112, 124]]], ["The morning rush hour peak in CO, NO 2 , and PM 2.5 is driven largely by fresh emissions; thus, the difference between the morning peak and overnight trough is an approximate indicator of total emissions in the airshed.", [["NO", "CHEMICAL", 34, 36], ["CO", "CHEMICAL", 30, 32], ["NO 2", "CHEMICAL", 34, 38], ["CO", "SIMPLE_CHEMICAL", 30, 32], ["NO", "SIMPLE_CHEMICAL", 34, 36], ["CO", "TEST", 30, 32], ["overnight trough", "TEST", 140, 156], ["fresh emissions", "OBSERVATION", 73, 88]]], ["Thus, the intra-day differences should be less impacted by meteorology than the average concentrations.ACHD SitesMarch/April 2019 March 2020 preclosuresACHD SitesMarch/April 2020 post-closures PM 2.5 12.2 11.9 8.0 CO 302 321 249 Table S4 .", [["CO", "TEST", 214, 216]]], ["Shown are the mean PM 2.5 and CO measurements over the March/April 2019, March 2020 pre-COVID related closure period, and the March/April COVID-related closure period from Allegheny County Health Department regulatory monitoring sites.", [["CO", "CHEMICAL", 30, 32], ["CO measurements", "TEST", 30, 45], ["the March/April COVID", "TREATMENT", 122, 143], ["closure period", "OBSERVATION", 102, 116], ["closure", "OBSERVATION", 152, 159]]], ["For CO there were only three measurement sites with data in our time range.", [["CO", "CHEMICAL", 4, 6], ["CO", "SIMPLE_CHEMICAL", 4, 6]]], ["These three CO sites are classified as follows: 1 Urban Residential and 2 High Traffic.", [["CO", "CHEMICAL", 12, 14], ["CO sites", "DNA", 12, 20]]], ["The reductions in PM 2.5 post closures are 32% and 39% from March 2020 pre-closures and March/April 2019, respectively.", [["closures", "TEST", 30, 38], ["reductions", "OBSERVATION_MODIFIER", 4, 14]]], ["The reductions in CO post closures are 22% and 23% from March 2020 pre-closures and", [["CO", "CHEMICAL", 18, 20], ["The reductions in CO post closures", "TREATMENT", 0, 34], ["pre-closures", "TEST", 67, 79], ["reductions", "OBSERVATION_MODIFIER", 4, 14]]]], "0133fb8ec3f2139835f7f8a58559290ab9018791": [["INTRODUCTIONThe new severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is spreading daily throughout the world, reaching more than 5 million patients in May 2020 with more than 2 million recovered patients.", [["acute respiratory syndrome coronavirus", "DISEASE", 27, 65], ["SARS-CoV-2", "ORGANISM", 69, 79], ["patients", "ORGANISM", 151, 159], ["patients", "ORGANISM", 207, 215], ["patients", "SPECIES", 151, 159], ["patients", "SPECIES", 207, 215], ["severe acute respiratory syndrome coronavirus", "SPECIES", 20, 65], ["SARS-CoV-2", "SPECIES", 69, 79], ["new severe acute respiratory syndrome coronavirus", "PROBLEM", 16, 65], ["severe", "OBSERVATION_MODIFIER", 20, 26], ["acute", "OBSERVATION_MODIFIER", 27, 32], ["respiratory syndrome coronavirus", "OBSERVATION", 33, 65]]], ["Almost all studies are primarily focused on description of the epidemiological, clinical, biological, and radiological characteristics of patients with confirmed coronavirus disease 2019 (COVID-19).", [["coronavirus disease", "DISEASE", 162, 181], ["patients", "ORGANISM", 138, 146], ["patients", "SPECIES", 138, 146], ["all studies", "TEST", 7, 18], ["coronavirus disease", "PROBLEM", 162, 181], ["COVID", "TEST", 188, 193], ["coronavirus", "OBSERVATION", 162, 173]]], ["1,2 However, only a few studies, mainly case reports, have addressed the importance of the follow-up of recovered patients.", [["patients", "ORGANISM", 114, 122], ["patients", "SPECIES", 114, 122]]], ["3, 4 To date, the clinical and virologic course of SARS-CoV-2 infection remain to be investigated.", [["SARS", "DISEASE", 51, 55], ["infection", "DISEASE", 62, 71], ["SARS-CoV-2", "ORGANISM", 51, 61], ["SARS-CoV-2", "SPECIES", 51, 61], ["SARS", "PROBLEM", 51, 55], ["CoV", "PROBLEM", 56, 59], ["2 infection", "PROBLEM", 60, 71], ["infection", "OBSERVATION", 62, 71]]], ["In particular, there are no conclusive data showing how long patients with COVID-19 continue to have symptoms and test positive for the SARS-CoV-2 virus, even after 2 consecutive negative real-time reverse transcription polymerase chain reaction (RT-PCR) tests.", [["SARS", "DISEASE", 136, 140], ["patients", "ORGANISM", 61, 69], ["SARS-CoV-2 virus", "ORGANISM", 136, 152], ["patients", "SPECIES", 61, 69], ["SARS-CoV-2 virus", "SPECIES", 136, 152], ["COVID", "TEST", 75, 80], ["symptoms", "PROBLEM", 101, 109], ["test", "TEST", 114, 118], ["the SARS", "PROBLEM", 132, 140], ["CoV", "TEST", 141, 144], ["chain reaction", "TEST", 231, 245], ["RT-PCR) tests", "TEST", 247, 260], ["no", "UNCERTAINTY", 25, 27]]], ["5, 6 The WHO criteria for hospital discharge or discontinuation of COVID-19 quarantine have been described.", [["COVID-19 quarantine", "CHEMICAL", 67, 86], ["discontinuation of COVID", "TREATMENT", 48, 72]]], ["7 Nevertheless, data show that some patients are positive on nasopharyngeal swab after being declared recovered, and thus the appropriate timing of ending COVID-19 quarantine remains undetermined.", [["nasopharyngeal swab", "ANATOMY", 61, 80], ["patients", "ORGANISM", 36, 44], ["nasopharyngeal swab", "ORGANISM_SUBSTANCE", 61, 80], ["patients", "SPECIES", 36, 44], ["nasopharyngeal swab", "TREATMENT", 61, 80], ["COVID", "TEST", 155, 160], ["positive", "OBSERVATION", 49, 57], ["nasopharyngeal", "ANATOMY", 61, 75]]], ["8, 9 Overall, there is no information about signs and symptoms that can predict a new positive test in patients declared recovered from COVID-19.INTRODUCTIONThe fact that some patients could develop a potentially long-lasting viral presence highlights an important point of vigilance for controlling the pandemic both at the individual and collective level.", [["COVID-19.", "CHEMICAL", 136, 145], ["patients", "ORGANISM", 103, 111], ["patients", "ORGANISM", 176, 184], ["patients", "SPECIES", 103, 111], ["patients", "SPECIES", 176, 184], ["signs and symptoms", "PROBLEM", 44, 62], ["a new positive test", "PROBLEM", 80, 99], ["COVID", "TEST", 136, 141], ["a potentially long-lasting viral presence", "PROBLEM", 199, 240], ["the pandemic", "PROBLEM", 300, 312], ["no", "UNCERTAINTY", 23, 25]]], ["10 The aim of the present study is to identify potential risk factors associated with a new positive nasopharyngeal swab RT-PCR test (after 2 negative tests) in a large sample of patients who recovered from COVID-19.METHODSThe Gemelli Against COVID-19 Post-Acute Care (GAC19-PAC) project was an initiative developed by the Department of Geriatrics, Neuroscience and Orthopedics of the Catholic University of the Sacred Heart (Rome, Italy) to answer an important open question: Once recovered from COVID-19, what happens to patients, and how has the virus impacted their body?", [["nasopharyngeal swab", "ANATOMY", 101, 120], ["body", "ANATOMY", 570, 574], ["patients", "ORGANISM", 179, 187], ["patients", "ORGANISM", 523, 531], ["body", "ORGANISM_SUBDIVISION", 570, 574], ["patients", "SPECIES", 179, 187], ["patients", "SPECIES", 523, 531], ["the present study", "TEST", 14, 31], ["potential risk factors", "PROBLEM", 47, 69], ["a new positive nasopharyngeal swab RT", "PROBLEM", 86, 123], ["PCR test", "TEST", 124, 132], ["COVID", "TEST", 207, 212], ["COVID", "TEST", 243, 248], ["Acute Care (GAC19-PAC", "TREATMENT", 257, 278], ["nasopharyngeal", "ANATOMY", 101, 115], ["Sacred Heart", "ANATOMY", 412, 424]]], ["In this respect, the Fondazione Policlinico Universitario A. Gemelli IRCSS has set up a multidisciplinary healthcare service called \"Day Hospital Post-COVID-19\" for all patients recovered from SARS-CoV-2 infection.", [["SARS-CoV-2 infection", "DISEASE", 193, 213], ["patients", "ORGANISM", 169, 177], ["SARS-CoV-2", "ORGANISM", 193, 203], ["patients", "SPECIES", 169, 177], ["SARS-CoV-2", "SPECIES", 193, 203], ["SARS", "PROBLEM", 193, 197], ["CoV", "PROBLEM", 198, 201], ["2 infection", "PROBLEM", 202, 213], ["infection", "OBSERVATION", 204, 213]]], ["The complete GAC19-PAC study protocol has been described in detail elsewhere.", [["GAC19", "GENE_OR_GENE_PRODUCT", 13, 18], ["GAC19", "DNA", 13, 18], ["The complete GAC19-PAC study protocol", "TEST", 0, 37]]], ["11, 12 This study was approved by the Catholic University/Fondazione Policlinico Gemelli IRCCS Institutional Ethics Committee (protocol ID number: 0013008/20).", [["This study", "TEST", 7, 17]]], ["Written informed consent was obtained from the participants.", [["participants", "SPECIES", 47, 59]]], ["The manuscript was prepared in compliance with the STROBE reporting guidelines for observational studies.Study SampleOnly the COVID-19 patients who met the following WHO criteria for discontinuation of quarantine were admitted to the follow-up study project: (1) being fever free without feverreducing medications for 3 consecutive days; (2) improvement in any symptoms related to COVID-19, including reduced coughing and shortness of breath; (3) \u22657 days since the onset of the first symptom related to COVID-19; and (4) testing negative for the SARS-CoV-2 virus twice (at least 24 hours apart), with nucleic acid RT-PCR.", [["fever", "DISEASE", 269, 274], ["COVID-19", "CHEMICAL", 381, 389], ["coughing", "DISEASE", 409, 417], ["shortness of breath", "DISEASE", 422, 441], ["SARS", "DISEASE", 546, 550], ["nucleic acid", "CHEMICAL", 601, 613], ["COVID-19", "CHEMICAL", 503, 511], ["patients", "ORGANISM", 135, 143], ["SARS-CoV-2 virus", "ORGANISM", 546, 562], ["patients", "SPECIES", 135, 143], ["CoV-2 virus", "SPECIES", 551, 562], ["SARS-CoV-2 virus", "SPECIES", 546, 562], ["observational studies", "TEST", 83, 104], ["discontinuation of quarantine", "TREATMENT", 183, 212], ["fever", "PROBLEM", 269, 274], ["feverreducing medications", "TREATMENT", 288, 313], ["any symptoms", "PROBLEM", 357, 369], ["COVID", "TEST", 381, 386], ["reduced coughing", "PROBLEM", 401, 417], ["shortness of breath", "PROBLEM", 422, 441], ["the first symptom", "PROBLEM", 474, 491], ["COVID", "TEST", 503, 508], ["testing", "TEST", 521, 528], ["the SARS", "PROBLEM", 542, 550], ["CoV", "TEST", 551, 554], ["nucleic acid RT", "TEST", 601, 616], ["reduced", "OBSERVATION_MODIFIER", 401, 408], ["coughing", "OBSERVATION", 409, 417]]], ["If the clinical characteristics and testing conditions are met, both the WHO and U.S. Centers for Disease Control and Prevention consider the patient officially recovered from COVID- 19.", [["COVID- 19", "CHEMICAL", 176, 185], ["patient", "ORGANISM", 142, 149], ["patient", "SPECIES", 142, 149], ["Disease Control", "TREATMENT", 98, 113], ["COVID", "TEST", 176, 181]]], ["3 Between April 21 and May 21, 2020, a total of 137 individuals who officially recovered from COVID-19 were enrolled in the present study.", [["individuals", "ORGANISM", 52, 63], ["COVID", "TEST", 94, 99], ["the present study", "TEST", 120, 137]]], ["Six patients (4 men and 2 women) refused to participate for personal reasons; as a consequence, a sample of 131 patients was considered.Study SampleThis outpatient service is currently ongoing and further details about the post-acute outpatient service and evaluation of the patients have been described elsewhere.", [["patients", "ORGANISM", 4, 12], ["men", "ORGANISM", 16, 19], ["women", "ORGANISM", 26, 31], ["patients", "ORGANISM", 112, 120], ["patients", "ORGANISM", 275, 283], ["patients", "SPECIES", 4, 12], ["men", "SPECIES", 16, 19], ["women", "SPECIES", 26, 31], ["patients", "SPECIES", 112, 120], ["patients", "SPECIES", 275, 283], ["evaluation", "TEST", 257, 267]]], ["12MeasuresAll patients who agreed to be screened underwent individual assessment.", [["patients", "ORGANISM", 14, 22], ["patients", "SPECIES", 14, 22], ["individual assessment", "TEST", 59, 80]]], ["Even though the patients were formally considered recovered from COVID-19, a new RT-PCR test was repeated at the time of post-acute care admission.", [["patients", "ORGANISM", 16, 24], ["COVID-19", "DNA", 65, 73], ["patients", "SPECIES", 16, 24], ["COVID", "TEST", 65, 70], ["a new RT-PCR test", "TEST", 75, 92]]], ["Demographic information, medical and medication history, laboratory findings, and radiological features were collected.", [["laboratory findings", "TEST", 57, 76]]], ["A multidisciplinary approach, including internal medicine, geriatric, ophthalmologic, otolaryngologic, pneumologic, cardiologic, neurological, immunologic, and rheumatologic evaluations, has been put in place for a comprehensive assessment of all the possible damage caused by the SARS-CoV-2 virus.", [["SARS", "DISEASE", 281, 285], ["SARS-CoV-2 virus", "ORGANISM", 281, 297], ["CoV-2 virus", "SPECIES", 286, 297], ["SARS-CoV-2 virus", "SPECIES", 281, 297], ["internal medicine", "TREATMENT", 40, 57], ["rheumatologic evaluations", "TEST", 160, 185], ["a comprehensive assessment", "TEST", 213, 239], ["damage", "PROBLEM", 260, 266], ["the SARS-CoV-2 virus", "PROBLEM", 277, 297]]], ["11, 12 In particular, during the first visit, a specific focus is paid to collecting information and data about the persistence of signs and symptoms related to COVID-19: cough, fatigue, diarrhea, headache, smell disorders, dysgeusia, red eyes, joint pain, shortness of breath, loss of appetite, sore throat, and rhinitis.", [["red eyes", "ANATOMY", 235, 243], ["joint", "ANATOMY", 245, 250], ["cough", "DISEASE", 171, 176], ["fatigue", "DISEASE", 178, 185], ["diarrhea", "DISEASE", 187, 195], ["headache", "DISEASE", 197, 205], ["smell disorders", "DISEASE", 207, 222], ["dysgeusia", "DISEASE", 224, 233], ["joint pain", "DISEASE", 245, 255], ["shortness of breath", "DISEASE", 257, 276], ["loss of appetite", "DISEASE", 278, 294], ["sore throat", "DISEASE", 296, 307], ["rhinitis", "DISEASE", 313, 321], ["eyes", "ORGAN", 239, 243], ["joint", "ORGANISM_SUBDIVISION", 245, 250], ["signs and symptoms", "PROBLEM", 131, 149], ["COVID", "TEST", 161, 166], ["cough", "PROBLEM", 171, 176], ["fatigue", "PROBLEM", 178, 185], ["diarrhea", "PROBLEM", 187, 195], ["headache", "PROBLEM", 197, 205], ["smell disorders", "PROBLEM", 207, 222], ["dysgeusia", "PROBLEM", 224, 233], ["red eyes", "PROBLEM", 235, 243], ["joint pain", "PROBLEM", 245, 255], ["shortness of breath", "PROBLEM", 257, 276], ["loss of appetite", "PROBLEM", 278, 294], ["sore throat", "PROBLEM", 296, 307], ["rhinitis", "PROBLEM", 313, 321], ["eyes", "ANATOMY", 239, 243], ["joint", "ANATOMY", 245, 250], ["sore throat", "ANATOMY", 296, 307], ["rhinitis", "OBSERVATION", 313, 321]]], ["Body weight was measured through an analogue medical scale.", [["Body", "ANATOMY", 0, 4], ["Body", "ORGANISM_SUBDIVISION", 0, 4], ["Body weight", "TEST", 0, 11], ["an analogue medical scale", "TREATMENT", 33, 58]]], ["Body height was measured using a standard stadiometer.", [["Body", "ANATOMY", 0, 4], ["Body", "ORGANISM_SUBDIVISION", 0, 4], ["Body height", "TEST", 0, 11], ["a standard stadiometer", "TREATMENT", 31, 53]]], ["BMI was defined as weight (kilograms) divided by the square of height (meters).Statistical AnalysisContinuous variables were expressed as mean (SD), and categorical variables as frequencies by absolute value and percentage of the total.", [["BMI", "TEST", 0, 3], ["Statistical AnalysisContinuous variables", "TEST", 79, 119], ["mean (SD), and categorical variables", "PROBLEM", 138, 174], ["absolute value", "TEST", 193, 207]]], ["Descriptive statistics were used to describe demographic and key clinical characteristics of the study population according to COVID-19 nucleic acid RT-PCR test results.", [["COVID-19 nucleic acid", "CHEMICAL", 127, 148], ["the study population", "TEST", 93, 113], ["COVID", "TEST", 127, 132], ["nucleic acid RT", "TEST", 136, 151], ["PCR test", "TEST", 152, 160]]], ["The differences in proportions and means of covariates between patients who tested positive and negative for the nasopharyngeal swab were assessed using Fisher's exact test and t-test statistics, respectively.", [["nasopharyngeal swab", "ANATOMY", 113, 132], ["patients", "ORGANISM", 63, 71], ["nasopharyngeal swab", "MULTI-TISSUE_STRUCTURE", 113, 132], ["patients", "SPECIES", 63, 71], ["the nasopharyngeal swab", "TEST", 109, 132], ["Fisher's exact test", "TEST", 153, 172], ["t-test statistics", "TEST", 177, 194], ["nasopharyngeal", "ANATOMY", 113, 127]]], ["Cox proportional hazard models with robust variance estimates assessed the association between clinical characteristics and persistent positive RT-PCR tests.", [["Cox proportional hazard models", "PROBLEM", 0, 30], ["robust variance estimates", "PROBLEM", 36, 61], ["persistent positive RT-PCR tests", "PROBLEM", 124, 156], ["robust variance", "OBSERVATION", 36, 51], ["persistent", "OBSERVATION_MODIFIER", 124, 134], ["positive", "OBSERVATION_MODIFIER", 135, 143]]], ["Candidate variables to be included in the Cox model were selected on the basis of biological and clinical plausibility as a potential risk factor for persistent positive RT-PCR tests.", [["persistent positive RT-PCR tests", "PROBLEM", 150, 182]]], ["To identify factors independently associated with positive nasopharyngeal swab tests, crude prevalence rate ratios and 95% CIs-controlling for age and sex-were first estimated.", [["nasopharyngeal swab", "ANATOMY", 59, 78], ["nasopharyngeal swab", "MULTI-TISSUE_STRUCTURE", 59, 78], ["positive nasopharyngeal swab tests", "PROBLEM", 50, 84], ["crude prevalence rate ratios", "TEST", 86, 114], ["CIs", "TEST", 123, 126], ["nasopharyngeal", "ANATOMY", 59, 73]]], ["A multivariable Cox model was computed including all the variables that were associated with the outcome at \u03b1 level of 0.1, after adjustment for age and sex.", [["A multivariable Cox model", "TEST", 0, 25]]], ["All analyses were performed in June 2020 using SPSS, version 11.0.RESULTSOf the 131 patients admitted to the follow-up protocol who repeated a nasopharyngeal swab, During the first follow-up visit, the persistence of the symptoms most frequently associated with COVID-19 was assessed ( Table 1) .", [["nasopharyngeal swab", "ANATOMY", 143, 162], ["COVID-19", "CHEMICAL", 262, 270], ["patients", "ORGANISM", 84, 92], ["patients", "SPECIES", 84, 92], ["All analyses", "TEST", 0, 12], ["a nasopharyngeal swab", "TEST", 141, 162], ["the symptoms", "PROBLEM", 217, 229], ["COVID", "TEST", 262, 267], ["nasopharyngeal", "ANATOMY", 143, 157]]], ["None of the patients had fever and all reported global improvement in their overall clinical condition.", [["fever", "DISEASE", 25, 30], ["patients", "ORGANISM", 12, 20], ["patients", "SPECIES", 12, 20], ["fever", "PROBLEM", 25, 30], ["global", "OBSERVATION_MODIFIER", 48, 54], ["improvement", "OBSERVATION_MODIFIER", 55, 66]]], ["However, some symptoms such as fatigue (51%), dyspnea (44%), and coughing (17%) were still present in a significant percentage of patients.", [["fatigue", "DISEASE", 31, 38], ["dyspnea", "DISEASE", 46, 53], ["coughing", "DISEASE", 65, 73], ["patients", "ORGANISM", 130, 138], ["patients", "SPECIES", 130, 138], ["some symptoms", "PROBLEM", 9, 22], ["fatigue", "PROBLEM", 31, 38], ["dyspnea", "PROBLEM", 46, 53], ["coughing", "PROBLEM", 65, 73]]], ["However, for most of these symptoms, no difference was observed between patients with a negative test compared to those with a positive test.", [["patients", "ORGANISM", 72, 80], ["patients", "SPECIES", 72, 80], ["these symptoms", "PROBLEM", 21, 35], ["a positive test", "TEST", 125, 140]]], ["The only 2 symptoms that showed a higher and significant prevalence in patients with a positive test were sore throat (18% vs 4%, p=0.04) and signs of rhinitis (27% vs 12%, p=0.05).", [["sore throat", "DISEASE", 106, 117], ["rhinitis", "DISEASE", 151, 159], ["patients", "ORGANISM", 71, 79], ["patients", "SPECIES", 71, 79], ["2 symptoms", "PROBLEM", 9, 19], ["a positive test", "PROBLEM", 85, 100], ["sore throat", "PROBLEM", 106, 117], ["p", "TEST", 130, 131], ["rhinitis", "PROBLEM", 151, 159], ["p", "TEST", 173, 174], ["significant", "OBSERVATION_MODIFIER", 45, 56], ["rhinitis", "OBSERVATION", 151, 159]]], ["Table 2 shows the treatments received during the acute phase of COVID-19.", [["COVID-19", "CHEMICAL", 64, 72], ["the treatments", "TREATMENT", 14, 28], ["COVID", "TEST", 64, 69]]], ["Regarding the prevalence of pharmacological treatments (antiviral drugs, hydroxychloroquine, antiinterleukin-6 receptor drugs, antibiotics, enoxaparin, corticosteroids) and oxygen therapy, no significant differences were observed between patients with positive and negative RT-PCR tests.RESULTSFinally, in the unadjusted model, there was a direct association between sore throat and a positive RT-PCR test (prevalence ratio=5.43, 95% CI=1.23, 24.0) ( Table 3 ).", [["hydroxychloroquine", "CHEMICAL", 73, 91], ["antiinterleukin-6", "CHEMICAL", 93, 110], ["enoxaparin", "CHEMICAL", 140, 150], ["corticosteroids", "CHEMICAL", 152, 167], ["oxygen", "CHEMICAL", 173, 179], ["sore throat", "DISEASE", 367, 378], ["hydroxychloroquine", "CHEMICAL", 73, 91], ["enoxaparin", "CHEMICAL", 140, 150], ["corticosteroids", "CHEMICAL", 152, 167], ["oxygen", "CHEMICAL", 173, 179], ["hydroxychloroquine", "SIMPLE_CHEMICAL", 73, 91], ["antiinterleukin-6 receptor drugs", "SIMPLE_CHEMICAL", 93, 125], ["antibiotics", "SIMPLE_CHEMICAL", 127, 138], ["enoxaparin", "SIMPLE_CHEMICAL", 140, 150], ["corticosteroids", "SIMPLE_CHEMICAL", 152, 167], ["oxygen", "SIMPLE_CHEMICAL", 173, 179], ["patients", "ORGANISM", 238, 246], ["patients", "SPECIES", 238, 246], ["pharmacological treatments", "TREATMENT", 28, 54], ["antiviral drugs", "TREATMENT", 56, 71], ["hydroxychloroquine", "TREATMENT", 73, 91], ["antiinterleukin", "TREATMENT", 93, 108], ["6 receptor drugs", "TREATMENT", 109, 125], ["antibiotics", "TREATMENT", 127, 138], ["enoxaparin", "TREATMENT", 140, 150], ["corticosteroids", "TREATMENT", 152, 167], ["oxygen therapy", "TREATMENT", 173, 187], ["PCR tests", "TEST", 277, 286], ["sore throat", "PROBLEM", 367, 378], ["PCR test", "TEST", 397, 405], ["prevalence ratio", "TEST", 407, 423], ["CI", "TEST", 434, 436]]], ["In the fully adjusted model, the likelihood of testing positive for SARS-CoV-2 infection was significantly higher among participants with persistent sore throat (prevalence ratio=6.50, 95% CI=1.38, 30.6) and symptoms of rhinitis (prevalence ratio=3.72, 95% CI=1.10, 12.5).", [["SARS", "DISEASE", 68, 72], ["infection", "DISEASE", 79, 88], ["sore throat", "DISEASE", 149, 160], ["rhinitis", "DISEASE", 220, 228], ["SARS-CoV-2", "ORGANISM", 68, 78], ["CoV-", "SPECIES", 73, 77], ["participants", "SPECIES", 120, 132], ["SARS-CoV", "SPECIES", 68, 76], ["testing", "TEST", 47, 54], ["SARS", "PROBLEM", 68, 72], ["CoV", "TEST", 73, 76], ["2 infection", "PROBLEM", 77, 88], ["persistent sore throat", "PROBLEM", 138, 160], ["prevalence ratio", "TEST", 162, 178], ["CI", "TEST", 189, 191], ["symptoms", "PROBLEM", 208, 216], ["rhinitis", "PROBLEM", 220, 228], ["prevalence ratio", "TEST", 230, 246], ["CI", "TEST", 257, 259], ["persistent", "OBSERVATION_MODIFIER", 138, 148], ["sore throat", "ANATOMY", 149, 160], ["rhinitis", "OBSERVATION", 220, 228]]], ["In the light of these observations, it is very difficult to affirm whether these patients were really contagious.DISCUSSIONTo date, few studies conducted during the SARS-CoV-2 outbreak in China described some similar data.", [["SARS", "DISEASE", 165, 169], ["patients", "ORGANISM", 81, 89], ["patients", "SPECIES", 81, 89], ["SARS-CoV", "SPECIES", 165, 173], ["few studies", "TEST", 132, 143], ["the SARS", "TEST", 161, 169]]], ["One study showed 4 cases of healthcare professionals who tested positive after hospital discharge and discontinuation of quarantine, 8 This study provides a given rate of patients (16.7%) who still have a positive RT-PCR test for SARS-CoV-2 nucleic acid after recovering from COVID-19.", [["SARS-CoV-2 nucleic acid", "CHEMICAL", 230, 253], ["patients", "ORGANISM", 171, 179], ["patients", "SPECIES", 171, 179], ["One study", "TEST", 0, 9], ["discontinuation of quarantine", "TREATMENT", 102, 131], ["This study", "TEST", 135, 145], ["PCR test", "TEST", 217, 225], ["SARS", "PROBLEM", 230, 234], ["CoV", "TEST", 235, 238], ["nucleic acid", "TEST", 241, 253], ["COVID", "TEST", 276, 281]]], ["According to the WHO guidelines, these 22 patients were eligible to be considered recovered from COVID-19 and thus be discontinued from quarantine.", [["COVID-19", "CHEMICAL", 97, 105], ["patients", "ORGANISM", 42, 50], ["patients", "SPECIES", 42, 50], ["COVID", "TEST", 97, 102]]], ["13 The present data suggest that some symptoms continue to be present-in a milder form than in the acute phase of the disease-in a high rate of patients, but without substantial differences between those with negative RT-PCR test results compared to patients who still test positive.", [["patients", "ORGANISM", 144, 152], ["patients", "ORGANISM", 250, 258], ["patients", "SPECIES", 144, 152], ["patients", "SPECIES", 250, 258], ["some symptoms", "PROBLEM", 33, 46], ["the disease", "PROBLEM", 114, 125], ["PCR test", "TEST", 221, 229], ["acute", "OBSERVATION_MODIFIER", 99, 104], ["disease", "OBSERVATION", 118, 125]]], ["The only 2 symptoms that seem to correlate with the persistence of a positive test are sore throat and signs of rhinitis.DISCUSSIONConsequently, the persistence of these 2 symptoms should not be underestimated and should be adequately assessed in all patients considered recovered from COVID-19.DISCUSSIONIt is important to highlight that COVID-19 patients testing positive after recovery represent an important public health problem.", [["sore throat", "DISEASE", 87, 98], ["rhinitis", "DISEASE", 112, 120], ["COVID-19", "CHEMICAL", 286, 294], ["patients", "ORGANISM", 251, 259], ["patients", "ORGANISM", 348, 356], ["patients", "SPECIES", 251, 259], ["patients", "SPECIES", 348, 356], ["2 symptoms", "PROBLEM", 9, 19], ["a positive test", "PROBLEM", 67, 82], ["sore throat", "PROBLEM", 87, 98], ["rhinitis", "PROBLEM", 112, 120], ["these 2 symptoms", "PROBLEM", 164, 180], ["COVID", "TEST", 286, 291], ["COVID", "TEST", 339, 344], ["patients testing", "TEST", 348, 364], ["rhinitis", "OBSERVATION", 112, 120]]], ["As an emerging infectious disease, the clinical and virologic course of SARS-CoV-2 infection requires further study.", [["infectious disease", "DISEASE", 15, 33], ["SARS-CoV-2 infection", "DISEASE", 72, 92], ["SARS-CoV-2", "ORGANISM", 72, 82], ["CoV-2", "SPECIES", 77, 82], ["SARS-CoV-2", "SPECIES", 72, 82], ["SARS", "PROBLEM", 72, 76], ["CoV-2 infection", "PROBLEM", 77, 92], ["further study", "TEST", 102, 115], ["infectious", "OBSERVATION", 15, 25], ["infection", "OBSERVATION", 83, 92]]], ["Although it is not possible to draw definitive conclusions for public health actions based upon the present data and other reported evidence, 14 these results emphasize relevant clinical characteristics that are important to evaluate, including the extensive clinical course, persistence of signs and symptoms related to COVID-19, the presence of viral RNA fragments after disease recovery, and the potential failure of viral antibody for the clearance of the virus.", [["viral RNA fragments", "DNA", 347, 366], ["viral antibody", "PROTEIN", 420, 434], ["public health actions", "TREATMENT", 63, 84], ["signs", "PROBLEM", 291, 296], ["symptoms", "PROBLEM", 301, 309], ["COVID", "TEST", 321, 326], ["viral RNA fragments", "PROBLEM", 347, 366], ["disease recovery", "PROBLEM", 373, 389], ["viral antibody", "PROBLEM", 420, 434], ["the virus", "PROBLEM", 456, 465], ["not possible", "UNCERTAINTY", 15, 27], ["viral RNA fragments", "OBSERVATION", 347, 366], ["viral antibody", "OBSERVATION", 420, 434]]], ["15LimitationsDespite this study dealing with a highly relevant issue, some limitations should be noted.LimitationsThese include the lack of information on symptom history before acute COVID-19 infection and the lack of details on symptom severity.", [["infection", "DISEASE", 193, 202], ["this study", "TEST", 21, 31], ["acute COVID-19 infection", "PROBLEM", 178, 202], ["symptom severity", "PROBLEM", 230, 246], ["infection", "OBSERVATION", 193, 202]]], ["Furthermore, this is a single center study with a relatively small number of patients, without a control group of patients discharged from hospital for other acute illnesses.", [["patients", "ORGANISM", 77, 85], ["patients", "ORGANISM", 114, 122], ["patients", "SPECIES", 77, 85], ["patients", "SPECIES", 114, 122], ["a single center study", "TEST", 21, 42], ["other acute illnesses", "PROBLEM", 152, 173], ["small", "OBSERVATION_MODIFIER", 61, 66], ["acute", "OBSERVATION_MODIFIER", 158, 163], ["illnesses", "OBSERVATION", 164, 173]]], ["For example, patients with pneumonia can also suffer from persistent symptoms, 16 suggesting these findings could be not exclusive to COVID-19.", [["pneumonia", "DISEASE", 27, 36], ["COVID-19", "CHEMICAL", 134, 142], ["patients", "ORGANISM", 13, 21], ["patients", "SPECIES", 13, 21], ["pneumonia", "PROBLEM", 27, 36], ["persistent symptoms", "PROBLEM", 58, 77], ["COVID", "TEST", 134, 139], ["pneumonia", "OBSERVATION", 27, 36], ["persistent", "OBSERVATION_MODIFIER", 58, 68]]], ["In particular, sore throat and rhinitis are subjective symptoms, rather than objective parameters, which may have bias among the patients and are not easy to analyze quantitatively.", [["sore throat", "DISEASE", 15, 26], ["rhinitis", "DISEASE", 31, 39], ["patients", "ORGANISM", 129, 137], ["patients", "SPECIES", 129, 137], ["sore throat", "PROBLEM", 15, 26], ["rhinitis", "PROBLEM", 31, 39], ["subjective symptoms", "PROBLEM", 44, 63], ["objective parameters", "TEST", 77, 97], ["sore throat", "ANATOMY", 15, 26], ["rhinitis", "OBSERVATION", 31, 39]]], ["However, the clinical characteristics of the participants make it possible to exclude that other acute illnesses were present at the time of evaluation.", [["participants", "SPECIES", 45, 57], ["other acute illnesses", "PROBLEM", 91, 112], ["evaluation", "TEST", 141, 151], ["acute", "OBSERVATION_MODIFIER", 97, 102], ["illnesses", "OBSERVATION", 103, 112]]], ["Unfortunately, objective laboratory parameters-such as the peak level of viral RNA, first duration of viral RNA positivity, and viral antibodies yielded when the viral RNA become negative-are not available to minimize subjectivity and aid in quantitative assessment.", [["viral RNA", "RNA", 73, 82], ["viral RNA", "RNA", 102, 111], ["viral antibodies", "PROTEIN", 128, 144], ["viral RNA", "RNA", 162, 171], ["objective laboratory parameters", "TEST", 15, 46], ["viral RNA", "PROBLEM", 73, 82], ["viral RNA positivity", "PROBLEM", 102, 122], ["viral antibodies", "TEST", 128, 144], ["the viral RNA", "TEST", 158, 171], ["quantitative assessment", "TEST", 242, 265], ["viral RNA", "OBSERVATION", 73, 82]]], ["Another important limitation of the study is the methodology used to diagnose SARS-CoV-2 infection.", [["SARS-CoV-2 infection", "DISEASE", 78, 98], ["SARS-CoV-2", "ORGANISM", 78, 88], ["SARS-CoV-2", "SPECIES", 78, 88], ["the study", "TEST", 32, 41], ["CoV-2 infection", "PROBLEM", 83, 98], ["infection", "OBSERVATION", 89, 98]]], ["Recent data report the risk of eliciting false-negative and false-positive results with RT-PCR in diagnosing COVID-19.", [["COVID-19", "DNA", 109, 117], ["RT-PCR", "TEST", 88, 94], ["diagnosing COVID", "TEST", 98, 114]]], ["It is well known that results from RT-PCR using primers for different genes can be affected by the variation of viral RNA sequences.", [["viral RNA sequences", "RNA", 112, 131], ["RT-PCR", "TEST", 35, 41], ["primers", "TREATMENT", 48, 55], ["viral RNA sequences", "TEST", 112, 131]]], ["In fact, genetic diversity and a possible rapid evolution of this novel coronavirus have been observed in different studies.", [["coronavirus", "DISEASE", 72, 83], ["coronavirus", "ORGANISM", 72, 83], ["genetic diversity", "PROBLEM", 9, 26], ["this novel coronavirus", "PROBLEM", 61, 83], ["different studies", "TEST", 106, 123], ["genetic diversity", "OBSERVATION", 9, 26], ["possible", "UNCERTAINTY", 33, 41], ["rapid", "OBSERVATION_MODIFIER", 42, 47], ["coronavirus", "OBSERVATION", 72, 83]]], ["17, 18 Finally, these data should be considered preliminary and require validation from larger data samples.CONCLUSIONSApart from these limitations, this study offers a unique opportunity to investigate the clinical sequelae of COVID-19.", [["COVID-19", "CHEMICAL", 228, 236], ["these data", "TEST", 16, 26], ["this study", "TEST", 149, 159], ["COVID", "TEST", 228, 233]]], ["In particular, the criteria for discontinuation of quarantine and assessment of patients who recovered from COVID-19 with specific follow-up protocols need to be implemented.", [["COVID-19", "CHEMICAL", 108, 116], ["patients", "ORGANISM", 80, 88], ["patients", "SPECIES", 80, 88], ["discontinuation of quarantine", "TREATMENT", 32, 61], ["assessment", "TEST", 66, 76], ["COVID", "TEST", 108, 113]]], ["19 To contain the spread of the virus, it is extremely important to better evaluate all patients who recovered from COVID-19 but still test positive for the virus.", [["patients", "ORGANISM", 88, 96], ["patients", "SPECIES", 88, 96], ["the virus", "PROBLEM", 28, 37], ["COVID", "TEST", 116, 121], ["the virus", "PROBLEM", 153, 162]]], ["20 This will be a crucial contribution to better understanding both the natural history of COVID-19 as well as the public health implications of viral shedding.", [["COVID", "TREATMENT", 91, 96], ["viral shedding", "PROBLEM", 145, 159], ["viral", "OBSERVATION", 145, 150]]], ["The main question for the containment of the SARS-CoV-2 pandemic infection that still needs to be answered is whether the persistent presence of virus fragments means that the patient is still contagious.CONCLUSIONSTests are conducted using RT-PCR, which looks for small fragments of viral RNA.", [["SARS", "DISEASE", 45, 49], ["infection", "DISEASE", 65, 74], ["SARS-CoV-2", "ORGANISM", 45, 55], ["patient", "ORGANISM", 176, 183], ["viral RNA", "RNA", 284, 293], ["patient", "SPECIES", 176, 183], ["the SARS", "PROBLEM", 41, 49], ["CoV", "PROBLEM", 50, 53], ["2 pandemic infection", "PROBLEM", 54, 74], ["virus fragments", "PROBLEM", 145, 160], ["contagious", "PROBLEM", 193, 203], ["RT-PCR", "TEST", 241, 247], ["small fragments of viral RNA", "PROBLEM", 265, 293], ["main", "OBSERVATION_MODIFIER", 4, 8], ["infection", "OBSERVATION", 65, 74], ["persistent", "OBSERVATION_MODIFIER", 122, 132], ["virus fragments", "OBSERVATION", 145, 160], ["small", "OBSERVATION_MODIFIER", 265, 270], ["fragments", "OBSERVATION", 271, 280], ["viral RNA", "OBSERVATION", 284, 293]]], ["A positive nasopharyngeal swab test can reveal whether a patient is still shedding viral fragments but is not able to discern whether they are still infectious.", [["nasopharyngeal swab", "ANATOMY", 11, 30], ["fragments", "ANATOMY", 89, 98], ["patient", "ORGANISM", 57, 64], ["patient", "SPECIES", 57, 64], ["A positive nasopharyngeal swab test", "TEST", 0, 35], ["still shedding viral fragments", "PROBLEM", 68, 98], ["infectious", "PROBLEM", 149, 159], ["nasopharyngeal", "ANATOMY", 11, 25], ["viral fragments", "OBSERVATION", 83, 98], ["infectious", "OBSERVATION", 149, 159]]], ["7, 8 It is important to highlight that also in other viral diseases, such as Zika, it has been documented that specific RNA can be identified long after the clearance of the virus.", [["viral diseases", "DISEASE", 53, 67], ["other viral diseases", "PROBLEM", 47, 67], ["Zika", "PROBLEM", 77, 81], ["specific RNA", "PROBLEM", 111, 123], ["the virus", "PROBLEM", 170, 179], ["viral diseases", "OBSERVATION", 53, 67]]], ["21 RT-PCR is unable to differentiate between infectious virus and non-infectious RNA.", [["non-infectious RNA", "RNA", 66, 84], ["infectious virus", "SPECIES", 45, 61], ["RT-PCR", "TEST", 3, 9], ["infectious virus", "PROBLEM", 45, 61], ["non-infectious RNA", "PROBLEM", 66, 84], ["infectious", "OBSERVATION", 45, 55], ["non-infectious RNA", "OBSERVATION", 66, 84]]], ["22 In patients with clinical improvement, who are completely asymptomatic, 23 a post-negative positive RT-PCR test result does not necessarily reflect reinfection or viral carriage.", [["patients", "ORGANISM", 6, 14], ["patients", "SPECIES", 6, 14], ["PCR test", "TEST", 106, 114], ["reinfection", "PROBLEM", 151, 162], ["viral carriage", "PROBLEM", 166, 180], ["not necessarily reflect", "UNCERTAINTY", 127, 150], ["reinfection", "OBSERVATION", 151, 162]]], ["24 Evidence on SARS-CoV-2 infection and COVID-19 increases each day and new guidelines about the recovery criteria will continue to change.", [["SARS-CoV-2 infection", "DISEASE", 15, 35], ["SARS-CoV-2", "ORGANISM", 15, 25], ["SARS-CoV", "SPECIES", 15, 23], ["SARS", "PROBLEM", 15, 19], ["CoV", "PROBLEM", 20, 23], ["2 infection", "PROBLEM", 24, 35], ["COVID", "TEST", 40, 45], ["SARS", "OBSERVATION", 15, 19], ["CoV", "OBSERVATION_MODIFIER", 20, 23], ["infection", "OBSERVATION", 26, 35]]], ["In clinical practice, it is urgent to have criteria to identify patients who, even if declared recovered, continue to test positive.", [["patients", "ORGANISM", 64, 72], ["patients", "SPECIES", 64, 72]]], ["If patients continue to have symptoms potentially related to COVID-19, such as sore throat or rhinitis, it is reasonable to be cautious in avoiding close contact, wearing a face mask, and possibly repeating a nasopharyngeal swab.", [["face", "ANATOMY", 173, 177], ["nasopharyngeal swab", "ANATOMY", 209, 228], ["sore throat", "DISEASE", 79, 90], ["rhinitis", "DISEASE", 94, 102], ["patients", "ORGANISM", 3, 11], ["patients", "SPECIES", 3, 11], ["symptoms", "PROBLEM", 29, 37], ["COVID", "TEST", 61, 66], ["sore throat", "PROBLEM", 79, 90], ["rhinitis", "PROBLEM", 94, 102], ["a face mask", "TREATMENT", 171, 182], ["a nasopharyngeal swab", "TEST", 207, 228], ["rhinitis", "OBSERVATION", 94, 102], ["nasopharyngeal", "ANATOMY", 209, 223]]]]}